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Summary 
 
The forensic toxicologist faces challenges in the detection of drugs and poisons 
in biological samples due to transformations which occur both during life and 
after death. For example, changes can result from drug metabolism during life 
or from the use of formalin solution for post mortem embalming purposes. The 
former requires the identification of drug metabolites and the latter the 
identification of chemical reaction products in order to know which substances 
had been administered. The work described in this thesis was aimed at providing 
ways of tackling these challenges and was divided into two parts. Part 1 
investigated the use of in vitro drug metabolism by human liver microsomes 
(HLM) to obtain information on drug metabolites and Part 2 investigated the 
chemical reactions of drugs and a carbamate pesticide with formalin solution 
and formalin-blood. 
The initial aim of part I was to develop an in vitro metabolism method using 
HLM, based on a literature review of previous studies of this type. MDMA was 
chosen as a model compound to develop the HLM method because its 
metabolism was known and standards of its metabolites were commercially 
available. In addition, a sensitive and selective method was developed for the 
identification and quantitation of hydrophilic phase I drug metabolites using 
LC/MS/MS with a conventional reverse-phase (C18) column. In order to obtain 
suitable retention factors for polar drug metabolites on this column, acetyl 
derivatives were evaluated for converting the metabolites to more lipophilic 
compounds and an optimal separation system was developed. Acetate 
derivatives were found to be stable in the HPLC mobile phase and to provide 
good chromatographic separation of the target analytes. 
In vitro metabolism of MDMA and, subsequently, of other drugs involved 
incubation of 4 µg drug substance in pH 7.4 buffer with an NADPH generating 
system (NGS) at 37oC for 90 min with addition of more NGS after 30 min.  The 
reaction was stopped at 90 min by the addition of acetonitrile before extraction 
of the metabolites. 
Acetate derivatives of MDMA metabolites were identified by LC/MS/MS using 
multiple reaction monitoring (MRM). Three phase I metabolites (both major and 
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minor metabolites) of MDMA were detected in HLM samples. 3,4-dihydroxy-
methamphetamine and 4-hydroxy-3-methoxymethamphetamine were found to 
be major metabolites of MDMA whereas 3,4-methylenedioxyamphetamine was 
found to be a minor metabolite. Subsequently, ten MDMA positive urines were 
analysed to compare the metabolite patterns with those produced by HLM. An 
LC/MS method for MDMA and its metabolites in urine samples was developed and 
validated. The method demonstrated good linearity, accuracy and precision and 
insignificant matrix effects, with limits of quantitation of 0.025 µg/ml. 
Moreover, derivatives of MDMA and its metabolites were quantified in all 10 
positive human urine samples. The urine metabolite pattern was found to be 
similar to that from HLM. 
The second aim of Part 1 was to use the HLM system to study the metabolism of 
some new psychoactive substances, whose misuse worldwide has necessitated 
the development of analytical methods for these drugs in biological specimens.   
Methylone and butylone were selected as representative cathinones and para-
methoxyamphetamine (PMA) was chosen as a representative ring-substituted 
amphetamine, because of the involvement of these drugs in recent drug-related 
deaths, because of a relative lack of information on their metabolism, and 
because reference standards of their metabolites were not commercially 
available.  
An LC/MS/MS method for the analysis of methylone, butylone, PMA and their 
metabolites was developed. Three phase I metabolites of methylone and 
butylone were detected in HLM samples. Ketone reduction to β-OH metabolites 
and demethylenation to dihydroxy-metabolites were found to be major phase I 
metabolic pathways of butylone and methylone whereas N-demethylation to nor-
methylone and nor-butylone were found to be minor pathways. Also, 
demethylation to para-hydroxyamphetamine was found to be a major phase I 
metabolic pathway of PMA whereas β-hydroxylation to β-OH-PMA was found to 
be a minor pathway. 
Formaldehyde is used for embalming, to reduce decomposition and preserve 
cadavers, especially in tropical countries such as Thailand. Drugs present in the 
body can be exposed to formaldehyde resulting in decreasing concentrations of 
the original compounds and production of new substances. The aim of part II of 
the study was to evaluate the in vitro reactions of formaldehyde with selected 
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drug groups including amphetamines (amphetamine, methamphetamine and 
MDMA), benzodiazepines (alprazolam and diazepam), opiates (morphine, 
hydromorphone, codeine and hydrocodone) and with a carbamate insecticide 
(carbosulfan). The study would identify degradation products to serve as markers 
for the parent compounds when these were no longer detectable. 
Drugs standards were spiked in 10% formalin solution and 10% formalin blood. 
Water and whole blood without formalin were used for controls. Samples were 
analysed by LC/MS/MS at different times from the start, over periods of up to 30 
days.  
Amphetamine, methamphetamine and MDMA were found to rapidly convert to 
methamphetamine, DMA and MDDMA respectively, in both formalin solution and 
formalin blood, confirming the Eschweiler-Clarke reaction between amine-
containing compounds and formaldehyde. 
Alprazolam was found to be unstable whereas diazepam was found to be stable 
in both formalin solution and water. Both were found to hydrolyse in formalin 
solution and to give open-ring alprazolam and open-ring diazepam. Other 
alprazolam conversion products attached to paraformaldehyde were detected in 
both formalin solution and formalin blood. 
Morphine and codeine were found to be more stable than hydromorphone and 
hydrocodone in formalin solution. Conversion products of hydromorphone and 
hydrocodone attached to paraformaldehyde were tentatively identified in 
formalin solution. Moreover, hydrocodone and hydromorphone rapidly decreased 
within 24 h in formalin blood and could not be detected after 7 days. 
Carbosulfan was found to be unstable in formalin solution and was rapidly 
hydrolysed within 24 h, whereas in water it was stable up to 48 h. Carbofuran 
was the major degradation product, plus smaller amounts of other products, 3-
ketocarbofuran and 3-hydrocarbofuran. By contrast, carbosulfan slowly 
hydrolysed in formalin-blood and was still detected after 15 days.  
 
It was concluded that HLM provide a useful tool for human drug metabolism 
studies when ethical considerations preclude their controlled administration to 
humans. The use of chemical derivatisation for hydrophilic compounds such as 
polar drug metabolites for analysis by LC/MS/MS with a conventional C18 column 
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is effective and inexpensive, and suitable for routine use in the identification 
and quantitation of drugs and their metabolites. The detection of parent drugs 
and their metabolites or conversion and decomposition products is potentially 
very useful for the interpretation of cases in forensic toxicology, especially when 
the original compounds cannot be observed. 
  
V 
 
Table of Contents 
Summary…… ...............................................................................     I 
Table of Contents .......................................................................... V 
List of Tables ............................................................................... XV 
List of Figures ............................................................................ XVII 
Ethical Approvals for this Thesis ...................................................... XXIV 
Acknowledgments ....................................................................... XXV 
Abbreviations ............................................................................ XXVI 
Chapter 1 General introduction ........................................................ 1 
1.1 Forensic toxicology ............................................................... 1 
1.2 Drug transformations ............................................................. 2 
1.3 General aims....................................................................... 3 
Chapter 2 Metabolism studies ........................................................... 4 
2.1 Introduction ....................................................................... 4 
2.2 Drug metabolism .................................................................. 4 
2.3 In vitro metabolism studies ..................................................... 5 
2.3.1 Human liver microsomes (HLM) .............................................. 6 
2.3.2 S9 fractions ..................................................................... 6 
2.4 In vivo metabolism studies ...................................................... 7 
2.4.1 Animal models .................................................................. 7 
2.4.2 Human model ................................................................... 7 
Chapter 3 Derivatisation ................................................................. 8 
3.1 Acylation: acetylation ............................................................ 9 
3.1.1 Acetic anhydride ............................................................... 9 
3.1.2 Pentafluoropropionic anhydride (PFPA) .................................... 9 
3.2 Silylation .......................................................................... 10 
3.2.1 N-Methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) ............... 10 
Chapter 4 Method validation ........................................................... 12 
VI 
 
4.1 Introduction ...................................................................... 12 
4.2 Selectivity and specificity ...................................................... 12 
4.3 Linearity ........................................................................... 13 
4.4 Lower limit of quantitation and limit of detection ......................... 14 
4.5 Accuracy and precision.......................................................... 14 
4.6 Matrix effects ..................................................................... 15 
Chapter 5 Gas chromatography/mass spectrometry (GC/MS) ..................... 17 
5.1 Introduction ...................................................................... 17 
5.2 Gas chromatography ............................................................. 17 
5.3 Mass spectrometry ............................................................... 18 
5.3.1 Introduction ................................................................... 18 
5.3.2 Electron impact ionisation .................................................. 19 
5.3.3 Quadrupole mass analyser ................................................... 19 
Chapter 6 Liquid chromatography/tandem mass spectrometry................... 21 
6.1 Introduction ...................................................................... 21 
6.2 Liquid chromatography .......................................................... 21 
6.3 Triple quadrupole mass spectrometer ........................................ 23 
6.3.1 Introduction ................................................................... 23 
6.3.2 Electrospray ionisation ....................................................... 23 
6.3.3 Triple quadrupole mass analyser ........................................... 24 
Chapter 7 New psychoactive substances ............................................. 26 
7.1 Introduction ...................................................................... 26 
7.2 Phenethylamine derivatives .................................................... 27 
7.2.1 3,4-Methylenedioxymethamphetamine (MDMA) .......................... 28 
7.2.1.1 Chemical properties ................................................... 29 
7.2.1.2 Metabolism and excretion ............................................. 29 
7.2.1.3 Toxicity of MDMA ....................................................... 32 
7.2.2 para-Methoxyamphetamine (PMA) ......................................... 32 
7.2.2.1 Chemical properties ................................................... 32 
VII 
 
7.2.2.2 Metabolism and excretion ............................................. 33 
7.2.2.3 Toxicity of PMA ......................................................... 34 
7.3 Synthetic cathinones ............................................................ 35 
7.3.1 Methylone ...................................................................... 38 
7.3.1.1 Chemical properties ................................................... 38 
7.3.1.2 Metabolism and excretion ............................................. 38 
7.3.1.3 Toxicity of methylone ................................................. 40 
7.3.2 Butylone ........................................................................ 41 
7.3.2.1 Chemical properties ................................................... 41 
7.3.2.2 Metabolism and excretion ............................................. 42 
7.3.2.3 Toxicity of butylone ................................................... 43 
Chapter 8 In vitro and in vivo metabolism studies on MDMA using human liver 
microsomes and LC/MS/MS with chemical derivatisation ........................... 46 
8.1 Introduction ...................................................................... 46 
8.2 Aims ................................................................................ 47 
8.3 Review of previous analytical methods for the determination of MDMA 
and its metabolites ..................................................................... 47 
8.4 GC/MS method development ................................................... 56 
8.4.1 Derivatisation methods ...................................................... 56 
8.4.1.1 Acetic anhydride (AA) ................................................. 56 
8.4.1.2 Pentafluoropropionic anhydride (PFPA) ............................. 57 
8.4.1.3 N-Methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) ......... 57 
8.4.2 Identification method ........................................................ 57 
8.4.2.1 Gas chromatography/mass spectrometry conditions .............. 57 
8.4.2.2 GC/MS method for TMS-derivatives.................................. 58 
8.4.2.3 GC/MS method for PFPA-derivatives ................................ 58 
8.4.2.4 GC/MS method for Ac-Derivatives ................................... 59 
8.4.3 Results of derivatisation with GC/MS analysis ............................ 59 
8.4.3.1 Optimised GC/MS conditions for trimethylsilyl derivatives ...... 59 
VIII 
 
8.4.3.2 Optimised GC/MS conditions for acetate derivatives ............. 62 
8.4.3.3 Optimised GC/MS conditions for PFPA derivatives ................ 64 
8.4.3.4 Comparison of derivatisation methods .............................. 66 
8.5 LC/MS method development ................................................... 68 
8.5.1 Optimisation of LC/MS conditions .......................................... 68 
8.5.1.1 LC separation ........................................................... 69 
8.5.1.2 MRM optimisation ...................................................... 72 
8.5.2 Solid phase extraction ....................................................... 75 
8.5.2.1 Extraction method ..................................................... 75 
8.5.2.1.1 Oasis® MCX and Clean Screen® DAU .............................. 75 
8.5.2.1.2 Oasis® WCX ........................................................... 76 
8.5.2.2 Results of solid phase extraction .................................... 76 
8.5.2.2.1 Clean Screen® DAU .................................................. 76 
8.5.2.2.2 Oasis® MCX ........................................................... 78 
8.5.2.2.3 Oasis® WCX ........................................................... 79 
8.5.2.3 Comparison of SPE methods .......................................... 81 
8.6 Methods and materials .......................................................... 82 
8.6.1 Reagents and standards ...................................................... 82 
8.6.1.1 Preparation of 0.1 M phosphate buffer pH 6 ....................... 83 
8.6.1.2 Preparation of 0.1 M acetate buffer pH 4.5 ........................ 83 
8.6.1.3 Preparation of phosphate buffer saline (PBS) pH 7.4 ............. 83 
8.6.1.4 Preparation of 0.1 M sodium acetate buffer pH 5 ................. 83 
8.6.1.5 Preparation of NADPH generating system .......................... 84 
8.6.1.6 Preparation of MDMA in phosphate buffer pH 7.4 ................. 84 
8.6.1.7 Preparation of 0.1 M acetic acid ..................................... 84 
8.6.1.8 Preparation of 0.1 M sodium acetate................................ 84 
8.6.1.9 Preparation of 0.1 M monobasic sodium phosphate ............... 84 
8.6.1.10 Preparation of 0.1 M dibasic sodium phosphate ................... 85 
8.6.1.11 Preparation of quality control samples ............................. 85 
IX 
 
8.6.2 In vitro assay (human liver microsomes) .................................. 85 
8.6.3 In vivo assays (MDMA positive urine samples) ............................ 85 
8.6.3.1 Non-hydrolysed extraction method .................................. 86 
8.6.3.2 Enzymatically hydrolysed extraction method ...................... 86 
8.6.4 Derivatisation ................................................................. 86 
8.6.4.1 Acetic anhydride derivatisation (AA) ................................ 86 
8.6.4.2 Stability of derivatives of standards ................................. 86 
8.6.5 Liquid chromatography/mass spectrometry conditions ................. 87 
8.6.6 Method validation ............................................................ 88 
8.6.6.1 Blank urine samples .................................................... 88 
8.6.6.2 Selectivity/specificity ................................................. 88 
8.6.6.3 Linearity ................................................................. 89 
8.6.6.4 Lower limit of quantitation ........................................... 89 
8.6.6.5 Accuracy and precision ................................................ 89 
8.6.6.6 Matrix effects ........................................................... 90 
8.6.7 Post mortem case materials ................................................ 90 
8.7 Results and discussion ........................................................... 90 
8.7.1 Stability of Ac-derivatives ................................................... 90 
8.7.2 Method validation ............................................................ 93 
8.7.2.1 Selectivity/specificity ................................................. 93 
8.7.2.2 Linearity ................................................................. 95 
8.7.2.3 Lower limit of quantitation ........................................... 98 
8.7.2.4 Accuracy and precision ............................................... 100 
8.7.2.5 Matrix effects .......................................................... 102 
8.7.3 In vitro metabolism studies ................................................ 102 
8.7.4 In vivo metabolism studies ................................................. 106 
8.7.4.1 Non-hydrolysed urine analysis ....................................... 106 
8.7.4.2 Hydrolysed urine analysis ............................................ 107 
8.7.4.3 Comparison of hydrolysed and non-hydrolysed urine samples .. 110 
X 
 
8.7.5 Post mortem case samples ................................................. 112 
8.8 Conclusions ...................................................................... 114 
Chapter 9 In vitro metabolism studies on methylenedioxy-substituted 
amphetamines using human liver microsomes and LC/MS/MS with chemical 
derivatisation ............................................................................. 116 
9.1 Introduction ..................................................................... 116 
9.2 Aims ............................................................................... 116 
9.3 Review of previous analytical methods for the determination of 
methylone, butylone and their metabolites in biological samples ............. 117 
9.4 Methods and materials ......................................................... 122 
9.4.1 Reagents and standards ..................................................... 122 
9.4.1.1 Preparation of phosphate buffer saline (PBS) pH 7.4 ............ 123 
9.4.1.2 Preparation of NADPH generating system ......................... 123 
9.4.1.3 Preparation of methylone and butylone in phosphate buffer pH 
7.4 ....................................................................... 123 
9.4.2 In vitro assay (human liver microsomes) ................................. 123 
9.4.3 Derivatisation ................................................................ 123 
9.4.4 Liquid chromatography/mass spectrometry conditions ................ 123 
9.4.4.1 Liquid chromatography conditions .................................. 123 
9.4.4.2 Mass spectrometry conditions ....................................... 124 
9.5 Results and discussion .......................................................... 125 
9.5.1 Optimisation of LC/MS conditions ......................................... 125 
9.5.1.1 LC separation .......................................................... 125 
9.5.1.2 MRM optimisation ..................................................... 126 
9.5.2 General approach for metabolite identification ........................ 129 
9.5.3 Methylone metabolite identification ..................................... 130 
9.5.3.1 Predicted mass spectral fragmentation of methylone metabolites
 ........................................................................... 131 
9.5.3.2 Residual methylone identification in HLM samples ............... 132 
XI 
 
9.5.3.3 In vitro nor-methylone (MDC) identification ...................... 133 
9.5.3.4 In vitro HHMC identification ......................................... 134 
9.5.3.5 In vitro HMMC identification ......................................... 135 
9.5.4 Butylone metabolite identification ....................................... 138 
9.5.4.1 Identification of residual butylone in HLM samples .............. 139 
9.5.4.2 In vitro nor-butylone identification ................................ 140 
9.5.4.2.1 Predicted mass spectral fragmentation of nor-butylone (bk-
BDB)………. ....................................................................... 140 
9.5.4.2.2 Identification of nor-butylone in HLM samples ................ 141 
9.5.4.3 In vitro dihydroxy metabolite of butylone identification ....... 142 
9.5.4.3.1 Predicted mass spectral fragmentation of the dihydroxy 
metabolite of butylone ........................................................ 142 
9.5.4.3.2 Identification of the dihydroxy metabolite of butylone in HLM 
samples…. ....................................................................... 144 
9.5.4.4 In vitro β-OH and 4-OH-3-MeO metabolites of butylone 
identification .......................................................... 145 
9.5.4.4.1 Predicted mass spectral fragmentation of β-OH and 4-OH-3-
MeO metabolites of butylone ................................................. 145 
9.5.4.4.2 Identification of β-OH and 4-OH-3-MeO metabolites of 
butylone in HLM samples ...................................................... 147 
9.6 Conclusions ...................................................................... 148 
Chapter 10 In vitro metabolism study on PMA using human liver microsomes and 
LC/MS/MS with chemical derivatisation .............................................. 150 
10.1 Introduction ..................................................................... 150 
10.2 Aims ............................................................................... 151 
10.3 Review of previous analytical methods for the determination of PMA and 
its metabolites ......................................................................... 151 
10.4 Methods and materials ......................................................... 154 
10.4.1 Reagents and standards ................................................... 154 
10.4.2 In vitro assay (human liver microsomes) ............................... 154 
XII 
 
10.4.3 Derivatisation ............................................................... 154 
10.4.4 Liquid chromatography/mass spectrometry conditions .............. 154 
10.4.4.1 Liquid chromatography conditions .................................. 154 
10.4.4.2 Mass spectrometry conditions ....................................... 154 
10.5 Results and discussion .......................................................... 155 
10.5.1 Optimisation of LC/MS conditions ....................................... 155 
10.5.1.1 LC separation .......................................................... 155 
10.5.1.2 MRM optimisation ..................................................... 156 
10.5.2 Predicted mass spectral fragmentation of PMA metabolites ........ 158 
10.5.3 In-vitro metabolism studies of PMA ..................................... 160 
10.6 Conclusions ...................................................................... 165 
Chapter 11 Formaldehyde/formalin ................................................... 166 
11.1 Chemical properties ............................................................ 166 
11.2 Pharmacokinetics of formaldehyde .......................................... 167 
11.3 Tissue fixation ................................................................... 167 
11.4 Previous studies on the reactions between drugs and formalin .......... 168 
Chapter 12 In vitro reactions of formaldehyde with drugs and poisons: 
introduction and experimental section ............................................... 172 
12.1 Introduction ..................................................................... 172 
12.2 Aims ............................................................................... 172 
12.3 Amphetamine-type Stimulants (ATS) ........................................ 173 
12.3.1 Mechanism of action ....................................................... 174 
12.3.2 Amphetamine ............................................................... 174 
12.3.3 Methamphetamine ......................................................... 175 
12.3.4 MDMA......................................................................... 176 
12.4 Benzodiazepines ................................................................ 176 
12.4.1 Mechanism of action ....................................................... 177 
12.4.2 Alprazolam .................................................................. 178 
12.4.3 Diazepam .................................................................... 179 
XIII 
 
12.5 Opioids ........................................................................... 179 
12.5.1 Mechanism of action ....................................................... 180 
12.5.2 Morphine and hydromorphone ........................................... 180 
12.5.3 Codeine and hydrocodone ................................................ 182 
12.6 Carbamate Insecticides ........................................................ 183 
12.6.1 Mechanism of action ....................................................... 184 
12.6.2 Carbosulfan ................................................................. 185 
12.7 Methods and materials ......................................................... 187 
12.7.1 Reagents and standards ................................................... 187 
12.7.1.1 Preparation of stock standard solutions ........................... 187 
12.7.1.2 Preparation of formalin solutions ................................... 188 
12.7.2 Reaction of formalin solution with drugs and pesticide .............. 188 
12.7.2.1 Spiked samples in formalin solution ................................ 188 
12.7.2.2 Spiked samples in control solution .................................. 188 
12.7.3 Reaction of formalin blood with drugs .................................. 188 
12.7.3.1 Spiked samples in formalin blood ................................... 188 
12.7.3.2 Spiked samples in whole blood ...................................... 189 
12.7.4 Liquid-liquid extraction ................................................... 189 
12.7.4.1 Liquid-liquid extraction for carbosulfan ........................... 189 
12.7.4.2 Liquid-liquid extraction for LC/MS .................................. 189 
12.7.5 Instrumentation ............................................................ 190 
12.7.5.1 Gas chromatography/mass spectrometry conditions ............. 190 
12.7.5.2 Liquid chromatography/mass spectrometry conditions.......... 190 
Chapter 13 In vitro reaction of formaldehyde with drugs and poisons: 
identification of the conversion products ............................................ 193 
13.1 Introduction ..................................................................... 193 
13.2 Reactions of formaldehyde with ATS ........................................ 193 
13.2.1 Reactions of ATS in formalin solution ................................... 193 
13.2.2 Reactions of ATS in formalin blood ...................................... 198 
XIV 
 
13.3 Reactions of formaldehyde with benzodiazepines ......................... 200 
13.3.1 Reactions of benzodiazepines in formalin solution ................... 200 
13.3.2 Reactions of benzodiazepines in formalin blood ...................... 206 
13.4 Reactions of formaldehyde with opiates .................................... 208 
13.4.1 Reactions of opiates in formalin solution ............................... 208 
13.4.2 Reactions of opiates in formalin blood ................................. 213 
13.5 Reactions of formaldehyde with a carbamate insecticide ................ 215 
13.5.1 Reactions of carbosulfan in formalin solution ......................... 215 
13.5.2 Reactions of carbosulfan in formalin blood ............................ 220 
13.6 Conclusions ...................................................................... 222 
Chapter 14 General conclusions ....................................................... 223 
Chapter 15 Future work ................................................................. 225 
List of references ......................................................................... 226 
Appendices: Publications in support of this Thesis .................................. 249 
  
XV 
 
List of Tables 
Table 8-1: Previous GC/MS and LC/MS methods for MDMA and its metabolites. . 54 
Table 8-2: SIM conditions for TMS-derivatives of MDMA and its metabolites. .... 58 
Table 8-3: SIM conditions for PFPA-derivatives of MDMA and its metabolites. ... 59 
Table 8-4: SIM conditions for Ac-derivatives of MDMA and its metabolites. ...... 59 
Table 8-5: Comparison of response intensity of the three derivatisation methods.
 ............................................................................................... 66 
Table 8-6: Physico-chemical properties of MDMA and its metabolites. ........... 69 
Table 8-7: SPE recoveries of MDMA and its metabolites. ............................ 81 
Table 8-8: MRM conditions for derivatives of MDMA and metabolites. ............ 88 
Table 8-9: Regression models, correlation coefficients (R2) and LLOQs for 
LC/MS/MS analysis of acetate derivatives of MDMA and its metabolites in urine.
 ............................................................................................... 96 
Table 8-10: Inter-day assay precision and accuracy for determination of MDMA 
and its metabolites in urine (n = 6). ................................................... 101 
Table 8-11: Inter-day assay accuracy and precision at the LLOQs (n = 6). ...... 101 
Table 8-12: Urine matrix effects at low analyte concentrations (0.1 µg/ml) as 
percent of signal obtained with pure reference standards. ........................ 102 
Table 8-13: Urine matrix effects at high analyte concentrations (1 µg/ml) as 
percent of signal obtained with pure reference standards. ........................ 102 
Table 8-14: Concentrations of analytes in non-hydrolysed urine samples (µg/ml).
 .............................................................................................. 107 
Table 8-15: Concentration of analytes in hydrolysed urine samples (µg/ml). ... 108 
Table 8-16: Percentage differences in analyte concentrations between 
hydrolysed and non-hydrolysed urine samples (µg/ml). ............................ 111 
Table 8-17: Concentrations of MDMA and its metabolites in non-hydrolysed urine 
from MDMA-positive post mortem cases. ............................................. 113 
Table 9-1: Previous GC/MS and LC/MS methods for the analysis of methylone, 
butylone and their metabolites in biological samples. ............................. 118 
Table 9-2: MRM conditions for acetate derivatives of methylone and its 
metabolites. ............................................................................... 124 
Table 9-3: MRM conditions for acetate derivatives of butylone and its 
metabolites. ............................................................................... 125 
XVI 
 
Table 9-4: The predicted ESI-LC/MS/MS fragmentation patterns of a dihydroxy 
metabolite of butylone. ................................................................. 142 
Table 9-5: The predicted ESI-LC/MS/MS fragmentation patterns of β-hydroxy and 
4-OH-3-MeO metabolites of butylone.................................................. 147 
Table 10-1: Previous GC/MS and LC/MS methods for PMA and its metabolites. 153 
Table 10-2: MRM conditions for acetate derivatives of PMA and its metabolites.
 .............................................................................................. 155 
Table 12-1: MRM conditions for amphetamines, benzodiazepines, opiates and 
carbosulfan. ............................................................................... 192 
  
XVII 
 
List of Figures 
Figure 3-1: Chemical structures of acetic anhydride and PFPA. ................... 10 
Figure 3-2: Chemical structure of MSTFA and its by-product. ...................... 11 
Figure 7-1: Structures of amphetamine, phenethylamine and MDA. .............. 27 
Figure 7-2: Structures of methamphetamine, mescaline and MDMA (* chiral 
centre). ..................................................................................... 29 
Figure 7-3: Chemical structures of MDMA and its metabolites...................... 30 
Figure 7-4: Chemical structures of amphetamine and PMA. ........................ 33 
Figure 7-5: Chemical structures of PMA and its metabolites. ....................... 34 
Figure 7-6: Structures of phenethylamine, cathinone and cathine. ............... 36 
Figure 7-7: Chemical structures of well-known synthetic cathinones. ............ 37 
Figure 7-8: Chemical structures of methylone and its metabolites. ............... 39 
Figure 7-9: Chemical structures of butylone and its metabolites. ................. 42 
Figure 8-1: Mass spectral patterns of TMS-derivatives of MDMA and its 
metabolites. ................................................................................ 60 
Figure 8-2: Mass spectral patterns of Ac-derivatives of MDMA and its metabolites.
 ............................................................................................... 62 
Figure 8-3: Mass spectral patterns of PFP-derivatives of MDMA and its 
metabolites. ................................................................................ 64 
Figure 8-4: TIC chromatograms of PFP-derivatives of MDMA and its metabolites 
with temperature ramps of 3, 4 and 4.5oC/min. ..................................... 68 
Figure 8-5: LC/MS chromatograms of underivatised MDMA and its metabolites 
using a Gemini C18 column. ............................................................. 70 
Figure 8-6: Structures of HHMA, HMA and their Ac-derivatives. ................... 71 
Figure 8-7: LC/MS/MS MRM chromatograms for MDMA-Ac and its metabolites 
following extraction from urine (concentration 0.25 µg/ml). ...................... 72 
Figure 8-8: Mass spectra of Ac-derivatives of MDMA and its metabolites at a CE of 
20 eV in product ion scan mode. Under optimised conditions, most ion reactions 
have different optimum CEs. The spectra illustrated here demonstrate typical 
patterns, although the ion ratios under optimised conditions may be different. 73 
Figure 8-9: LC/MS/MS MRM chromatograms of HHMA-3Ac ions after extraction 
with Clean Screen® DAU. The retention time of HHMA-3Ac is 3.6 min on Gemini 
column (arrowed). ........................................................................ 77 
XVIII 
 
Figure 8-10: LC/MS/MS MRM chromatograms for HMA-2Ac, HMMA-2Ac and MDMA-
Ac after extraction with Clean Screen® DAU. ......................................... 77 
Figure 8-11: LC/MS/MS MRM chromatograms of HHMA-3Ac ions after extraction 
with Oasis® MCX. The retention time of HHMA-3Ac is 3.6 min on Gemini column 
(arrowed). .................................................................................. 78 
Figure 8-12: LC/MS/MS MRM chromatograms for HMA-2Ac, HMMA-2Ac and MDMA-
Ac after extraction with Oasis® MCX. ................................................... 79 
Figure 8-13: LC/MS/MS MRM chromatograms of HHMA-3Ac, HMMA-2Ac and HMA-
2Ac after extraction with SPE Oasis® WCX. ............................................ 80 
Figure 8-14: LC/MS/MS MRM chromatograms of MDMA-Ac after extraction with 
SPE Oasis® WCX. ........................................................................... 81 
Figure 8-15: Stability of Ac-derivatives of standards of MDMA and its metabolites 
in the HPLC mobile phase at low and high concentrations over a 96 h period. A 
non-linear scale has been applied to the x-axis to improve visibility of the points 
up to 30 h. .................................................................................. 92 
Figure 8-16: MRM chromatograms obtained by LC/MS/MS analysis of an 
acetylated extract of blank urine spiked with internal standard MDMA-d5, 
showing absence of interferences at the retention times of MDMA and its 
metabolites (selectivity). ................................................................ 93 
Figure 8-17: MRM chromatograms obtained by LC/MS/MS analysis of a spiked 
urine sample. Retention times of analytes are indicated (arrowed). ............. 94 
Figure 8-18: Calibration curves (0.025-1.5 µg/ml) for LC/MS/MS analysis of 
acetate derivatives of MDMA and its metabolites in urine. LLOQs are indicated 
(arrowed). Concentrations of standards are 0.025, 0.050, 0.1, 0.25, 0.50, 0.75, 1 
and 1.5 µg/ml. ............................................................................. 96 
Figure 8-19: LC/MS/MS MRM chromatograms for the analysis of acetate 
derivatives of MDMA metabolites from urine at a concentration of 0.025 µg/ml 
(LLOQ). The S/N ratios are greater than 10 in each chromatogram. .............. 98 
Figure 8-20: LC/MS/MS MRM chromatograms of MDMA metabolites in HLM 
samples compared with Ac-derivatives of reference standards. .................. 104 
Figure 8-21: LC/MS MRM chromatograms of MDMA metabolites in an HLM sample.
 .............................................................................................. 105 
Figure 8-22: LC/MS/MS MRM chromatograms of hydrolysed and non-hydrolysed 
urine, showing increased concentrations of free HMA and HMMA after hydrolysis.
 .............................................................................................. 112 
XIX 
 
Figure 8-23: LC/MS/MS chromatograms of acetate derivatives of MDMA and its 
metabolites extracted from a post mortem human urine case sample. ......... 114 
Figure 9-1: Chemical structures of methylone and butylone. ..................... 117 
Figure 9-2: Chromatograms of methylone-Ac and butylone-Ac on a Gemini C18 
column. .................................................................................... 126 
Figure 9-3: Keto–enol tautomerism of methylone and butylone. .................. 127 
Figure 9-4: Product ion scan spectra of the Ac-derivative of a methylone 
standard at CEs of 10 and 20 eV. The optimum CE values for each ion are listed 
in Table 9-2................................................................................ 127 
Figure 9-5: Mass spectral fragmentation of methylone-Ac. ........................ 128 
Figure 9-6: Product ion scan spectra of the Ac-derivative of a butylone standard 
at CE of 10 and 20 eV. The optimum CE values for each ion are listed in Table 9-
3. ............................................................................................ 128 
Figure 9-7: Mass spectral fragmentation of butylone-Ac. .......................... 129 
Figure 9-8: Mass spectral fragmentation of MDC-Ac and HHMC-3Ac. ............. 132 
Figure 9-9: Specimen LC-MS/MS MRM chromatograms of methylone-Ac in HLM 
samples compared with the Ac-derivative of a methylone standard. ............ 133 
Figure 9-10: Specimen LC/MS/MS MRM chromatograms for nor-methylone-Ac in 
HLM samples. ............................................................................. 134 
Figure 9-11: Specimen LC-MS/MS MRM chromatograms for dihydroxy-
methcathinone-3Ac in HLM samples. .................................................. 135 
Figure 9-12: Specimen LC/MS/MS MRM chromatograms for 4-hydroxy-3-
methoxymethcathinone-2Ac in HLM samples. ........................................ 136 
Figure 9-13: Structures of HMMC and methylone ketone-reduction metabolites.
 .............................................................................................. 137 
Figure 9-14: Specimen LC-MS/MS MRM chromatograms for methylone metabolites 
in an HLM sample. ........................................................................ 138 
Figure 9-15: Specimen LC/MS/MS MRM chromatograms of butylone-Ac in HLM 
sample compared with the Ac-derivative of a butylone standard. ............... 140 
Figure 9-16: Specimen LC-MS/MS MRM chromatograms of nor-butylone-Ac in HLM 
samples. ................................................................................... 141 
Figure 9-17: Predicted ESI LC/MS/MS fragmentation patterns of acetate 
derivatives of butylone metabolites (4-OH-3-MeO-M-2Ac and di-OH-M-3Ac). 
Fragmentations are marked in red. Hydrogen transfers are indicated by an “H” 
adjacent to the bond which is broken. ................................................ 143 
XX 
 
Figure 9-18: Specimen LC/MS/MS MRM chromatograms for di-OH-M-3Ac in HLM 
samples. ................................................................................... 144 
Figure 9-19: Predicted ESI LC/MS/MS fragmentation patterns of acetate 
derivatives of butylone metabolites (4-OH-3-MeO-M-2Ac and β-OH-M-2Ac). 
Fragmentations are marked in red. Hydrogen transfers are indicated by an “H” 
adjacent to the bond which is broken. ................................................ 146 
Figure 9-20: Specimen LC/MS/MS MRM chromatograms for β-OH-M-2Ac (at 10.3 
min) and 4-OH-3MeO-M-2Ac (at 8.8 min) in two HLM samples. .................... 148 
Figure 10-1: LC/MS/MS MRM chromatograms of a PMA-Ac standard on a Gemini 
C18 column. ............................................................................... 156 
Figure 10-2: LC/MS/MS product ion scan spectra of the Ac-derivative of PMA 
standard at CE of 10 and 25 eV. The optimum CE values for each ion are listed in 
Table 10-2. ................................................................................ 157 
Figure 10-3: Mass spectral fragmentation of PMA and PMA-Ac. ................... 157 
Figure 10-4: Postulated ESI LC/MS fragmentation pattern of PHA-2Ac. .......... 159 
Figure 10-5: Postulated ESI LC/MS/MS fragmentation pattern of β-OH-PMA-2Ac.
 .............................................................................................. 160 
Figure 10-6: Examples of LC/MS/MS MRM chromatograms for PMA-Ac in two HLM 
samples compared with the Ac-derivative of a PMA standard. .................... 161 
Figure 10-7: Examples of LC/MS/MS MRM chromatograms for PHA-2Ac in two HLM 
samples. ................................................................................... 162 
Figure 10-8: Mass spectrum of the Ac-derivative of PHA-2Ac in HLM samples at CE 
of 20 eV in product ion scan mode. .................................................... 163 
Figure 10-9: Examples of LC/MS/MS MRM chromatograms for β-OH-PMA-2Ac in 
HLM samples. ............................................................................. 163 
Figure 10-10: Examples of LC/MS/MS MRM chromatograms for 4-HMA-2Ac in an 
HLM sample compared with the 4-HMA-2Ac standard. .............................. 165 
Figure 11-1: Chemical structure of formaldehyde. .................................. 166 
Figure 12-1: Chemical structures of amphetamine and methamphetamine. .... 175 
Figure 12-2: Core chemical structure of benzodiazepines. ........................ 177 
Figure 12-3: Chemical structures of alprazolam and diazepam. .................. 178 
Figure 12-4: Chemical structures of morphine and hydromorphone. ............. 181 
Figure 12-5: Chemical structures of codeine and hydrocodone. .................. 182 
Figure 12-6: General structure of carbamates (A), methomyl and aldicarb. .... 183 
XXI 
 
Figure 12-7: The mechanism of inhibition of AChE with carbamate pesticides. 
The diagram on the left shows the normal mode of action of the enzyme, 
through which ACh is cleaved into choline plus acetic acid. When a carbamate is 
cleaved by AChE, the carbamoyl group binds (reversibly) to the active site and 
blocks its action, as shown in the diagram on the right. ........................... 184 
Figure 12-8: Chemical structures of carbosulfan and carbofuran. ................ 185 
Figure 12-9: The overall scheme of carbosulfan metabolism. ..................... 186 
Figure 13-1: EICs of unextracted standards of amphetamine, methamphetamine 
and DMA analysed by LC/MS. ........................................................... 194 
Figure 13-2: MRM chromatograms from LC/MS/MS analysis of amphetamine (AP) 
spiked samples in 10% formalin and in water at days 1 and 7 showing the 
formation of methamphetamine (MA) on days 1 and 7. ............................ 195 
Figure 13-3: LC/MS/MS MRM chromatograms of methamphetamine-spiked 
samples in 10% formalin and in water at days 0 and 7. ............................. 196 
Figure 13-4: LC/MS EIC chromatograms of unextracted standards of MDMA and 
MDDMA. .................................................................................... 197 
Figure 13-5: LC/MS/MS MRM chromatograms of MDMA-spiked samples in 10% 
formalin and in water at days 0 and 7................................................. 197 
Figure 13-6: LC/MS/MS MRM chromatograms of amphetamine (AP)-spiked 
samples in 10% formalin blood and in control (whole) blood at day 7. Arrows 
indicate retention times of conversion products methamphetamine (MA) and 
DMA. ........................................................................................ 199 
Figure 13-7: LC/MS/MS MRM chromatograms of MDMA-spiked samples in 10% 
formalin blood and in control (whole) blood at day 7. Arrows indicate retention 
time of the conversion product MDDMA. .............................................. 199 
Figure 13-8: Relative peak area of alprazolam in 10% formalin and water over 30 
days as a percent of the peak area of the starting material. ...................... 201 
Figure 13-9: LC/MS chromatograms of alprazolam samples in 10% formalin after 
spiking (day 0). ........................................................................... 202 
Figure 13-10: LC/MS chromatograms of alprazolam samples in 10% formalin at 
day 30 and chemical structure of open-ring alprazolam. .......................... 202 
Figure 13-11: LC/MS chromatograms of alprazolam-d5 samples in 10% formalin 
after spiking (day 0) and mass spectra of open-ring alprazolam-d5, alprazolam-d5 
and the conversion product with M-H+ at m/z 404. ................................. 203 
XXII 
 
Figure 13-12: Relative peak area of diazepam in 10% formalin and water over 30 
days as a percent of the peak area of the starting material. ...................... 204 
Figure 13-13: LC/MS chromatograms of diazepam samples in 10% formalin at day 
1 and chemical structure of open-ring diazepam. ................................... 205 
Figure 13-14: LC/MS/MS product ion scans of alprazolam conversion products in 
10% formalin solution. ................................................................... 205 
Figure 13-15: (A) Percentage peak area of alprazolam in 10% formalin blood and 
control blood over 30 days. (B) Percentage peak area of alprazolam conversion 
products formed in 10% formalin blood compared with alprazolam. The EIC of 
m/z 327 is for open ring alprazolam and of m/z 399 is for the adduct of 
alprazolam with formaldehyde. ........................................................ 207 
Figure 13-16: Percentage peak areas of codeine and morphine in 10% formalin 
and water over 30 days. ................................................................. 208 
Figure 13-17: Percentage peak area of hydrocodone and hydromorphone in 10% 
formalin and water over 30 days. ...................................................... 209 
Figure 13-18: LC/MS overlay chromatograms and mass spectra of hydrocodone 
samples in 10% formalin at day 1. ..................................................... 210 
Figure 13-19: LC/MS overlay chromatograms and mass spectra of hydromorphone 
samples in 10% formalin at day 1. ..................................................... 211 
Figure 13-20: LC/MS product ion scans of conversion products of hydrocodone 
and hydromorphone in 10% formalin. ................................................. 212 
Figure 13-21: Percentage of codeine and morphine in 10% formalin blood and 
control blood over 30 days. ............................................................. 213 
Figure 13-22: Percentage of hydrocodone and hydromorphone in 10% formalin 
blood and control blood over 30 days. ................................................ 214 
Figure 13-23: GC/MS chromatogram (A) and EI+ mass spectrum (B) of 
carbosulfan. ............................................................................... 216 
Figure 13-24: GC/MS chromatograms of carbosulfan in 10% formalin solution at 
days 0 and 1. The degradation product at 6.5 min is 7-phenolcarbofuran. ...... 217 
Figure 13-25: GC/MS chromatogram (A) and EI+ mass spectrum (B) of 7-
phenolcarbofuran formed in GC inlet in a spiked formalin sample at day 1. .... 218 
Figure 13-26: Percentage peak area of carbosulfan and its degradation compound 
(carbofuran) in 10% formalin and water over 30 days. ............................. 219 
Figure 13-27: LC/MS overlay chromatograms of carbosulfan in spiked formalin 
and control samples at day 1. .......................................................... 220 
XXIII 
 
Figure 13-28: LC/MS chromatograms of carbosulfan and carbofuran in formalin-
blood and control-blood samples at day 15. ......................................... 221 
  
XXIV 
 
Ethical Approvals for this Thesis 
The human biological specimens used in the work described in this thesis are 
listed below along with details of applicable ethical approval requirements. 
 
Blank urine 
specimens used in 
method 
development and 
validation studies 
Existing blank urine samples from a previous research 
project, obtained with informed consent and appropriately 
stored in Forensic Medicine and Science, were used. The 
chair of the University Medical Research Ethics Committee, 
Dr Jesse Dawson, Institute of Cardiovascular and Medical 
Sciences, University of Glasgow confirmed that approval 
would not be needed for these samples.  
 
Post mortem urine 
samples 
Three post mortem urine samples known to be positive for 
MDMA were analysed and reported as part of the medico-
legal investigation of the three cases. Ethical approval and 
consent are not required if the analytical results are 
reported to the Procurator Fiscal. 
 
Clinical urine 
samples 
Human urine samples which were known to be positive for 
MDMA were obtained from Glasgow Royal Infirmary for 
routine toxicology service analysis and the results of the 
analyses were reported as part of the case investigation. 
The Infirmary Ethics Committee advised Dr Hazel Torrance 
that ethical approval was not required as the work formed 
part of medical systems development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XXV 
 
Acknowledgments 
I would firstly like to thank Dr Robert A. Anderson for his help, support and 
guidance as supervisor and encouragement during my laboratory experimental 
work and in writing my thesis. I will miss him for his kindness and care during 
these three years under his supervision. 
 
I would also like to thank Dr Hazel Torrance, my second supervisor, and all 
toxicologists and staff in Forensic Medicine and Science who gave me support 
and advice during my studies. Also I would like to thank all students in the 
section for giving me a good time. 
 
I would also like to thank my whole family who has always supported me and 
gave me strength in my study and in my life.  
 
Finally I would like to thank the Royal Thai Government for supporting me 
financially during my studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XXVI 
 
Abbreviations 
 
2C-B   2,5-Dimethoxy-4-bromophenethylamine 
3-HMMA  3-Hydroxy-4-methoxymethamphetamine 
4-HMC   4-Hydroxy-3-methoxycathinone 
4-HMMA  4-Hydroxy-3-methoxymethamphetamine 
A/D   Analog/Digital 
AA   Acetic anhydride 
ACh   Acetylcholine 
AChE   Acetylcholinesterase 
amu   Atomic mass unit 
API   Atmospheric pressure ionisation 
ATS   Amphetamine-type stimulants  
AUC   Area under the curve 
bk-BDB  Nor-butylone 
bk-MBDB  Butylone 
CE   Collision energy  
CID   Collision-induced dissociation 
Cmax   Maximum concentration 
CNS   Central nervous system   
COMT   Catechol-O-methyltransferase 
CYPs    Cytochromes  
Da   Dalton 
DC   Direct-current   
DMA   N,N-dimethylamphetamine  
DOM   4-Methyl-2,5-dimethoxyamphetamine  
ECD   Electron capture detector  
EDTA   Ethylenediaminetetraacetic acid 
EI   Electron impact ionisation 
EIC   Extracted-ion chromatogram 
ELISA    Enzyme-linked immunosorbent assay  
EMCDDA   European Monitoring Centre on Drugs and Drug Addiction  
ESI    Electrospray ionisation  
FID   Flame ionisation detector   
FMOs    Flavin-containing monooxygenases  
XXVII 
 
FPD   Flame photometric detector  
FV   Fragmentor voltage   
G6P   D-glucose 6-phosphate dipotassium salt hydrate 
G6PD   Glucose-6-phosphate dehydrogenase 
GABA   Gamma-aminobutyric acid 
GC   Gas chromatography 
GC/MS  Gas chromatography/mass spectrometry 
GC-NICI-MS   GC/MS with negative ion chemical ionisation  
GHB    Gamma-hydroxybutyrate  
GLC   Gas-liquid chromatography 
Gluc   Glucuronide 
GST   Glutathione S-transferase  
HFBA    Heptafluorobutyric acid anhydride  
HHMA   3,4-Dihydroxymethamphetamine 
HHMC   3,4-Dihydroxymethcathinone 
HILIC   Hydrophilic interaction chromatography 
HLM   Human liver microsomes 
HMA   4-Hydroxy-3-methoxyamphetamine 
HMC   3,4-Methylenedioxycathinone 
HMMA   Hydroxymethoxymethamphetamine 
HMMC   4-Hydroxy-3-methoxymethcathinone 
HPLC   High-performance liquid chromatography 
HPLC/DAD   High-performance liquid chromatography/diode array 
detection  
HPLC/ED   High-performance liquid chromatography/electrochemical 
detection   
IPs    Identification points  
IS   Internal standard 
k′   Retention factors  
LC   Liquid Chromatography 
LC/MS   Liquid chromatography/mass spectrometry 
LC/MS/MS  Liquid chromatography/tandem mass spectrometry 
LLOQ   Lower limit of quantitation  
LOD   Limit of detection 
LSD    Lysergic acid diethylamide  
XXVIII 
 
m/z   Mass-to-charge ratio 
MBTFA  N-Methyl-bis(trifluoroacetamide) 
MDA   3,4-Methylenedioxyamphetamine 
MDC   3,4-Methylenedioxycathinone 
MDDMA  3,4-Methylenedioxydimethylamphetamine 
MDMA   3,4-Methylenedioxymethamphetamine 
MDMA-d5  3,4-Methylenedioxymethamphetamine-d5 
MDPV   3,4-Methylenedioxypyrovalerone 
ME   Matrix effect  
MRM   Multiple reaction monitoring 
MS   Mass spectrometer 
MSTFA   N-Methyl-N-(trimethylsilyl)-trifluoroacetamide 
NADP   Nicotinamide adenine dinucleotide phosphate  
NAT   N-Acetyl transferase   
NGS   NADPH generating system 
NIDA   National Institute on Drug Abuse 
NPD   Nitrogen-phosphorus detector   
NPS   New psychoactive substances 
PE   Process efficiency 
PFPA   Pentafluoropropionic acid anhydride  
PHA   para-Hydroxyamphetamine/4-Hydroxyamphetamine 
PMA   para-Methoxyamphetamine 
QC   Control samples/quality control 
QqQ   Triple quadrupole mass analyser 
R2   Correlation coefficient 
RE   Recovery   
RF   Radio-frequency/Response factors 
RPC   Reverse-phase chromatography 
RSD    Relative standard deviation  
S-HFBPCl   S-Heptafluoro-butyrylprolyl chloride  
SIM   Selected ion monitoring 
SNS   Sympathetic nervous system 
SPE   Solid phase extraction 
SRM   Selected reaction monitoring 
ST   Sulphotransferase  
XXIX 
 
Sul   Sulphate 
TCD   Thermal conductivity detector  
TFA   Trifluoroacetic acid anhydride  
TMS   Trimethylsily 
tR    Retention time  
UDPGA  Uridine diphosphate glucuronic acid  
UGTs   Uridine diphosphoglucuronosyl transferases   
UN   United Nations 
UNODC  United Nations Office on Drugs and Crime 
β-NADP  β-Nicotinamide adenine dinucleotide phosphate hydrate  
 
1 
 
Chapter 1 General introduction 
1.1 Forensic toxicology 
Toxicology is the study of how toxic substances (toxins) or poisons interact with 
living organisms resulting in harmful effects or death after exposure. All 
substances can be poisons depending on the size of the dose. Drugs are used for 
treatment within therapeutic levels. At higher doses, drugs may cause harm to 
the human body or death at lethal doses. There are many subdivisions of 
toxicology such as medical toxicology, clinical toxicology, environmental 
toxicology, forensic toxicology and others1,2. 
 
Forensic toxicology is involved with the identification, detection and 
interpretation of the presence of drugs and poisons for medico-legal purposes. 
Two main purposes of forensic toxicology are to assist in death investigations 
and in drug of abuse testing in the living. Forensic toxicology also includes drug 
facilitated crimes, road safety, workplace drug testing and the development of 
analytical methods for identification and confirmation of drugs and poisons. 
Studies on pharmacokinetics (absorption, distribution, metabolism, and 
excretion) are also important for toxicologists to understanding the likely effects 
of drugs and for interpretation of reported results3,4. 
 
The most common substances involved in forensic analysis are amphetamine-
type stimulants, benzodiazepines, barbiturates, cocaine alkaloids, opioids such 
as heroin, morphine and codeine and cannabis products. However, other 
substances can also be targeted such as ketamine, gamma-hydroxybutyrate 
(GHB), lysergic acid diethylamide (LSD), pesticides and new psychoactive 
substances whose misuse continues to increase. 
 
Samples for forensic toxicology analysis are biological fluids such as blood and 
urine. However, other biological samples such as vitreous humour, bile, stomach 
contents, liver, kidney and other organ tissues, hair and oral fluid are also 
required for toxicology analysis in some cases. The major work of the forensic 
toxicologist in post mortem cases involves the identification and quantitation of 
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drugs or poisons which are present in the samples and which may be relevant to 
the cause of death. 
 
The results obtained from forensic toxicological analysis are important to the 
investigation of crimes or accidents. Analytical methods with high selectivity, 
sensitivity and rapidity are required. The most common analytical methods are 
immunoassay, which is used as a screening method, and chromatography-based 
methods which are used as confirmatory methods. To interpret the analytical 
results, many parameters need to be considered such as post mortem changes, 
post mortem redistribution and drug biotransformation which will convert drugs 
to other forms (metabolites)3. 
 
1.2 Drug transformations 
Chemical transformation is defined as the conversion of a substrate to a product. 
Drugs are transformed both inside and outside the body. Inside the body, drugs 
are processed via the chemical and biochemical modifications made by a living 
organism, so-called “biotransformation”. Lipophilic compounds are converted to 
hydrophilic compounds, so-called “metabolites”, and excreted from the body 
mainly via the urinary system. Not only for formation of metabolites, 
biotransformation also includes drug interactions, bioactivation, substrate 
inhibition, enzyme induction and carcinogenesis. Basic reactions for 
biotransformation are functionalisation and synthetic conjugation reactions5. 
 
Outside the body, drugs are transformed through chemical reactions usually 
resulting in a reduction in drug concentrations. Drugs can form degradation 
products which may be toxic substances via both chemical and physical reactions 
such as photo-degradation. The expiration date is one parameter that expresses 
the degradation of drugs6. Chemical reactions will occur when drugs or 
compounds are exposed to environmental conditions such as heat, radiation, 
humidity and acidic or basic solvents. The most common reactions are 
hydrolysis, oxidation and reduction. In the analytical process, chemical 
transformations are sometimes used deliberately by the toxicologist, for 
example, chemical derivatisation is used to transform a target substance to a 
product with desirable properties.  
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Forensic toxicologists have been able to respond to the challenge of detecting 
drug transformation. Analytical methods in the forensic laboratory should be 
able to detect drug metabolites or decomposition products which affect the 
concentrations of the original substances measured in samples. It is necessary to 
quantitate parent drug, metabolites and decomposition products to obtain 
information on the drug concentrations before the transformation(s) for the 
interpretation of reported results. 
 
1.3 General aims 
The general aims of this study were to identify in vitro transformation reactions 
related to forensic toxicology including the identification of drug metabolites 
using human liver microsomes and the identification of products of the reaction 
between formaldehyde with various drugs and poisons. Specific aims were: 
 
• To identify MDMA metabolites using in vitro metabolism with human liver 
microsomes and analysis by LC/MS/MS. 
• To identify methylone, butylone and PMA metabolites using in vitro 
metabolism with human liver microsomes and analysis by LC/MS/MS. 
• To identify conversion products of the reactions between formaldehyde 
and amphetamine, methamphetamine, MDMA, alprazolam, diazepam, 
codeine, hydrocodone, morphine, hydromorphone and carbosulfan. 
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Chapter 2 Metabolism studies 
2.1 Introduction 
In recent years, a large number of new drugs from new drug classes such as 
synthetic cathinones or synthetic cannabinoids have appeared on the illicit drug 
market. Previous studies have shown that some active metabolites can 
contribute a toxic effect greater than that of their parent drugs, such as the 
metabolites of MDMA7,8. Knowledge of the metabolism of new drugs is important 
in clinical and forensic toxicology for developing an analytical method. However, 
current knowledge on the human metabolism of new drugs is very limited. This 
chapter will review basic concepts of drug metabolism relevant to the studies 
reported subsequently. 
 
2.2 Drug metabolism 
Drugs are introduced into the body via many routes such as oral, dermal or 
intravascular. After a drug has entered the body, it is eliminated either as 
unchanged drug or as metabolism products, including both active and inactive 
metabolites. Drugs are removed from the body by biological processes called 
“metabolism” or “bio-transformation” which occur in two steps, phase I and 
phase II. Metabolites are usually removed from the human body faster than the 
parent drug due to their chemical structures which are commonly more water-
soluble than their parent drugs and more readily excreted by the kidney which is 
the major route of elimination of most drugs9-11. Biotransformation occurs in 
many human organs such as the liver, kidneys, lungs and intestines. However, 
most biotransformation occurs in the liver. 
 
Phase I drug metabolism typically involves oxidation, reduction, and hydrolysis 
of xenobiotics to generate more polar derivatives such as alcohols, phenols or 
carboxylic acid compounds whereas phase II metabolism is responsible for 
conjugation reactions such as glucuronidation, sulphation or addition of amino 
acids such as glycine. Typically phase I oxidation is involved mainly with hepatic 
cytochromes P450 (CYPs) that utilize NADPH and oxygen in their catalytic cycle. 
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CYPs play an important role in the metabolism of drugs, steroids and biogenic 
amines and can also transform nontoxic chemicals into toxic or carcinogenic 
products. Other metabolic enzymes are alcohol dehydrogenases, aldehyde 
dehydrogenases or flavin-containing monooxygenases (FMOs). Some of the 
metabolites produced by phase I reactions can undergo excretion, but many 
others require additional transformation by phase II metabolism. Enzymes that 
are involved in phase II metabolism include uridine diphosphoglucuronosyl 
transferases (UGTs) which are generally bound to the endoplasmic reticulum, 
with liver a major, but not the only, location, glutathione S-transferases (GSTs) 
which are located mainly in the cytoplasm but are also present in the nucleus, 
mitochondria and peroxisomes, and N-acetyl transferases (NATs), and 
sulphotransferases (STs) which are located in the cytosol in a range of tissues 
including the liver12-15. 
 
However, there are some disadvantages of drug metabolism. Some metabolites 
are still pharmacologically active and toxic after the parent drug structure has 
been modified, such as morphine-6-glucuronide, and some are more toxic than 
their parents, such as the neurotoxic metabolites of MDMA16-18. Therefore, the 
relationship between drug biotransformation and toxicity needs to be evaluated. 
There are multiple methods used in the investigation of drug metabolism such as 
in vitro and in vivo methods. 
 
2.3 In vitro metabolism studies 
There are many different in vitro methods or models used to study drug 
metabolism. In vitro data can be used to predict the metabolic pathway of each 
drug or toxic substance in humans. Because metabolism of drugs and toxic 
compounds occurs mainly in the liver, the majority of in vitro metabolism 
studies are derived from liver tissue, which contains drug metabolising enzymes. 
There are many liver preparations used for in vitro metabolism studies such as 
liver homogenates, isolated hepatocytes and sub cellular liver fractions (S9 
fraction or microsomes) that constitute a different level of complexity and 
capability14,19. However, results obtained from in vitro experiments need to be 
confirmed by in vivo studies. This review focuses on phase I metabolism studies 
using human liver microsomes. 
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2.3.1 Human liver microsomes (HLM) 
Human liver microsomes (HLM) are amongst the most popular in vitro 
metabolism study methods due to their price and method of use. Microsomes are 
subcellular fractions derived from the endoplasmic reticulum of hepatic cells. 
They are prepared and isolated from other cellular components by 
homogenisation of liver followed by differential centrifugation at 10,000 g and 
100,000 g20. HLM contain only the membrane-bound metabolising enzymes such 
as CYPs, FMOs and UGTs which can produce partial metabolic profiles. 
  
To evaluate phase I metabolism using HLM, a cofactor such as nicotinamide 
adenine dinucleotide phosphate (NADP) needs to be added. HLM can also be 
applied to glucuronidation studies (phase II) by the addition of uridine 
diphosphate glucuronic acid (UDPGA). Pooled HLM is a mixture of microsomes 
from different donors and is recommended to reduce the inter-individual 
variations in the activity of HLM13. 
 
The general method for the determination of drug metabolites using HLM is 
incubation of HLM with drugs in buffer and NADPH generating system, which 
usually consists of β-NADP and glucose-6-phosphate dehydrogenase. These are 
incubated at 37oC for an appropriate time (40, 60, 90 min, etc.) depending on 
the target drugs. To stop the reaction, a stop reagent is added to the incubation 
mixture to precipitate or denature the proteins, including the enzymes. 
 
2.3.2 S9 fractions 
S9 liver fractions have been used to study both phase I and phase II drug 
metabolism since the 1970s. The S9 fraction contains both microsomal and 
cytosolic fractions which offer a more complete metabolic profile than HLM. S9 
fractions also need to be applied with an NADPH generating system. However, 
the concentrations of metabolites produced by S9 fractions are lower because 
they contain lower enzyme activities compared to microsomes13. 
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2.4 In vivo metabolism studies 
In vivo animal or human studies have been used in drug development for the 
determination of pharmacokinetic properties and identification of metabolites. 
It is the most useful tool to obtain full information on drug biotransformation, 
especially an in vivo human model. However, in vivo models have some 
limitations such as the low amount of drugs that can ethically be administered to 
animals or humans, potentially resulting in a low concentration of drug 
metabolites in plasma or urine. Moreover, some intermediate metabolites may 
not be observed with these models. In vivo biotransformation studies have been 
applied in both animal and human models19,21. 
 
2.4.1 Animal models 
Animal models give information for understanding the role of drug-metabolising 
enzymes in the organism. However, animal studies cannot entirely predict all 
metabolism pathways that occur in humans due to species differences. Common 
animals used for in vivo biotransformation studies are small rodents, guinea pigs 
and rabbits. However, animal studies remain a legal requirement in most 
countries22,23. 
 
2.4.2 Human model 
The human model involves drug biotransformation experiments with human 
volunteers. The use of human volunteers for these studies provides full drug 
metabolic profiles. However, bio-variability amongst volunteers such as age or 
ethnicity needs to be identified. There are multiple parameters that need to be 
considered with in vivo human studies such as concentration of drug, single or 
multiple dose administration and route of administration. Moreover, ethical 
issues and the risk to volunteers participating in clinical studies should also be 
considered22,23. 
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Chapter 3 Derivatisation 
Derivatisation is a chemical reaction of an analyte which transforms it into a 
product with desirable properties, a so-called “derivative”, by adding an extra 
group to the molecule. Derivatisation can be applied in chromatography 
techniques in both off-line mode and automatic mode and can be done before 
(pre-derivatisation) or after the separation step (post-column derivatisation)24. 
However, only pre-derivatisation is mentioned in this chapter. 
 
In forensic toxicology, GC/MS, which is suitable for volatile and temperature-
stable compounds, is a gold standard method for identification and quantitation 
of drugs and poisons. However, many drugs or poisons are compounds whose 
structures contain polar functional groups (hydroxyls, ketones, carboxylic acids 
and amines), especially metabolites of drugs which are often of extremely high 
polar character. It is necessary to convert some analytes chemically to another 
form to make them appropriate for GC/MS analysis. Derivatisation is used in GC 
to increase the volatility and thermal stability of an analyte. Furthermore, it can 
also improve the gas chromatographic properties of a compound resulting in a 
more symmetrical peak shape and give more characteristic fragments in mass 
spectra for identification25-27. 
 
For LC/MS, derivatisation is often applied in metabolomic proﬁling, 
identification and quantitation of drug metabolites or polar compounds such as 
aliphatic amines, carboxylic acids and alcohols which are difficult to detect at 
low concentrations to make them suitable for reverse-phase HPLC. Derivatisation 
is used in LC/MS to increase the capacity factors of hydrophilic compounds, 
improve selectivity, improve stability and enhance sensitivity by increasing the 
chargeability and hydrophobicity of the analytes28-30. 
 
To perform derivatisation, analytes must have at least one functional group in 
their structure with an active hydrogen, such as –COOH, –OH, –NHR and –NH2, 
and the derivative should have adequate stability. Most common derivatisation 
reactions involve alkylation, silylation and acylation24,31. 
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3.1 Acylation: acetylation 
Acylation is a common derivatisation method used for drugs analysis. Active 
hydrogens on an analyte contained in -OH, -SH, -NH2, or -NHR functional groups 
are replaced with an acyl group (–CO–R) and converted to esters, thioesters or 
amides using the action of a carboxylic acid or carboxylic acid derivative. There 
are three main types of reagents used for acylation derivatisation: acid 
anhydrides, acyl halides and reactive acyl derivatives. The acylation reagents 
used most often are acid anhydrides such as acetic acid anhydride (acetic 
anhydride, AA), heptafluorobutyric acid anhydride (HFBA), pentafluoropropionic 
acid anhydride (PFPA) and trifluoroacetic acid anhydride (TFA) because the 
excess reagent, which can affect the stability of the derivatives, is easier to 
remove24-26. Moreover, pyridine is a common solvent used as a basic catalyst in 
the acylation reaction. 
 
3.1.1 Acetic anhydride 
Acetic anhydride is an acylation reagent with the formula (CH3CO)2O, see Figure 
3-1. Acetic anhydride is usually used with pyridine which acts as an accepter for 
the reaction by-products. Acylation with acetic anhydride has been used in 
systematic forensic toxicology analysis to derivatise a wide range of drugs due to 
the significant improvement to their chromatographic properties25. A common 
procedure for acetic anhydride derivatisation is incubation of the dry analyte 
with a mixture of acetic anhydride and pyridine at the optimum temperature 
and time for each analyte. 
 
3.1.2 Pentafluoropropionic anhydride (PFPA) 
Pentafluoropropionic anhydride (PFPA) is a widely used acylation reagent with 
the formula (CF3CF2CO)2O, see Figure 3-1. Derivatisation with PFPA can not only 
improve the volatility and thermal stability of an analyte, but also usually gives 
mass spectra with abundant ions at high m/z values. Moreover, derivatisation 
with PFPA produces a volatile acid by-product that is easily removed before 
analysis by GC. PFP derivatives can be prepared using PFPA with or without a 
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basic catalyst or using perfluoro-acylimidazoles25. As is the case for acetic 
anhydride, the derivatisation procedure needs to be optimised for each analyte. 
 
 
 
Figure 3-1: Chemical structures of acetic anhydride and PFPA. 
 
3.2 Silylation 
Silylation is another common derivatisation technique used for drugs analysis. 
Active protons on analytes are replaced with an alkylsilyl group, most commonly 
the trimethylsilyl (TMS, −Si(CH3)3) group but can also be others such as the 
dimethyl-(tert-butyl)-silyl group (TBDMS,−Si(CH3)2−C(CH3)3) to produce silyl 
ethers, esters or amines27. This reaction can be applied to alcohols, carboxylic 
acids, amines, amides, thiols, and the enol form of carbonyl compounds. The 
ability of active functional groups to form silyl derivatives is in the following 
order: alcohols > phenols > carboxylic acids > amines > amides. Because both the 
silylation reagents and the derivatives are sensitive to water, silylation must be 
performed under anhydrous conditions to prevent the degradation of reagent or 
derivatives24,25. 
 
There are many reagents developed for silylation reactions with different 
functional groups and products such as TMS-amines, TMS-amides and TMS-esters. 
The common silylation reagents include BSTFA, MSTFA, TMSCl and TMSI. 
 
3.2.1 N-Methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) 
N-Methyl-N-(trimethylsilyl)-trifluoroacetamide or MSTFA is one of the most 
commonly used silylation reagents. It is the most volatile TMS-amide which is 
offered as a liquid reagent. MSTFA is a highly reactive TMS donor and can 
produce a volatile by-product, N-methyltrifluoroacetamide, which often elutes 
with the GC solvent peak, see Figure 3-2. A common procedure for MSTFA 
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derivatisation is incubation of the dry analyte with MSTFA at 60oC for 1 h. 
However, the derivatisation temperature and time should be optimised for each 
analyte24-26. 
 
 
 
Figure 3-2: Chemical structure of MSTFA and its by-product. 
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Chapter 4 Method validation 
4.1 Introduction 
Reliable analytical data are very important in forensic and clinical toxicology. 
Toxicological investigations depend on reliable information for correct 
interpretation. Unreliable results can lead to misinterpretation or wrong clinical 
treatment32. Routine analytical methods in forensic toxicology include methods 
that are able to differentiate drugs in analytical specimens, especially drugs in 
the same class which have similar chemical properties and similar chemical 
structures, such as amphetamine, methamphetamine, MDMA, MDA, or new drug 
groups, such as synthetic cathinones or synthetic cannabinoids. To ensure 
reliable results, a developed method must be validated before application in 
routine analysis. Method validation parameters such as sensitivity, selectivity, 
precision and accuracy need to be examined to ensure that the method is 
suitable for forensic toxicology investigation. 
 
4.2 Selectivity and specificity 
Selectivity is defined as the ability of the bioanalytical method to determine the 
analyte(s) in the analysed matrices without interference. Specificity is defined 
as the ability of the bioanalytical method to measure unequivocally and 
differentiate the analyte(s) in the presence of other components, which may be 
expected to be present. Typically, these might include metabolites, impurities, 
degradants and matrix components32. Both quantitative and qualitative methods 
need to be evaluated with respect to their selectivity and specificity to confirm 
that they are able to differentiate analytes of interest from the matrix 
components, endogenous compounds and other drugs. 
 
Selectivity of the method can be determined using a blank matrix whereas 
specificity of the method can be determined using a blank matrix spiked with 
drugs of interest. A lack of response in a blank matrix or a lack of response 
interfering with the signal of analytes of interest and internal standards prove 
that the method is selective and specific. However, a small degree of 
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interference is accepted as long as accuracy and precision (see below) at the 
lower limit of quantitation (LLOQ) are within the acceptance criteria (±20%). Ten 
to twenty different sources of blank samples are recommended for checking the 
absence of interference from endogenous compounds and matrix components. 
Spiked samples (blank samples spiked with common drugs or compounds of 
interest) are recommended for checking for interference from xenobiotic 
compounds that are expected to be present in authentic specimens, particularly 
in forensic cases that often contain many different drugs and poisons33,34. 
Moreover, the number of compounds spiked in blank samples depends on the 
purpose of the method. 
 
4.3 Linearity 
To obtain a reliable quantification, the relationship between the measuring 
signals and the concentration of analytes in the sample needs to be determined. 
Linearity is defined as the ability of a method to obtain a corresponding 
response proportional to the concentration of the analyte35. The working range 
of a method is defined as “the interval over which the method provides results 
with an acceptable uncertainty”36. For any quantitative method it is necessary 
to confirm that the method can be used over the working range. 
 
The range of the calibration curve is chosen depending on the purpose of the 
analytical method, such as the concentration of drugs found in the body 
(therapeutic or toxic range). Five to eight different concentrations of calibrator 
across the calibration range is recommended to assess the calibration curve. 
Spiked calibration standards in blank samples are analysed using the optimised 
method and the corresponding response of each target analyte is plotted versus 
the corresponding concentration. To calculate concentrations of unknown 
samples, regression analysis is used to obtain the regression equation, which 
expresses the relation of corresponding response to analyte concentration37. The 
equation of a linear relationship can be written as below (Equation 4-1). Note 
that non-linear calibration curves can also meet the validation criteria. 
 
Equation 4-1             y = mx+b 
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where y is the corresponding response, x is the analyte concentration, m is the 
slope and b is the y-intercept. 
 
Linear regression is used to provide the relationship between the x and y 
variables in a data set (concentration of an analyte and its corresponding 
response from an analytical technique)38,39. The linear relationship between x 
and y can be determined by the linear correlation coefficient (R2), the value of 
which should be close to 1. For quantitative analysis, a correlation coefficient 
(R2) of 0.99 or better is required. However, a correlation coefficient of 0.98 is 
minimally acceptable40. 
 
4.4 Lower limit of quantitation and limit of detection 
The lower limit of quantification (LLOQ) is defined as the lowest concentration 
of an analyte in a specimen that can be quantified with acceptable precision and 
accuracy32. The recommended acceptance criteria for precision and accuracy at 
the LLOQ is ±20%. The limit of detection (LOD) is the lowest concentration of 
analyte at which the analyte can reliably be detected in the sample. LLOQ can 
be determined with different procedures. The traditional procedure is to 
determine the LLOQ based on the signal-to-noise ratio (S/N). S/N ratios ≥10 and 
≥3 are required for the LLOQ and LOD, respectively36. However, this method is 
quite difficult if matrix peaks are eluted close to the peak of interest. 
 
An alternative procedure is to determine the LLOQ based on the specific 
calibration curve. For chromatographic assays, LOD and LLOQ can also be 
defined in terms of the lowest concentrations of calibrator which are within the 
acceptable precision and accuracy if results are reported above the value of the 
lowest calibrator. Moreover, calibration curves used in the method must be in 
the determination range with acceptable precision and accuracy, and therefore 
LOD and LLOQ do not need to be determined experimentally40. 
 
4.5 Accuracy and precision 
Accuracy is defined as the closeness of a test result to a reference value. To 
determine the accuracy of method, both systematic and random effects need to 
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be assessed. Therefore, the measurement of accuracy normally includes both 
“precision” for random error and “trueness” for systematic error36. 
 
Precision is defined as the closeness of agreement between independent test 
results obtained under stipulated conditions37,41. Precision is the measurement of 
random error and is not the measurement of true value. Measurements of 
precision are carried out using two main conditions; “repeatability” also called 
“intra-assay precision” and “reproducibility” also called “inter-day precision”. 
Repeatability expresses the precision under the same analysis conditions such as 
replicate single analyses on one instrument over a short timescale whereas 
reproducibility expresses the precision on different instruments, with different 
analysts, over an extended period of time or between laboratories. The precision 
of a method is measured in terms of the percentage relative standard deviation 
(%RSD), with an acceptable limit of less than ±20%40. 
 
Trueness is defined as closeness of agreement between the average value 
obtained from a series of test results and an accepted reference value41. 
Trueness is usually determined in terms of bias. Bias is usually measured in 
terms of percentage deviation from the accepted reference value (%bias), with 
an acceptable limit of less than ±20%. 
 
Equation 4-2             Bias(%) = 
𝑋−𝜇
𝜇
 x100 
 
Where 𝑋 is the observed mean value and 𝜇 is the reference value32. 
 
Precision and bias can be determined by analysing quality control (QC) samples 
on the same day and between days using the same extraction and analytical 
method. QC samples should include low, medium and high concentrations of 
analyte related to the method working range. 
 
4.6 Matrix effects 
One parameter that needs to be assessed for LC/MS analysis is the matrix effect. 
This phenomenon was ﬁrst described by Kebarle and Tang in 1993. Matrix effects 
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(also known as ion suppression or enhancement) occur in the ionisation step of 
LC/MS, especially in the electrospray ionisation (ESI) interface. Co-eluting 
compounds can alter the ionisation efficiency by suppression or enhancement of 
the signal depending on the sample preparation procedure, sample matrix, 
mobile phase additives or ionisation interface42-45. Because matrix effects may 
affect validation parameters such as LOD, LLOQ, precision and accuracy, studies 
of ion suppression or ion enhancement need to be an integral part of the 
validation of an LC/MS method. Matrix effects can be examined using two 
methods. The first approach is post-column infusion of a solution of the analyte 
via a post-column tee connection with a syringe pump. However, this approach 
does not provide a quantitative level of matrix effect. A second approach was 
published in 2003 by Matuszewski et al.46 who determined the peak areas of 
analyte in three different sets of samples. Set A is neat standards concentration, 
set B is blank matrix spiked after extraction and set C is blank matrix spiked 
before extraction. This method can calculate matrix effect (ME), recovery (RE) 
and process efficiency (PE) according to the equations below (Equations 4-3 to 4-
5). 
 
Equation 4-3             ME (%) = 
𝐵
𝐴
 x 100 
 
Equation 4-4             RE (%) = 
𝐶
𝐵
 x 100 
 
Equation 4-5             PE (%) = 
𝐶
𝐴
 x 100 
 
Matrix effect assessment in this study was determined using the second 
approach. Replicate neat standards and blank samples obtained from five 
different sources spiked after and before extraction at low and high 
concentrations were evaluated. 
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Chapter 5 Gas chromatography/mass spectrometry 
(GC/MS) 
5.1 Introduction 
Gas chromatography (GC) is one of the most widely used separation and 
quantitation techniques for volatile and thermally stable compounds in 
analytical chemistry. Not only separating and analysing compounds, GC can also 
be used as a sample preparation technique to purify compounds from a mixture. 
The mass spectrometer (MS) is one of the most powerful GC detectors, that 
provides high selectivity and sensitivity, and the mass spectrum can be used for 
spectral library matching.  
 
Both GC and MS were developed in the beginning of the 1900s and the first 
application of the gas-liquid chromatography (GLC) technique was published in 
1952 by James and Martin47. Nowadays, gas chromatography in combination with 
a mass spectrometric detector (GC/MS) is the most frequently used 
chromatographic technique in modern forensic toxicology laboratories, 
especially in amphetamine-type stimulants determination47-49. 
 
5.2 Gas chromatography 
Chromatography (“colour writing”) is a generic term for separation processes 
involving differential partitioning of the components to be separated between a 
mobile and stationary phase. The chromatography technique was developed by 
Russian scientist Mikhail Tswett for the separation of plant pigments in the early 
1900s. 
 
Gas chromatography is a separation technique in which the mobile phase is a 
carrier gas such as helium or nitrogen and the stationary phase is a solid support, 
usually coated with liquid polymer. GC is usually used for separating small, 
volatile and thermally stable compounds. The volatility of a compound depends 
on the size and polarity of the molecule. Therefore, GC techniques are suitable 
for nonpolar or weakly polar compounds with a molecular mass and boiling point 
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below 600 Da and 500oC, respectively. A GC system includes the carrier gas 
supply, injector, column, column oven and connection to the detector. 
 
To separate the compound, a sample is introduced to the GC column via the 
injector and heated at a temperature in the inlet sufficient to volatilise the 
sample into the gas phase. The sample is transferred to the analytical column 
(containing the stationary phase) and carried to the detector by a carrier gas 
(usually helium). Each compound is eluted from the GC column at a different 
time resulting in a different “retention time” for each of the individual analytes. 
The GC separation is dependent on the vaporisation of compounds, the polarity 
of the stationary phase (column) and the temperature that is applied to the GC 
oven (usually up to 350oC). Today, the most widely used GC columns are fused 
silica capillary columns; a long narrow capillary tube coated on the inner wall of 
the tube with a thin film of a highly viscous polymeric liquid (usually chemically 
bonded to the surface of the silica) or a thin layer of an adsorbent50. 
 
There are many detectors that can be used with GC of which some are 
destructive such as the flame ionisation detector (FID), the nitrogen-phosphorus 
detector (NPD), the flame photometric detector (FPD) and the mass 
spectrometer (MS) and some are non-destructive such as the thermal 
conductivity detector (TCD) and the electron capture detector (ECD)51. The FID 
has been the most common GC detector since 1958. The FID is virtually a 
universal detector for organic compounds whereas the NPD is only suitable for 
nitrogen and phosphorus-containing compounds. The TCD is also a universal 
detector that is usually used for compounds that do not give a signal in the FID. 
However, only the mass spectrometer was used in this work. 
 
5.3 Mass spectrometry 
5.3.1 Introduction 
Mass spectrometry is an analytical method that is often used to identify and 
confirm substances. Mass spectrometry was first developed in 1910 by the 
physicist J.J. Thompson. There are three major components of a mass 
spectrometer: the ion source, mass analyser, and detector. In GC/MS, a fourth 
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component is the interface. After analytes are eluted from the GC column, the 
interface transfers as much of the analytes as possible into the mass 
spectrometer. Analytes are ionised in the ion source (usually by electron impact 
ionisation, EI) to form a charged molecular ion and subsequent fragment ions. 
Ions are transferred to the mass analyser to separate them according to their 
mass-to-charge ratio (m/z) values before they arrive at the detector. The 
fragmentation pattern of each compound is characteristic depending on the 
structure of the molecule and the height of each spectral peak relative to other 
peaks provides the details used to distinguish compounds – the so-called “mass 
spectrum pattern”. 
 
5.3.2 Electron impact ionisation  
Electron impact ionisation was first introduced by Dempster in 1921 for the 
measurement of lithium and magnesium isotopes. It is the most common 
technique to form ions in a mass spectrometer that is connected with a gas 
chromatograph (GC/MS instrument). The gaseous molecules enter the ion source 
from the GC/MS interface and ions are produced by directing an electron beam 
into the gaseous molecules. The electron beam is emitted from a heated 
filament made from rhenium, tungsten or platinum. An ionisation energy of 70 
eV is currently used as standard in all commercial GC/MS instruments. This 
energy is enough to lead to the formation of the molecular ion (M+.) and to 
initiate fragmentation processes. Fragmentation mass spectra obtained from EI 
at 70 eV are now generally reproducible between instruments and can be used 
for mass spectral library searching and compound identification52,53. 
 
5.3.3 Quadrupole mass analyser 
A mass analyser is an instrument that can separate ions according to their mass-
to-charge ratios. There are many types of mass analyser used in forensic 
toxicology such as the quadrupole, ion trap or time-of-flight analysers. However, 
the mass analyser that is usually connected to a gas chromatograph is the 
quadrupole. The principles of the quadrupole mass filter were published in 1953. 
A basic component of the quadrupole mass analyser is a set of four rods 
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(quadrupoles) working with a combination of direct-current (DC) and radio-
frequency (RF) potentials49,53. 
 
The ions created during ionisation are transferred to the mass analyser and are 
detected according to their mass-to-charge (m/z) ratios. Ions are allowed to 
pass through the quadrupole mass analyser depending on the selected mass 
range or m/z ratio by adjusting the DC potential and RF frequency. However, 
the mass range available with a quadrupole mass analyser is limited (typically 
25-1,000 amu). The ions are filtered by the mass analyser and directed toward 
the detector.  
 
Although GC/MS is usually applied in forensic toxicology as a standard technique 
for routine analysis, there are some limitations which apply to this technique for 
non-volatile or thermally labile compounds. 
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Chapter 6 Liquid chromatography/tandem mass 
spectrometry 
6.1 Introduction 
In the last decade, liquid chromatography/mass spectrometry (LC/MS) has 
become more important as an identification and confirmation technique than 
GC/MS in many routine analyses. From the early 2000s, the accuracy, resolution 
and sensitivity of LC/MS have been improved due to the development of 
atmospheric pressure ionisation (API) and electrospray ionisation (ESI) 
techniques54. These techniques offered solutions to the determination of 
compounds having a low concentration, thermal sensitivity, or high polarity. 
 
The increase in routine applications of LC/MS in forensic toxicology is due to the 
ability of LC/MS to separate components of a complex matrix, which assists in 
the identification of a wide range of drugs. Moreover, LC/MS is usually applied as 
a routine method for the analysis of drugs that are not detectable by GC/MS due 
to the properties of the compound, such as thermal instability and/or high 
polarity or due to the limitation of other techniques, such as poor selectivity. LC 
separation coupled with a triple quadrupole mass analyser is a common 
technique and gold standard method for trace analysis or quantitative analysis of 
low concentrations of substances in complex mixtures such as drugs in hair. The 
LC/MS system consists of two main components: the LC system and the mass 
analyser. 
 
6.2 Liquid chromatography 
Liquid chromatography (LC) is a separation technique in which the mobile phase 
is a liquid and the stationary phase is a solid or liquid held on solid support 
particles. Liquid chromatography can be applied to the analysis of any compound 
with solubility in a liquid that can be used as a mobile phase. LC separation is 
based on differential partitioning between the mobile and stationary phases. 
Differences in the solubility of compounds in the mobile phase give different 
partition (K) or distribution (D) coefficients resulting in differential retention on 
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the LC column (containing the stationary phase). Nowadays, LC is referred to as 
column chromatography in which the stationary phase is packed within a tube, 
the “column”. 
 
Nowadays, reversed-phase chromatography (RPC) is the most commonly-used 
technique in forensic and clinical toxicology. RPC is a liquid chromatography 
technique in which the mobile phase is significantly more polar than the 
stationary phase. The separation principle of this technique depends on the 
polarity of analytes in which more polar molecules are more soluble in the 
mobile phase and tend to be eluted earlier. Non-polar molecules in the mobile 
phase tend to absorb on the relatively non-polar packing material in the 
stationary phase which typically contains C8 or C18 carbon chains bonded to 
silica of a chosen particle size and require a less polar mobile phase (usually 
containing an aqueous organic solvent and buffer) for elution. 
 
The basic components of an LC system are the pump, injector, column and 
detector. The mobile phase is delivered through the system via an LC pump, 
typically at a flow rate of 0.1–1 ml/min depending on the type of LC system. The 
majority of pumps currently used in LC are dual piston-type pumps. Extracted 
samples are placed in an autosampler and subsequently injected by syringe into 
the injection port containing a fixed-volume loop held in a six-port valve55,56. 
The injection volume depends on the size of the sample loop which is typically in 
the range 10–100 µl. The sample is carried into the mobile phase and flows 
directly to the LC column which is connected to the MS analyser via the 
electrospray ionisation interface. 
 
The important parts in an LC method are the mobile phase and column. Both a 
single solvent (isocratic elution) and a variable mixture of organic solvents and 
water (gradient elution) can be used as the mobile phase depending on the 
solubility of the compounds and their range of polarities. Separation of analytes 
occurs in the analytical column. LC columns are made from stainless steel tubes 
packed with stationary phase particles inside. There are many types of LC 
column depend on the packing material and chromatography mode such as RP 
columns or ion-exchange columns. For reverse-phase LC, a common analytical 
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column is a C18 substituted silica-based (octadecasilyl, ODS) column which is 
offered in a wide range of particle and pore sizes56. 
 
6.3 Triple quadrupole mass spectrometer 
6.3.1 Introduction 
The principle of LC/MS is to generate ions from either organic or inorganic 
compounds in the MS ion source interface such as the ESI or APCI interfaces, to 
separate these ions by their mass-to-charge (m/z) ratios and to detect them by 
their corresponding m/z and abundances. Ion separation by m/z can be effected 
by static or dynamic electric or magnetic fields depending on the type of MS 
analyser57. However, soft ionisation techniques such as ESI usually produce only 
a single ion - the protonated molecular ion - and no fragment ions. This causes 
problems with respect to identification and quantitation of analytes and so 
LC/MS developed into LC/MS/MS by the introduction of additional components in 
the mass analyser which induce fragmentation of the molecular ion.  
 
An Agilent 6420 Triple Quad LC/MS/MS instrument was used for identification 
and quantitation of analytes in this work. The instrument has three main 
components: the LC system, ion source (ESI) and mass analyser (triple 
quadrupole mass analyser, QqQ). 
 
6.3.2 Electrospray ionisation 
Electrospray ionisation (ESI) is one amongst the group of atmospheric pressure 
ionisation (API) techniques. ESI was first introduced in 1968 by Dole and his 
colleagues and was first coupled to MS by Yamashita and Fenn in 198453. ESI is a 
soft ionisation technique that is able to produce gas-phase ions with no, or little, 
spontaneous decomposition, and is therefore suitable for large, non-volatile and 
chargeable molecules58,59. ESI is a common ion source for LC/MS instruments in 
forensic toxicology because of their applicability to a wide range of compounds. 
 
Modern ESI sources (so-called “ESI interfaces”) are based on the ESI designed by 
Fenn and colleagues in the mid-1980s. LC eluent is introduced into the ESI 
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interface through a capillary tube from the LC column by connecting the tube 
with the ESI inlet. Eluent is nebulised through the fine capillary needle which 
has applied to it a very high negative or positive potential of 3–4 kV and forms 
highly charged liquid droplets (“Taylor cone”) before passing through a 
countercurrent stream of hot nitrogen gas to vaporise the solvent. The droplets 
decrease in size and split into micro-droplets (“Coulombic explosion”) and 
subsequently form gaseous ions. Finally, only charged molecules can pass 
through the ion transfer capillary and set of skimmers into the mass analyser. 
Nowadays, solvents are evaporated by either a heated transfer capillary or a 
countercurrent stream of hot nitrogen, the “curtain gas”58. Moreover, a trace of 
formic acid is often added to the mobile phase to aid protonation of the sample 
molecules. 
 
The Agilent® ESI source consists of a needle, nebulising gas and heated nitrogen 
drying gas. To achieve the maximum sensitivity, several parameters such as 
capillary voltage, nebuliser, gas flow and gas temperature need to be optimised. 
 
6.3.3 Triple quadrupole mass analyser 
The word “quadrupole” describes the array of four cylindrical rods that is used 
to generate two electric potentials: radiofrequency (RF) and direct current (DC). 
The potential difference from two of the opposite parallel rods can create an 
oscillating electrical field and only a specified value of m/z will pass through 
this field by adjusting the DC potential and RF on the rods60. 
 
The term “tandem mass spectrometry” is defined as the techniques in which 
mass-selected ions are subjected sequentially (or in tandem) to a second mass 
spectrometric analysis (MS/MS). A triple quadrupole mass analyser (TQMS or 
QqQ) is a tandem-in-space instrument consisting of two quadrupole mass 
analysers (Q1 and Q3) and a collision-induced dissociation (CID) chamber in the 
second quadrupole located between Q1 and Q3. A triple quadrupole mass 
spectrometer works on the same principle as a single quadrupole mass analyser. 
It is a widely used instrument in bioanalysis. The first quadrupole (Q1) is used to 
select target ions from the charged species leaving the ionisation source. The 
selected ions are fragmented in the hexapole or octapole (second quadrupole, 
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“q”) which works as a collision cell with an inert gas such as helium or nitrogen. 
Fragmented ions are selected according to their m/z ratios in the second 
quadrupole mass filter (Q3) and then travel on to the detector. The most 
common detector is the electron multiplier61-64. The detector in the Agilent 6420 
triple quadrupole MS model is the high energy dynode detector. Ions are 
converted to electrons by dynodes before impacting the multiplier to produce 
more electrons. The signal current is converted by an A/D converter and 
transferred to the computer of the MS data acquisition system. 
 
In tandem mass spectrometry, ion fragmentation can be obtained by four main 
mechanisms: (1) collisions of ions with a gas such as collision induced 
dissociation (CID), (2) interactions of ions with electrons such as electron 
capture dissociation (ECD), (3) interactions of ions with surfaces and (4) 
interactions of ions with photons such as infrared multiphoton dissociation 
(IRMPD). However, the most prominent fragmentation technique is CID. Collision 
induced dissociation is a technique to induce fragmentation of gaseous ions. The 
selected ions are usually accelerated and collide with neutral molecules, 
generally helium, nitrogen or argon. Ion fragmentation generated by CID 
depends on a collision energy64. 
 
Tandem mass spectrometry can be performed in different modes such as product 
ion scan mode, in which a parent ion is selected with a given m/z value and its 
product ions are detected selectively, precursor ion scan mode, in which all 
precursor ions of a given fragment ion are detected, and neutral loss scan 
mode64. 
 
Selected reaction monitoring (SRM) is one of the methods used in tandem mass 
spectrometry in which a particular ion is selected in Q1 of a tandem mass 
spectrometer and a product ion from the precursor ion is selected for detection 
in Q3. Multiple reaction monitoring (MRM) is the application of SRM to select 
multiple fragment ions from one or more precursor ions within a single run. MRM 
provides high sensitivity and selectivity for identification and quantitation, 
especially with triple quadrupole instruments62. 
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Chapter 7 New psychoactive substances 
7.1 Introduction 
In 2013, almost a quarter of a billion people between the ages of 15 and 64 years 
were estimated by the United Nations Office on Drugs and Crime (UNODC) to use 
an illicit drug and approximately 27 million people suffered from problem drug 
use, including drug dependence or drug-use disorders65. In recent years, the use 
and production trend of new psychoactive substances (NPS) has been increasing 
globally, especially in Europe, Asia and the Americas66. In 2015, 101 NPS were 
reported to the EU Early Warning System, which was an increase of 25 % 
compared to 201367. 
 
“Designer drugs” or “new psychoactive substances” refers to synthetic analogues 
of controlled substances, usually prepared by modifying the chemical structures 
of existing drugs to varying degrees, which are created and marketed to 
circumvent legislative controls68-70. The term designer drugs has been known 
since 1984 and originally referred to heroin-like synthetic substances71. Designer 
drugs were defined as analogues or chemical cousins of controlled substances 
that are designed to produce effects similar to the controlled substances they 
mimic72. Examples of classical designer drugs are amphetamine derivatives such 
as methylenedioxyamphetamine, methylenedioxymethamphetamine, para-
methoxyamphetamine and fentanyl derivatives such as α-methylfentanyl. 
 
New psychoactive substances are defined as narcotic or psychotropic drugs that 
are not scheduled under the United Nations 1961 or 1971 Conventions, but which 
may pose a threat to public health comparable to scheduled  substances72. The 
word “new” means newly misused or available rather than newly invented which 
distinguishes them from classical illicit drugs such as amphetamine, heroin, 
cocaine and cannabis. There are various different structural types of NPS, such 
as substituted cathinones, synthetic cannabinoids and synthetic hallucinogens. In 
the early 2000s, NPS were subject to a huge explosion in internet marketing and 
were sold not as drugs but as “research chemicals”. Nowadays, NPS are available 
as powders or tablets and have been advertised and sold as “legal highs” with a 
variety of brand names and usually labelled with the phrase “not for human 
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consumption”69. However, almost all of those early substances have already 
been controlled in some countries such as UK, USA, Australia and Japan73,74. 
 
In the global NPS market, UNODC reported in 2014 that synthetic cannabinoids 
continued to be ranked as the first and accounted for 39% of NPS, followed by 
phenethylamine derivatives, accounting for 18%, and synthetic cathinones, 
accounting for 15% of the total number of NPS reported. 450 NPS substances 
have been reported to the UNODC early warning system from 95 member states 
and territories, an increase of 20 new substances from the 430 substances 
reported in 201365. This indicates that the NPS market is very dynamic.  NPS can 
be divided into six main groups according to the active drug substances they 
contain, i.e. phenethylamines, synthetic cathinones, synthetic cannabinoids, 
ketamine, piperazines and plant-based substances75. Ketamine is included 
because, although it has long been known as an anaesthetic, it has more 
recently been subject to abuse in a way similar to other NPS. However, data on 
NPS substances are still limited due to the large number of different NPS 
available on the market, and because almost all NPS have no history of medical 
use. 
 
7.2 Phenethylamine derivatives 
Phenethylamine derivatives or substituted phenethylamines refer to a class of 
compounds derived from phenethylamine with documented psychoactive and 
stimulant effects. Phenethylamine itself is not used as a prescribed drug because 
it is rapidly metabolise with a half-life of 5-10 min. The classical examples of 
compounds in this group are amphetamine-type stimulants such as 
amphetamine, methamphetamine, MDMA and MDA (see Figure 7-1), which have 
been widely abused for more than 20 years. 
 
 
 
Figure 7-1: Structures of amphetamine, phenethylamine and MDA. 
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The new drugs in this class include ring-substituted substances such as 2,5-
dimethoxyphenethylamines (the so-called 2C-X series), the D series drugs e.g. 
2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-chloroamphetamine 
(DOC) and p-methoxy-methamphetamine (PMMA)76. In the 2C-X series, X means 
an atom or chemical group substituted at the 4-position of 2,5-
dimethoxyphenethylamine, such as 2C-B (4-bromo-), 2C-I (4-iodo-) and 2C-T-2 
(4-ethyl-thio-)68. The psychoactive effects of 2C series drugs have been reported 
to be dose dependent, ranging from mere stimulant effects at lower doses to 
stimulant plus hallucinogenic and entactogenic effects at higher doses77. 
Moreover, the number of drugs in this class increased after the publication of 
the book “PIHKAL” (Phenethylamines I Have Known And Loved, 1991) which 
presented synthesis instructions and pharmacological explorations of hundreds of 
substances by Dr Alexander and Ann Shulgin78. Although some classical 
phenethylamine derivatives such as amphetamine, MDMA, PMA, 2C-B and 4-
methylthioamphetamine (4-MTA) are listed in Schedules I and II of the UN 
Convention on Psychotropic Drugs 1971, most of the new drugs such as the 2C-
series and the D-Series are not under international control. Among the 
phenethylamines, PMA, PMMA and 4-methylthioamfetamine (4-MTA) have more 
often been reported in association with drug-related deaths than other drugs75. 
 
The following sections deal with phenethylamines which were selected for study 
in the present work. 
 
7.2.1 3,4-Methylenedioxymethamphetamine (MDMA) 
3,4-Methylenedioxy-methamphetamine (MDMA, also known as “Adam”, 
“ecstasy”, “beans”, “E”, “X” “XTC” or “the love drug”) is a psychoactive 
compound. It was first synthesised by the German pharmaceutical company 
Merck under the name of “methylsafrylamin” in 1912 and was approved as a 
precursor for therapeutically active compounds79,80. MDMA was used as a 
therapeutic drug for couples therapy and anxiety disorders by psychotherapists 
in the mid-1970s and was first identified in street use by Gaston and Rasmussen 
in 197277. Abuse of MDMA become widespread from the late 1970s and early 
1980s primarily in California, Florida, New York and Texas as a so-called 
“wonder drug”81.  Because of the growing abuse of MDMA, it was categorised in 
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1977 under the UK Misuse of Drugs Act 1971 as a class A drug and placed in 
Schedule I of the Controlled Substances Act on May 31, 1985 by the US Drugs 
Enforcement Administration. 
 
7.2.1.1 Chemical properties 
MDMA is a ring-substituted amphetamine derivative structurally similar to 
methamphetamine and mescaline (a phenethylamine-type hallucinogen, see 
Figure 7-2). It is a semi-synthetic substance that can be synthesised from plant 
oils including saffron, sassafras, mace, nutmeg, dill, vanilla bean and parsley82. 
MDMA has a chiral centre with two enantiomeric forms (S-(+) MDMA and R-(-) 
MDMA) which have different stereoselective metabolism, different 
pharmacologic activity and different body disposition. Compared with the R-
isomer, S-MDMA is responsible for the empathic and psychostimulant effects83. 
However, MDMA is commonly sold in the illicit drug market as tablets that 
contain 50-150 mg of a racemic mixture of MDMA.HCl in a variety of shapes, 
colours, commercial logos or stamped figures70,84,85. 
 
 
Figure 7-2: Structures of methamphetamine, mescaline and MDMA (* chiral 
centre). 
 
7.2.1.2 Metabolism and excretion 
MDMA is typically taken by oral administration and is well absorbed from the 
gastrointestinal tract. The peak plasma concentration is obtained approximately 
2-3 h after administration and the plasma half-life ranges from 6 to 9 h86. MDMA 
is metabolised by cytochromes P450 2D6, 1A2, 2B6 and 3A4 through two main 
metabolic pathways. The major metabolic pathway in humans is preliminary 
demethylenation of the methylenedioxy ring to the intermediate metabolite 3,4-
dihydroxymethamphetamine (HHMA) followed by O-methylation to 4-hydroxy-3-
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methoxymethamphetamine (HMMA) catalysed by catechol-O-methyltransferase 
(COMT), see Figure 7-3. A minor pathway is N-dealkylation at the side chain to 
form a primary amine (3,4-methylenedioxyamphetamine, MDA) followed by 
demethylenation of the methylenedioxy ring to the intermediate metabolite 3,4 
dihydroxyamphetamine (HHA) and further O-methylation to 4-hydroxy-3-
methoxyamphetamine (HMA) catalysed by COMT87. CYP2D6 is the most important 
isoenzyme of cytochrome P450 regulating the demethylenation reaction88. The 
dihydroxy-metabolites, HHMA and HHA can undergo sulphate conjugation, while 
HMMA and HMA can be conjugated with both glucuronide and sulphate. These 
metabolites are mostly present in plasma and urine as their conjugated forms83. 
However, MDMA is excreted primarily in the unchanged form in human urine and 
HMMA and HHMA are reported to be the major urinary metabolites.  
 
 
 
 Figure 7-3: Chemical structures of MDMA and its metabolites. 
 
 
Studies of MDMA and its metabolites have been reported and published since the 
early 1980s. MDA was identified as an MDMA metabolite in humans in 1988 by 
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Verebey et al.89 In 1996, Helmlin et al.90 reported an analytical method for 
MDMA and its metabolites in human plasma. Plasma and urine samples were 
obtained from male and female patients over the period 0-530 min after oral 
administration of 1.5 mg MDMA per kg body-weight. MDMA was detected in 
plasma 15-30 min after administration and reached peak plasma levels 120 min 
after administration. The results showed that the major urinary metabolite of 
MDMA in human is 4-hydroxy-3-methoxymethamphetamine (HMMA). 4-hydroxy-3-
methoxyamphetamine (HMA) and 3,4-dihydroxymethamphetamine (HHMA) are 
formed as intermediate metabolites. 
  
Segura et al.91 described an in vivo metabolism study of MDMA in humans. 
Plasma and urine samples were obtained from four healthy male volunteers 
before and at intervals 0-24 h after the oral administration of a single 100 mg 
dose of MDMA. HHMA was reported as one of the major metabolites of MDMA and 
contributed approximately 18% of total MDMA dose recovery. The Cmax of HHMA 
was 0.155 µg/ml and AUC0-24h was 1.99 µg.h/ml which were similar to those 
obtained for MDMA (0.18 µg/ml and 1.47 µg.h/ml).  
 
In 2004, Jenkins et al.92 reported the determination of MDMA and its metabolites 
(MDA and HMMA) in three case studies. MDMA in human urine was detected at 
concentrations ranging from 6.8-12.6 µg/ml, MDA from 0.1-0.7 µg/ml and HMMA 
from 1.1-6.1 µg/ml. In 2006, Pirnay et al.93 developed a GC/MS method for 
measurement of MDMA and its metabolites (MDA, HMA, and HMMA) in human 
urine. A participant received 1.6 mg/kg oral MDMA and a urine specimen was 
collected at 1.2 h after administration. MDMA was detected in the urine at a 
concentration of 1.46 µg/ml, MDA at 0.047 µg/ml, HMA at 0.029 µg/ml and 
HMMA at 4.26 µg/ml. 
 
Shima et al.94 reported the determination of MDMA main metabolites, including 
the sulphate and glucuronide conjugates of HHMA, in humans and rats.  Human 
urine samples were obtained from 25 MDMA users. Rat urine samples were 
obtained from two male Wistar rats that were administered a single oral dose of 
3 mg/kg MDMA and urine was collected for 24 h. The human urinary 
concentrations ranged from 2.1-134 µg/ml for MDMA, 0.29-8.1 µg/ml for MDA, 
0.04-2.3 µg/ml for HMMA, <0.006-0.14 µg/ml for 3-OH-4-MeO-MA, 0.5-32.3 
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µg/ml for HMMA-Gluc and 1.8-55.6 µg/ml for HMMA-Sul. The concentrations of 
free-form 3-OH-4-MeO-MA were ten times lower than those of HMMA. The 
concentration of HMMA-Sul was higher than HMMA-Gluc in all samples. The ratio 
of HMMA-Sul to HMMA-Gluc ranged from 1.6 to 9.9 and the conjugated 
percentage of HMMA ranged from 72.7-99.3%. 
 
7.2.1.3 Toxicity of MDMA 
MDMA is a central nervous system (CNS) and sympathetic nervous system (SNS) 
stimulant which acts by releasing serotonin, dopamine and norepinephrine and 
by inhibiting their reuptake86. Consumption of MDMA is well known to be 
associated with acute or long-term neurotoxic effects and it is the most 
concerning issue of MDMA misuse95. Neurotoxic effects of MDMA include 
confusion, anxiety, depression and the loss of some cognitive functions such as 
memory and performance of complex tasks7,83,96. In animal experiments, direct 
injection of MDMA into rat brain does not generate the neurotoxic effects that 
were observed after peripheral administration8,97,98. These results suggest that 
neurotoxicity of MDMA results from its metabolites rather than from MDMA itself. 
 
7.2.2 para-Methoxyamphetamine (PMA) 
para-Methoxyamphetamine (PMA), also known as 4-methoxyamphetamine or 
“Death”, appeared in the illicit drugs market and was reported in 1973. It was 
produced by a clandestine laboratory in Canada. Even though PMA appeared 
more than 40 years ago, it was not included in the controlled substance 
legislation in some countries such as Israel99. PMA is one of a group of 
methoxylated phenethylamine derivatives that has strong hallucinogenic 
properties100 and is more toxic than MDMA101. It has been used as an illicit drug 
and has approximately 5 times the potency of mescaline102. 
 
7.2.2.1 Chemical properties 
PMA is an amphetamine derivative with a methoxy substituent at the 4-position 
of the benzene ring, see Figure 7-4. PMA alone or in combination with other 
drugs has frequently been found on the black market as “ecstasy”. PMA is 
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typically administered both orally and intravenously. It has different forms such 
as powder, pill or capsule. The usual dose in one tablet or capsule ranges from 
25-100 milligrams103. PMA is also one of the metabolites of amphetamine104 and 
PMMA104,105. However, few metabolism studies of PMA have been published. 
 
 
 
Figure 7-4: Chemical structures of amphetamine and PMA. 
 
7.2.2.2 Metabolism and excretion 
Previous studies on PMA and para-methoxymethamphetamine (PMMA) 
metabolism have shown that PMA has a variety of metabolic pathways similar to 
amphetamine. PMA is metabolised by cytochromes P450 2D6, 1A2 and 3A4106. 
The major metabolic pathway of PMA is O-demethylation to para-
hydroxyamphetamine (PHA), followed by hydroxylation at the 3´-position and 
then methylation by COMT of the 3´- or 4´-hydroxy group (4-HMA or 3-
HMA)107,108. A minor metabolic pathway is beta-hydroxylation of the side chain to 
form β-hydroxy-PMA, followed by 4-hydroxylation to 4-hydroxynorephedrine (see 
Figure 7-5)105. PHA (free and conjugated) has been reported as a major 
metabolite of PMA excreted in human urine109. 
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Figure 7-5: Chemical structures of PMA and its metabolites. 
 
Studies of PMA metabolites were first reported and published in the early 1970s. 
PHA was identified as a major metabolite of PMA in humans in 1979 by Kitchen 
et al.109 However, no in vivo metabolism studies of PMA were published after 
1979 until 2015. Lai et al.110 reported in vitro drug metabolism studies on seven 
phenethylamine-based designer drugs in humans using HLM. PHA was reported as 
the main phase I metabolite of PMA in HLM samples. Although no metabolism 
studies of PMA were published from 1979 until 2015, deaths related to PMA have 
been reported as recently as 201299. 
 
7.2.2.3 Toxicity of PMA 
Like MDMA, PMA is a central nervous system (CNS) stimulant that can produce 
hallucinogenic effects. The toxic effects of PMA have sympathomimetic and 
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serotonergic symptoms such as nausea, anxiety, agitation, hyperthermia and 
arrhythmia. Ling et al.111 reported a retrospective study of PMA poisoning cases. 
Symptoms of patients with PMA poisoning were tachycardia, hyperthermia, 
seizures, arrhythmias and coma. Moreover, two patients presented with severe 
hypoglycaemia with hyperkalaemia. PHA has been reported to be more potent 
than the parent compound in evoking neurotransmitter release and inhibiting 
dopamine reuptake112. 
 
Deaths from PMA were first reported in 1974 by Cimbura113. Nine deaths due to a 
new street drug, PMA, were found in Ontario. PMA was reported to have a 
powerful hallucinogenic effect with high toxicity. In 1998, Felgate et al.114 
reported six deaths involving PMA in Australia. Femoral blood PMA levels were 
reported in the range from 0.24 to 4.9 µg/ml (mean, 2.3 µg/ml) and liver PMA 
levels ranged from 1.4 to 21 mg/kg (mean, 8.9 mg/kg). Moreover, blood PMA 
levels greater than 0.5 µg/ml were reported to be associated with toxic effects. 
Kraner et al.106 also reported three fatalities related to PMA in the USA in 2001. 
Post mortem blood PMA concentrations were 1.07, 0.60 and 1.90 µg/ml and 
symptoms that were observed included hyperthermia, agitation, bruxism, 
convulsion and haemorrhage. In 2001, Martin reported three fatality cases from 
PMA overdose. Peripheral PMA blood levels were 0.6, 0.6 and 1.3 µg/ml115. 
 
In 2003, Refstad116 reported a lethal case from PMA poisoning in Norway. PMA 
was found to be more toxic than MDMA and to have a delayed effect after intake 
compared with MDMA that led to hypoglycaemia and hyperkalaemia. Moreover, 
an outbreak of PMA and PMMA poisoning cases in Israel was reported in 2012 by 
Luria et al.99 Twenty-four deaths involved with PMA and PMMA were reported 
and mean post mortem PMA and PMMA blood concentrations were 2.72±1.67 and 
0.35±0.24 µg/ml, respectively. 
 
7.3 Synthetic cathinones 
Cathinone is a principal psychostimulant ingredient in the leaves of the Catha 
edulis plant, commonly known as khat. It is the prototype of a wide range of 
psychoactive substances that have been developed, the so-called “synthetic 
cathinones”. The original habitat of the khat shrub was in the Horn of Africa and 
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the Arabian Peninsula and it is still particularly associated with Yemen. It has 
been known for several hundred years that chewing khat leaves produces 
psychostimulant effects such as euphoria117,118. The active substance “cathine” 
was first isolated from khat leaves in 1930 and it has the same chemical 
structure as d-norpseudoephedrine (see Figure 7-6), an alkaloid present in 
Ephedra species.  Methcathinone, the first of the cathinone derivatives, was 
originally synthesised for therapeutic purposes in 1928 and was marketed as an 
antidepressant during the 1930s and 1940s. In 1975, cathinone was isolated from 
the fresh leaves of khat and is 7 to 10 fold more potent than cathine but is less 
potent than amphetamine or methamphetamine. However, cathinone is unstable 
and degrades rapidly. It can undergo transformations to complex substances by 
rearrangement to cathine or isocathinones and form cyclic pyrazines.  Abuse of 
methcathinone (so-called “Cat” or “Jeff”) has been widespread in the Soviet 
Union from the 1970s and subsequently in the USA, particularly in Michigan, from 
the early 1990s. Finally, cathinone, cathine and methcathinone were controlled 
under Schedule I of the UN Convention on Psychotropic Substances in the early 
1990s119. 
 
 
 
Figure 7-6: Structures of phenethylamine, cathinone and cathine. 
 
The characteristic feature of substances in this group is the presence of a ketone 
group attached at the beta position on the side chain of the phenethylamine 
moiety (β-keto (bk) substituted phenethylamines or β-keto amphetamines 
derived from cathinone). There is no published clinical trial of current synthetic 
cathinones in humans, only some in vitro metabolism data are available. 
Pharmacologically synthetic cathinones are similar to amphetamine, MDMA and 
cathinone due to the shared features of their chemical structures120. The effects 
of synthetic cathinones include euphoria, increased energy, increased blood 
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pressure, vasoconstriction, increased heart rate, hyperthermia, agitation and 
aggression121. 
 
In the mid-2000s, synthetic cathinones appeared on the illicit drug market and 
increased in popularity due to their psychostimulant effects, similar to 
amphetamine-type stimulants, and their low prices compared with cocaine or 
MDMA. Methylone, the first synthetic cathinone, was reported to the European 
Monitoring Centre on Drugs and Drug Addiction (EMCDDA) in 2005.75 Nowadays, 
synthetic cathinones represent approximately 15% of the NPS available in illicit 
drug markets and most of them have been produced in China and South East Asia 
countries.  
 
 
 
Figure 7-7: Chemical structures of well-known synthetic cathinones. 
 
Some well-known synthetic cathinones are mephedrone (4-methylmeth-
cathinone), methylone (3,4-methylenedioxy-methcathinone), butylone (β-keto-
N-methyl-3,4-benzodioxyoly-butanamine), methedrone (4-methoxymeth-
cathinone), MDPV (methylenedioxy-pyrovalerone), 4-MEC (methylethcathinone), 
3-FMC (3-fluoromethcathinone), 4-FMC (4-fluoromethcathinone), buphedrone (α-
methylaminobutyrophenone) and naphyrone (naphthylpyrovalerone), see Figure 
7-7. Synthetic cathinones have been sold in internet shops as “legal highs”, 
“bath salts” or “plant food” with “not for human consumption” on the label to 
circumvent the Medicines Act 1968122,123. 
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7.3.1 Methylone 
Methylone was first synthesised by Jacob and Shulgin as an antidepressant and 
anti-Parkinsonian agent in 1996 and first appeared in the illicit drug market 
mixed with mCCP (meta-chlorophenylpiperazine) under the trade name 
“Explosion”. 
 
7.3.1.1 Chemical properties 
Methylone (3,4-methylenedioxy-N-methylcathinone or bk-MDMA) is a ring-
substituted N-methylcathinone derivative and it is a β-keto analogue of MDMA. 
Methylone hydrochloride salt is a white powder which is soluble in water. 
Because of the chiral centre at the C-2 carbon, methylone has two enantiomers, 
R-methylone and S-methylone, of which the S-form is more potent than the R-
form, similar to MDMA124. 
 
7.3.1.2 Metabolism and excretion 
A few previous studies on the metabolism of methylone found that methylone is 
metabolised through two main metabolic pathways, similar to MDMA. The major 
metabolic pathway in humans is preliminary demethylenation of the 
methylenedioxy ring to 3,4-dihydroxymethcathinone, followed by catechol-O-
methyltransferase (COMT)-catalysed methylation to 3-hydroxy-4-
methoxymethcathinone or 4-hydroxy-3-methoxymethcathinone plus subsequent 
conjugation with (mostly) glucuronide or sulphate. A minor pathway is N-
dealkylation at the side chain to form 3,4-methylenedioxycathinone, a primary 
amine, which is then partially conjugated (see Figure 7-8). In vitro studies found 
that methylone is metabolised mainly via CYP2DC and to a lesser extent via 
CYP1A2, CYP2B6 and CYP2C19120. 
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Figure 7-8: Chemical structures of methylone and its metabolites. 
 
Phase I metabolism of methylone in humans and rats was first studied by Kamata 
et al.125 in 2006. In human urine, 4-hydroxy-3-methoxymethcathinone (HMMC) 
and 3-hydroxy-4-methoxymethcathinone (3-OH-4-MeO-MC) were reported as 
major urinary metabolites and 3,4-methylenedioxycathinone (MDC) as a minor 
metabolite. In addition, no trace of β-keto reduction metabolite 3,4-
methylenedioxyephedrine (MDEP) was detected. Moreover, this study suggested 
that not only HMMC and 3-OH-4-MeO-MC can conjugate with both glucuronide 
and sulphate but also methylone and MDC. In 2010, Meyer et al.126 found an 
additional methylone metabolite, 4-hydroxy-3-methoxycathinone (4-HMC) in 
human urine samples. 
 
In 2012, MDC, dihydro-methylone and N-hydroxy-methylone were reported as in 
vitro methylone metabolites in HLM by Mueller and Rentsch127. Pederson et al.128 
also reported the in vitro metabolism of methylone using HLM and human liver 
S9 fraction in 2013. 3,4-Dihydroxymethcathinone (HHMC), the intermediate 
metabolite leading to HMMC, was first determined as a main metabolite of 
methylone. Moreover, N-hydroxy-methylone, dihydro-methylone and nor-
methylone were also detected in the in vitro experiments. 
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In 2015 Chen129 reported the metabolism of four designer drugs using rat liver 
microsome S9 fraction with analysis using LC-ion trap MS. An aliphatic hydroxy 
metabolite (3-OH-4-MeO-methcathinone) was identified as the main metabolite 
of methylone in rats. Moreover, Ellefsen  et al.130 also identified HHMC, HMMC 
and MDC as methylone metabolites in rat urine. 
 
7.3.1.3 Toxicity of methylone 
Methylone is a central nervous system (CNS) stimulant that can produce 
hallucinogenic effects by increasing the concentrations of monoamine 
neurotransmitters in the synaptic cleft. The presence of the β–keto moiety in the 
structure of synthetic cathinones increases their polarity and decreases their 
ability to cross through the blood-brain barrier131. The effects of methylone are 
comparable to MDMA but are slightly milder. Cozzi et al.132 reported that 
methylone is less potent than its phenylalkylamine analogue MDMA in an in vitro 
neurotransmitter uptake inhibition test. Methylone was more effective against 
serotonin uptake but less effective at inhibiting dopamine and norepinephrine 
uptake than was methamphetamine124. 
 
Elliott and Evans133 reviewed case data for a three-year period and reported 
methylone concentrations of 0.1, 4.31 and 11.0 µg/ml in post mortem blood. 
The second of these involved a 25-year old female who died after a party. A high 
concentration (5.83 µg/ml) of 4-MEC, see Figure 7-7, was also found in the 
blood. No additional information is available on the other two cases. 
 
McIntyre et al.134 reported a case involving A 19-year-old woman who was known 
to use illicit drugs who was found floating in the ocean 100 yards from the 
beach. The autopsy findings were consistent with drowning.  Post mortem blood 
screened positive for methamphetamine by ELISA and methylone was 
subsequently detected at concentrations of 3.4 µg/ml, 3.4 µg/ml, 4.3 µg/ml, 11 
mg/kg and 1.7 mg in the peripheral blood, central blood, vitreous, liver and 
gastric contents respectively. No other ATS were detected. 
 
Cawrse et al.135 reported 4 post mortem cases involving methylone. The first 
involved a 19-year old who died during exercise. The cause of death was cardiac 
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arrest associated with methylone which was found in cardiac blood at a 
concentration of 0.74 µg/ml, in peripheral blood at 0.67 µg/ml and in urine at 
38 µg/ml. The second incident involved the suicide by gunshot of a 38-year old 
male and the homicide of his 35-year old girlfriend. In the male, methylone was 
found in heart blood at 0.11 µg/ml and in urine at 0.25 µg/ml and in the female 
it was found in heart blood at 1.1 µg/ml. MDPV was also found in blood from the 
female at a concentration of 0.03 µg/ml. The fourth death involved the suicidal 
drowning of a female following a police car chase. Methylone was found in heart 
blood at a concentration of 0.06 µg/ml. MDPV was also found at a concentration 
of 0.47 µg/ml. 
 
A case of sudden cardiac death was reported by Carbone et al.136 involving a 
previously healthy 19-year-old man who collapsed while jogging outdoors in 
warm weather. Methylone was detected in post mortem blood at a 
concentration of 0.7 µg/ml. 
 
Pearson et al.137 reported three fatal intoxications due to methylone, all of 
which displayed symptoms of seizure-like activity and elevated body 
temperatures before death. Peripheral blood methylone concentrations were 
0.84, 3.3 and 0.56 µg/ml. The authors concluded that peripheral blood 
methylone concentrations in excess of 0.5 µg/ml may result in death due to its 
toxic properties, which can include elevated body temperature and other 
sympathomimetic-like symptoms. 
 
7.3.2 Butylone 
7.3.2.1 Chemical properties 
Butylone (2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one or bk-MBDB) 
is a ring-substituted N-methylcathinone derivative. Butylone is a β-keto analog 
of 1,3-benzodioxolyl-N-methylbutanamine (MBDB). Butylone has appeared in 
illicit drug markets as a methylone alternative drug and has been controlled in 
some countries such as Japan as a “designated substance”74. 
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7.3.2.2 Metabolism and excretion 
A few previous studies126,127,138 on the metabolism of butylone found that it is 
metabolised through three main metabolic pathways. The major metabolic 
pathway in humans is preliminary demethylenation of the methylenedioxy ring 
(dihydroxy metabolite), followed by catechol-O-methyltransferase (COMT)- 
catalysed methylation (4-OH-3-MeO metabolite or 3-OH-4-MeO metabolite) and 
subsequent conjugation with (mostly) glucuronide or sulphate. A minor pathway 
is N-dealkylation at the side chain to form a primary amine (nor-butylone or bk-
BDB) which is then partially conjugated, see Figure 7-9. Both metabolic 
pathways are similar to the metabolic pathway of MDMA. Moreover, the other 
major metabolic pathway that was reported by Zaitsu et al. is β-ketone 
reduction to amino-alcohol, β-OH-MBDB138. 
 
 
 
 
Figure 7-9: Chemical structures of butylone and its metabolites. 
 
Only a few studies have been reported for butylone and its metabolites. Phase I 
metabolites of butylone in human urine were first investigated by Zaitsu et al.138 
in 2009. A 4-OH-3-MeO metabolite and its isomer 3-OH-4-MeO metabolite were 
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reported as major metabolites and nor-butylone (bk-BDB) as a minor metabolite. 
However, the urinary ratios of 3-OH-4-MeO metabolite to 4-OH-3-MeO 
metabolite seemed higher than the urinary ratio of 3,4-HMMA to 4,3-HMMA the 
corresponding metabolites of MDMA. In addition, the β-ketone-reduced 
metabolite (β-OH-MBDB or dihydro-butylone) was identified in hydrolysed human 
urine samples. 
 
Mayer et al.126 reported a detection method for mephedrone, butylone and 
methylone and their metabolites in human and rat urine using GC/MS with 
derivatisation. Nor-butylone, butylone-metabolite (demethylenyl-methyl-) and 
dihydro-butylone were detected in both rat and human urine following analysis 
of their acetyl derivatives. All metabolites that were reported in that paper are 
consistent with the previously published work by Zaitsu et al.138 
 
In 2012 Mueller and Rentsch127 also studied the metabolism of 11 cathinones 
using automated online human liver microsomes with subsequent identification 
by LC/MS(n). A nor-metabolite and a hydroxy-metabolite were found as butylone 
and ethylone metabolites. However, the keto-reduction metabolites were not 
observed. 
 
7.3.2.3 Toxicity of butylone 
Little pharmacological literature for butylone is available. However, based on its 
structural similarity to methylone, butylone is likely to have stimulant effects on 
CNS along with hallucinogenic properties. Some drug forums report personal 
effects from butylone which are similar to methylone such as increase in energy, 
stimulation and euphoria139. An on-line drug forum reports doses in the range 20-
210 mg (threshold to strong doses, respectively)140.  
 
Some reports have appeared in the literature describing bioanalysis of butylone, 
often in combination with other drugs, but most do not contain quantitative 
analytical results118,141-143.  
 
A non-fatal case was reported by Wood et al.142, involving a 31 year old male 
who ingested 1 g of a powder containing butylone and 3,4-methylenedioxy-
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pyrovalerone (MDPV). Prior to arriving at a hospital emergency department, he 
had experienced an “intense high” and “racing heart” which persisted for 
several hours, along with insomnia, sweating, abdominal discomfort and 
“fluctuating body temperature. On hospital admission, 30 h after the ingestion, 
he had difficulty in sleeping, anxiety, agitation and dilated pupils. He was 
discharge 4 h after admission. 
 
A case of acute liver failure was reported in Ireland involving a 28 year old male 
who presented at the emergency department with symptoms which included 
acute psychosis, tachycardia, hypertension, hyperthermia and profuse 
sweating144. He had ingested twelve tablets containing butylone and MDPV 
although a detail of the composition of these is not known. The patient 
developed rhabdomyolysis and then acute liver failure, two days after 
admission. However, he was able to be discharged four days after admission. 
Preparations containing butylone and MDPV have also been reported in the UK145.  
 
A fatal case was reported by Warrick et al.146 dealing with simultaneous 
ingestion by a healthy 24 year old female of two capsules, each containing an 
estimated dose of 422 mg methylone and 53 mg butylone. The patient was 
admitted in an comatose state with hyperthermia, tachycardia, tachypnoea and 
hypertension. Despite treatment she subsequently died 48 h after admission due 
to multiple organ failure and death was attributed to serotonin syndrome. 
Qualitative urinalysis found only methylone and butylone.  
 
Another fatal case was reported in Poland, following the suicidal ingestion of 
twelve tablets containing butylone by a 21 year old male147. On hospital 
admission, he was conscious but confused, with tachycardia, hypertension, 
dilated pupils, hyperthermia and cariac arrhythmia. He subsequently developed 
seizures and died four hours and forty minutes after admission. Toxicological 
analysis gave butylone concentrations of 20 mg/l blood and 33 mg/kg liver. 
 
Elliott and Evans133 reviewed case data for a three-year period and reported 
butylone concentrations of <0.125 and 1.72 µg/ml in post mortem blood, but no 
additional information is available on these two cases. 
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No fatal cases involving butylone have been reported by Forensic Medicine and 
Science, University of Glasgow. 
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Chapter 8 In vitro and in vivo metabolism studies 
on MDMA using human liver microsomes 
and LC/MS/MS with chemical 
derivatisation 
 
8.1 Introduction 
In the past decade, the United Nations Office on Drugs and Crime (UNODC) has 
reported that amphetamine-type stimulants such as amphetamine, 
methamphetamine and MDMA are amongst the most widely used illicit drugs 
globally66.  MDMA is listed under the Misuse of Drugs Act 1971 as a Class A, 
Schedule 1 drug (for example, it has a high potential for abuse,  with no 
accepted medical application)148. MDMA has been reported to be safe by 
psychotherapists and users, however. Five deaths associated with the use of 
MDMA were reported in 1987 by Dowling et al.149 Moreover, in 1992 Henry et 
al.150 reported seven deaths from MDMA misuse in which the MDMA toxicity 
pattern included convulsions, fulminant hyperthermia, disseminated 
intravascular coagulation, rhabdomyolysis, and acute renal failure. The numbers 
of MDMA-related fatalities and emergency room admissions have led to 
pharmacology and toxicity studies on this substance. Previous studies7 in animals 
suggested that metabolites of MDMA have developed selective neurotoxic effects 
on the central serotonergic system. Moreover, MDA itself has been popular as a 
drug of abuse during the 1960s although several deaths related to MDA overdose 
have been reported151. 
 
For MDMA analysis, the usual screening method involves immunoassay, which is 
generally not sufficiently specific to distinguish between MDMA and its 
metabolites. For example, the immunoassay method for MDMA in the forensic 
toxicology laboratory, University of Glasgow uses Immunalysis® ELISA kits and the 
antibodies of these kits cross-react with both MDA and HMA. Routine analysis of 
MDMA in biological specimens such as serum, blood or urine detected only MDMA 
itself and MDA as an MDMA metabolite. However, MDA is a minor metabolite of 
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MDMA in humans whereas major metabolites in humans are HHMA and HMMA. 
Abraham et al.152 reported that HMMA was detected in urine samples longer than 
its parent MDMA in all participants after single dose oral administration of MDMA 
at 1.0 mg/kg (low dose, n = 8) and 1.6 mg/kg (high dose, n = 9). HMMA was 
detectable until 6 days after administration whereas the last detection of MDMA 
was 4 days after high dose administration. MDA and HMA were detectable for as 
long as 2.5 and 3 days, respectively. This result has shown that analysis of HMMA 
in urine specimen can extend the detection window of positive urine up to 6 
days after administration, which is consistent with the MDMA metabolites 
analysis method developed in this chapter. Determination of the other major 
MDMA metabolites, HMMA and HHMA, in urine samples is more useful than 
detecting only MDMA and MDA. 
 
8.2 Aims 
Although methods for quantitative MDMA and its active metabolites have been 
described in the literature, few methods have been developed for the 
determination of all its metabolites (MDA, HHMA, HMMA and HMA). The primary 
aim of the present study was to identify the metabolites of MDMA in humans 
both in vitro and in vivo. The secondary aim was to develop a reliable, sensitive, 
and selective method for identification and quantitation of MDMA and its 
metabolites in human urine by reversed-phase LC/MS/MS with derivatisation. 
 
8.3 Review of previous analytical methods for the 
determination of MDMA and its metabolites 
Analytical methods which have been described and used in forensic toxicology 
for the quantitation of MDMA and its metabolites (MDA, HHMA, HMMA and HMA) 
are reviewed below. These are summarised in Table 8-1. 
 
Analytical methods for MDMA and MDA were reported and published in the late 
1980s after widespread abuse of the drugs in 198581,153-155. In the first instance, 
all MDMA and MDA analytical methods were based on gas chromatography-mass 
spectrometry (GC/MS). Other active metabolites of MDMA in the rat such as 4-
hydroxy-3-methoxymethamphetamine or 3,4-dihydroxymethamphetamine were 
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reported and published in the early 1990s156,157. In 1996, Helmlin et al.90 
reported an analytical method for MDMA and its metabolites in human plasma 
and urine using high-performance liquid chromatography with diode array 
detection (HPLC/DAD) and GC/MS. (±)-3,4-Dihydroxymethamphetamine (HHMA), 
(±)-3,4-dihydroxyamphetamine (HHA), (±)-4-hydroxy-3-
methoxymethamphetamine (HMMA) and (±)-4-hydroxy-3-methoxyamphetamine 
(HMA) were synthesised and used as analytical standards. Urine was hydrolysed 
with 37% hydrochloric acid or enzymatic hydrolysis with 6,000 units of β-
glucuronidase/sulphatase (from Helix pomatia, type H-1) before extracting with 
a cation exchange SPE column (Adsorbex SCX, 100 mg). Analytes were separated 
by HPLC using a Spherisorb ODS-1 column (4.6 mm x 150 mm, 3 µm) and 
detected with DAD at 220 nm. For GC/MS, extracted samples were derivatised 
with heptafluorobutyric anhydride (HFBA) before analysis by GC/MS with a DB-5 
bonded-phase capillary column (20 m x 0.18 mm i.d., 0.40 µm) and detected by 
MS in full-scan mode (range from m/z 33-780) or SIM mode at m/z 389, 254, 210, 
162, 135 for MDMA-HFBA; m/z 375, 240, 162, 135 for MDA-HFBA; m/z 587, 360, 
254, 210 for HMMA-di-HFBA; m/z 573, 360, 240, 163 for HMA-di-HFBA; m/z 769, 
542, 515, 254, 210 for HHMA-tri-HFBA; and m/z 755, 542, 515, 240, 210 for HHA-
tri-HFBA. HMMA and HMA were detected and quantitated by HPLC/DAD in human 
urine and plasma after hydrolysis. However, HHMA was only identified in urine 
by HPLC and HHA was not detected due to the unstable nature of the 
dihydroxylated metabolite. 
 
The detection of dihydroxylated metabolites (HHMA and HHA) in biological 
samples has been limited by their catecholamine-like chemical properties that 
result in high reactivity and low stability. In 2001, Segura et al.91 described the 
first validated method for determination of HHMA in plasma and urine using 
strong cation-exchange solid-phase extraction followed by high-performance 
liquid chromatography/electrochemical detection (HPLC/ED). 3,4-Dihydroxy-
methamphetamine (HHMA) was synthesised and used as an analytical standard. 
Plasma and urine samples were obtained from four healthy male volunteers. 
Sodium bisulphite was added to all samples to prevent the oxidation of HHMA. 
Plasma and urine were hydrolysed with hydrochloric acid before extraction with 
Bond Elut® SCX columns (containing benzenesulphonic acid substituents). 
Analytes of interest were eluted with methanol/HCl (99:1 v:v) containing EDTA 
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and sodium bisulphite. Analytes were separated using a Kromasil® 100 C4 column 
(4.6 mm x 250 mm) and detected with a dual porous graphite electrode cell set 
at +0.05 V and +0.35 V. Recovery of HHMA was around 50% and the LLOQ and 
LOD were 31.8 µg/l and 10.5 µg/l, respectively. 
 
Jenkins et al.92 developed a mixed-mode solid phase extraction method for 
determination of MDMA and its metabolites in human urine using LC/MS, LC/UV 
or GC/NPD. Urine samples were hydrolysed with β-glucuronidase before being 
extracted with Oasis® MCX SPE columns followed by elution with 10% ammonium 
hydroxide in methanol. For LC/MS, MDMA, MDA and HMMA were separated using 
an XTerra® MS C18 column (2.1 mm x 150 mm x 0.3 µm) and detected with MS 
using in-source CID in the SRM mode at m/z 194.11>163.08 and 194.11>135.00 
for MDMA, 180.10>163.08 and 180.10>135.00 for MDA, 196.16>165.08 and 
196.08>137.00 for HMMA and 199.20>165.10 and 199.20>137.00 for MDMA-d5 (IS). 
The recovery for all analytes ranged from 83.9% to 108.0% and the LLOQ was 0.1 
µg/ml for MDMA and MDA and 0.04 µg/ml for HMMA. Quadratic calibration curves 
were reported over the range 0.2-20 µg/ml. For LC/UV, analytes were separated 
using an XTerra® MS C18 column (4.6 mm x 100 mm x 0.3 µm) and detected with 
a dual-wavelength UV detector at 210 and 280 nm. Linear calibration curves 
were reported over the range 0.2-20 µg/ml and the LLOQ was 1 µg/ml for MDMA, 
0.5 µg/ml for MDA and 2 µg/ml for HMMA. However, an interference was 
observed for HMMA detection. For GC-NPD, samples were derivatised with 
MBTFA before being separated with an RTX-5 capillary column (30 m x 0.32 mm 
i.d. x 0.25 µm). The LLOQ was 1 µg/ml for MDMA and MDA and 0.4 µg/ml for 
HMMA. 
 
Pirnay et al.93 developed a sensitive GC/MS method for measurement of MDMA 
and its metabolites MDA, HMA, and HMMA in human urine. HHMA and HHA were 
not included in this study. Analyte conjugates of interest were hydrolysed with 
hydrochloric acid and the pH adjusted to 5-6.5 with sodium hydroxide and 
phosphate buffer (pH 6.0) before being extracted with Clean Screen® ZSDAU020 
SPE cartridges. The SPE cartridges were conditioned with methanol, deionised 
water and phosphate buffer (pH 6.0) and washed with deionised water, acetic 
acid and methanol. Analytes were eluted with methylene chloride/iso-
propanol/ammonium hydroxide; (78/20/2 v/v/v). MDMA and its metabolites 
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were derivatised with HFBA before being separated with a DB-35MS capillary 
column (15 mm x 0.32 mm i.d. x 0.25 mm) and detected by MS using EI 
ionisation in the SIM mode at m/z 254, 210, 162 for MDMA, m/z 162, 135, 375 for 
MDA, m/z 240, 360, 333 for HMA, m/z 360, 254, 210 for HMMA, m/z 258, 213 for 
MDMA-d5 (IS), and m/z 167, 244 for MDA-d5 (IS). Recoveries for all analytes at 
concentrations of 0.030, 0.3 and 3 µg/ml were higher than 85.5%. Linear 
calibration curves were reported over the range 0.025-5 µg/ml and the LLOQ 
was 0.025 µg/ml for all analytes. Moreover, Pirnay et al.158 also developed and 
optimised hydrolysis conditions for quantification of urinary metabolites of 
MDMA. Urine samples were hydrolysed with 10,000 units/ml of β-glucuronidase 
from H. pomatia (type HP-2) and from Escherichia coli (E. coli, type XI-A) and 
these were compared with acid hydrolysis using concentrated hydrochloric acid 
at incubation temperatures of 100, 110, 120, 140 or 160oC for 20, 30, 40 or 60 
min. The optimal hydrolysis conditions for MDMA metabolites was acid hydrolysis 
with 100 µl of HCl to 1 ml of urine and incubation at 120oC for 40 min. 
 
Mueller et al.159 reported a validated LC/ESI-MS method for simultaneous 
determination of MDMA and its metabolites (MDA, HHMA and HMMA) in squirrel 
monkey plasma. Plasma samples were hydrolysed by glucuronidase from H. 
pomatia and extracted by protein precipitation using perchloric acid. Analytes of 
interest were separated using a Zorbax® 300-SCX column (2.1 mm x 150 mm, 5 
µm) with a mixture of aqueous ammonium formate (pH 3) and acetonitrile as 
mobile phase and detected with MS in positive ion SRM mode with the following 
transitions: m/z 194>163 for MDMA, 180>163 for MDA, 182>151 for HHMA, 
196>165 for HMMA, 199>165 for MDMA-d5(IS) and 185>168 for MDA-d5(IS). Linear 
calibration curves were reported over the range 0.02-1 µg/ml for MDMA, HHMA 
and HMMA and from 0.01-0.5 µg/ml for MDA. The LLOQ was 0.02 µg/ml for 
MDMA, HHMA and HMMA and 0.01 µg/ml for MDA. 
 
Shima et al.94 reported the urinary excretion in humans and rats of HMMA, the 
main metabolite of MDMA, including the sulphate and glucuronide conjugates.  
HMMA and 3-OH-4-MeO-MA were synthesised according to the procedures of Lim 
and Foltz154. HMMA-glucuronide (HMMA-Gluc) and HMMA-sulphate (HMMA-Sul) 
were synthesised following the method of Shima et al.160 and used as analytical 
standards. Urine samples were extracted with methanol and redissolved in 
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water. Analytes of interest were separated using an L-column® ODS (1.5 mm x 
150 mm, 5 µm) with a linear gradient of methanol and 10 mM ammonium 
formate buffer, pH 3.5 (15-35% methanol) as mobile phase. Mass detection was 
performed in the positive ion SIM mode with the following ions for quantitative 
analysis: m/z 194 for MDMA, m/z 180 for MDA, m/z 196 for HMMA and 3-OH-4-
MeO-MA, m/z 276 for HMMA-Sul and m/z 372 for HMMA-Gluc. The following ions 
were also monitored in the SIM mode as qualifier ions: m/z 163 and 135 for 
MDMA and MDA, m/z 165 and 137 for HMMA and 3-OH-4-MeO-MA and m/z 196 
and 165 for HMMA-Sul. Calibration curves were prepared over the range 0.017-
8.96 µg/ml for MDA, 0.037-18.5 µg/ml for HMMA-Gluc and 0.027-13.75 µg/ml for 
HMMA-Sul, 0.058-3.90 µg/ml for HMMA and 3-OH-4-MeO-MA and 1.93-193.25 
µg/ml for MDMA. 
 
Kolbrich et al.161 developed a two-dimensional GC/MS method with cryofocusing 
for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human 
plasma. Samples were hydrolysed with HCl and extracted using Polymeric Styre 
Screen DBX SPE columns before being derivatised with HFBA and back-extracted 
with pH 7.4 tris buffer. Analytes were separated using 2D-GC with 2 capillary GC 
columns in series with cryogenic capture of analytes at the inlet of the second 
column. The primary column was DB-1MS (15 m x 0.25 mm i.d. x 0.25 µm) and 
the secondary column was ZB-50 (30 m x 0. 32 mm i.d. x 0.25 µm). Analytes 
were monitored using one quantitative ion (bold) and 2 qualifier ions as follows: 
m/z 254, 210, 162 for MDMA, m/z 162, 135, 375 for MDA, m/z 210, 254, 360 for 
HMMA, m/z 240, 163, 360 for HMA, m/z 258, 213 MDMA-d5 and m/z 167, 380 for 
MDA-d5. Linear calibration curves were reported over the range 1-100 µg/l for 
MDA, 2.5-100 µg/l for HMA and 2.5-400 µg/l for MDMA and HMMA. The LLOQ of 
each analyte was the lowest concentration on the calibration curve. Recoveries 
were 85.6% to 107.2% for all analytes. 
 
Mueller et al.162 described a hydrolysis method for the determination of MDMA 
metabolite conjugates in human, squirrel monkey and rat plasma. They used a 
similar sample preparation method as previously published159 except acid 
hydrolysis with 0.5 M hydrochloric acid for 80 min at 100oC was performed 
before extraction by protein precipitation. MDMA and its metabolites MDA, 
HHMA, HMMA, HHMA-gluc and HMMA-gluc were separated by LC using a Zorbax® 
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300-SCX column (narrow-bore 2.1 mm x 150 mm, 5 µm) with a mobile phase 
consisting of 5 mM aqueous ammonium formate adjusted to pH 3 with formic 
acid and acetonitrile (70:30, v/v). HHMA-sul and HMMA-sul were separated by LC 
using a Spherisorb® C18 column (4.6 mm x 150 mm, 3 µm) with a mobile phase of 
5 mM aqueous ammonium formate adjusted to pH 9 with sodium hydroxide and 
acetonitrile (70:30, v/v). Mass detection was performed in the positive ion SIM 
mode with the following ions: m/z 182 and 151 for HHMA, m/z 196 and 165 for 
HMMA, m/z 358 and 182 for HHMA-gluc, m/z 372 and 196 for HMMA-gluc and 
negative ion SIM mode with m/z 260 and 180 for HHMA-sul and m/z 274 and 194 
for HMMA-sul. Only HMMA-gluc, HHMA-sul and HMMA-sul were detected in 
authentic human plasma. 
 
Fonsart et al.163 described a pharmacokinetic study of MDMA and its metabolite 
MDA in rats. (±)-HMA, (±)-HMMA, (±)-HHA, (±)-MDA and (±)-MDMA were 
synthesised and used as analytical standards. Plasma and urine samples were 
hydrolysed with hydrochloric acid and the pH was adjusted to 6-6.5 with 
ammonium carbonate before extraction with Oasis® WCX SPE cartridges. SPE 
cartridges were conditioned with methanol and deionised water, washed with 
deionised water and methanol and eluted with acetonitrile/methanol/10% TFA in 
water (63/27/10, v/v/v). Analytes were separated using a Nucleodur Pyramid® 
C18 column (2.1 mm x 250 mm, 5 µm) and each compound was detected by ESI-
MS in positive ion SIM mode at m/z 168 ± 0.5 for HHA, 182 ± 0.5 for HHMA and 
HMA, 196 ± 0.5 for HMMA, 180 ± 0.5 for MDA, 185 ± 0.5 for MDA-d5, 194 ± 0.5 for 
MDMA and 199 ± 0.5 for MDMA-d5. Linear calibration curves were reported over 
the range 2.5-375 µg/l for MDA, MDMA, HMMA and HMA, 12.5-750 µg/l for HHMA 
and 150-2250 µg/l for HHA and LLOQs were similar to the lowest calibration 
concentration.  
 
Schwaninger et al.164 developed validated LC-high resolution mass spectrometry 
(LC-HRMS) and GC/MS with negative ion chemical ionisation (GC-NICI-MS) 
methods for determination of MDMA and its phase I and II metabolites in human 
urine. R/S-HHMA sulphate, R/S-HMMA sulphate and single diastereoisomers of 
HMMA-gluc and the derivatisation reagent S-heptafluoro-butyrylprolyl chloride 
(S-HFBPCl) were synthesised and used. An LC-HRMS method was used to 
determine glucuronide and sulphate metabolites. Urine samples were extracted 
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with Isolute C18 SPE cartridges and separated using a Phenomenex Chirex 3012 
column (4.6 mm x 25 mm, 5 µm). Analytes were detected by HRMS in positive 
ion SIM mode with the following accurate masses: m/z 262.0744 for HHMA-sul, 
m/z 276.0900 for HMMA-sul and m/z 372.1653 for HMMA-gluc. No interference 
peaks were detected in blank samples and recoveries were over 75% for all 
analytes. Linear calibration curves were reported over the range 0.074-9.2 
µg/ml for S and R-HMMA-gluc, 0.054-18.3 µg/ml for S/R-HMMA-sul and 0.13-19.4 
µg/ml for S/R-HHMA 3-sul and S/R-HHMA 4-sul. The LLOQ of each analyte was 
the lowest concentration on the calibration curve. A GC-NICI-MS method was 
used to determine sulphate metabolites after cleavage. Urine samples were 
hydrolysed with sulphatase from Aerobacter aerogenes before being extracted 
and derivatised with S-HFBPCl and separated using an HP-5 MS column (30 m x 
0.25 mm i.d., 0.25 µm). Analytes were detected by NICI-MS in SIM mode with the 
following ions (quantifier ions are in bold): m/z 446, 426, 466 for MDMA, m/z 
432, 392, 412 for MDA, m/z 486, 271, 414 for HMA, m/z 420, 251, 492 for HHA, 
m/z 434, 356, 506 for HHMA, m/z 520, 448, 500 for HMMA, m/z 437, 397, 417 
for MDA-d5 and m/z 451, 431, 471 for MDMA-d5. Quadratic calibration curves 
were reported over the range 0.02-4.47 µg/ml for S and R-MDA, 0.02-4.52 µg/ml 
for S and R-HMA, 0.04-4.17 µg/ml for S and R-HHA, 0.02-24.12 µg/ml for S and R-
MDMA, 0.02-24.37 µg/ml for S and R-HMMA and 0.04-6.78 µg/ml for S and R-
HHMA. The LLOQ of each analyte was the lowest concentration on the 
calibration curve. 
 
Ramaley et al.165 described an in vitro study of MDMA in human hepatocytes. 
Female liver hepatocytes were incubated with 0.0625, 0.25 and 1 mM MDMA at 
37oC for 4 h. The supernatant was extracted with solvent B (95% acetonitrile, 5% 
H2O, 10 mM ammonium acetate, 10 mM acetic acid) before being analysed by 
LC/MS. MDMA and its metabolites were separated using an Atlantis HILIC® 
column (2.0 mm x 50 mm, 3 µm) and detected by QTrap® MS/MS in enhanced 
product ion scan mode at m/z 194 for MDMA, m/z 499 for MDMA-glutathione and 
m/z 487 for HHMA-glutathione. 
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Table 8-1: Previous GC/MS and LC/MS methods for MDMA and its metabolites. 
Analytes Matrix Chromatography Extraction Method Year 
MDMA 
MDA 
HHMA, HHA 
HMMA, HMA 
Human 
plasma & 
urine 
HPLC-DAD 
Column: Spherisorb ODS-1 (4.6 mm x 150 mm) 
Mobile phase: acetonitrile-water (96:904, v/v) + orthophosphoric acid and 
hexylamine. Flow rate: 1 ml/min. 
GC/MS 
Column: DB-5 capillary (20 m x 0.18 mm i.d. x 0.40 µm) 
Enzymatic hydrolysis 6,000 units 
SPE: Adsorbex SCX (100 mg) 
 
GC/MS: Derivatised with HFBA 
199690 
MDMA 
HHMA 
HMMA 
Human 
plasma & 
urine 
HPLC/ED  
Column: Kromasil C4 (4.6 mm x 250 mm) 
Mobile phase: 18% acetonitrile and 82% 0.1 M sodium acetate pH 3.1  
Flow Rate: 1 ml/min 
Acid hydrolysis 
SPE: Bond Elut SCX 
200191 
MDMA 
MDA 
HMMA 
Urine 
LC/MS  
Column: XTerra® MS C18 (2.1 mm x 150 mm, 3.5 µm) 
Mobile phase: 30% methanol and 70% 20 mM ammonium bicarbonate buffer pH 9;  
Flow Rate: 0.2 ml/min 
GC/NPD 
Column: RTX-5 capillary (30 m x 0.32 mm i.d. x 0.25 µm) 
Enzymatic hydrolysis 
SPE: Oasis MCX 
 
GC-NPD: Derivatised with MBTFA 
200492 
MDMA 
MDA 
HMMA 
HMA 
Human 
urine 
GC/MS (SIM) 
Column: DB-35MS capillary column (15 mm x 0.32 mm i.d. x 0.25 mm)  
Acid hydrolysis 
SPE: Clean Screen® ZSDAU020 
Derivatised with HFBA 
200693 
 
MDMA 
MDA 
HHMA 
HMMA 
Monkey 
plasma 
 
LC/MS  
Column: Zorbax 300-SCX (2.1 mm x 150 mm, 5 µm) 
Mobile phase: 5 mM aqueous ammonium formate adj. pH 3 with formic acid and 
acetonitrile in gradient mode 
Enzymatic hydrolysis 
Protein precipitation 
2007159 
 
MDMA 
MDA 
HMMA 
HMMA-gluc 
HMMA-sul 
Human 
& rat 
urine 
LC/MS (SIM) 
Column: L-column ODS (1.5 mm x 150 mm, 5 µm) 
Mobile phase: 10 mM ammonium formate buffer pH 3.5 and methanol in gradient 
mode 
Liquid/liquid extraction with 
MeOH 
200894 
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Table 8-1 (cont.): Previous GC/MS and LC/MS methods for MDMA and its metabolites. 
Analytes Sample Chromatography Extraction Method Ref. 
MDMA, MDA 
HMMA, HMA 
Plasma 
2D-GC/MS 
Column1: DB-1MS (15 m x 0.25 mm i.d. x 0.25 µm) 
Column2: ZB-50 (30 m x 0.32 mm i.d. x 0.25 µm) 
Acid hydrolysis 
SPE: Polymeric Styre Screen DBX 
Derivatised with HFAA 
2008161 
MDMA, MDA 
HHMA, HMMA 
HHMA-gluc 
HHMA-sul 
HMMA-gluc 
HMMA-sul 
Human, 
monkey & 
rat 
plasma 
 
LC/MS (glucuronide)  
Column: Zorbax 300-SCX (narrow bore 2.1 mm x 150 mm, 5 µm) 
Mobile phase: 70% (v/v) 5 mM aqueous ammonium formate adj. pH 3 with formic 
acid and 30% acetonitrile. 
LC/MS (sulphate)  
Column: Spherisorb C18 (4.6 mm x 150 mm, 3 µm) 
Mobile phase: 70% (v/v) 5 mM aqueous ammonium formate adj. pH 9 with NaOH 
and 30% acetonitrile. 
Acid hydrolysis with HCl & 
enzymatic hydrolysis 
Protein precipitation 
 
2009162 
MDMA, MDA 
HHMA, HHA 
HMMA, HMA 
Rat blood & 
urine 
LC/MS (Ion trap) 
Column: Nucleodur Pyramid C18 (2.1 mm x 250 mm, 5 µm) 
Mobile phase: 0.05% (V/V) TFA in water and acetonitrile in gradient mode  
Flow Rate: 0.2 ml/min 
Hydrolysis (Urine) 
SPE: Oasis® WCX 
 
2009163 
 
MDMA, MDA 
HHMA, HMMA 
HHMA-sul 
HMMA-gluc 
HMMA-sul 
Urine 
LC-HRMS  
Column: Phenomenex Chirex 3012 (4.6 mm x 250 mm, 5 µm) 
Mobile phase: ammonium formate buffer with 0.1% formic acid and acetonitrile 
with 0.1% formic acid; Flow Rate: 1 ml/min 
GC-NICI-MS 
Column: HP-5 MS column (30 m x 0.25 mm i.d., 0.25 µm) 
Hydrolysed with  
Aerobacter aerogenes 
SPE: Isolute C18 
 
2011164 
MDMA 
MDMA- 
glutathione 
HHMA- 
glutathione  
Human 
hepatocytes 
LC/MS (QTrap®) 
Column: Atlantis HILIC (2.0 mm x 50 mm, 3 µm) 
Mobile phase: gradient from 70 - 50% B, flow rate 0.3 ml/min 
A: 95% isopropyl alcohol, 5% H2O, 10 mM ammonium acetate, 10 mM acetic acid 
B: 95% acetonitrile, 5% H2O, 10 mM ammonium acetate, 10 mM acetic acid  
Incubated at 37oC for 4 h 
Liquid extraction with solvent B 
2014165 
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8.4 GC/MS method development 
To evaluate MDMA and its metabolites (MDA, HHMA, HMMA and HMA), an 
extraction method was developed and identification methods based on GC/MS 
and LC/MS were investigated.  
 
8.4.1 Derivatisation methods 
To identify MDMA and its hydrophilic metabolites by GC/MS, a derivatisation 
method was developed. The derivatising agents involved in this study were 
chosen from those used in previous studies and from the routine method for 
MDMA analysis in the forensic toxicology laboratory, University of Glasgow. 
Three types of derivatising agents were compared for the derivatisation of MDMA 
and its metabolites including HHMA, HMMA and HMA: acetic anhydride, 
pentafluoropropionic anhydride and N-methyl-N-(trimethylsilyl)-trifluoro-
acetamide. 
 
Subsequently, acetylation derivatisation was also used for LC/MS/MS analysis to 
improve the capacity factors of hydrophilic metabolites and the chromatographic 
separation of MDMA and its metabolites (see Section 8.5.1.1). 
 
8.4.1.1 Acetic anhydride (AA) 
Acetylation of MDMA and its metabolites was carried out using acetic anhydride 
(AA). 50 µl of AA: pyridine (3:2, v:v) was added to each dried extract in a screw-
capped vial, and heated at 60oC for 30 min. All samples were then evaporated to 
dryness at room temperature under a stream of nitrogen and residues were 
reconstituted in 200 µl of 10% acetonitrile in deionised water containing 0.1% 
formic acid for LC/MS or 100 µl of ethyl acetate or dry toluene for GC/MS and 
transferred to labelled 1.5 ml screw-capped autosampler vials with inserts 
before analysis by LC/MS/MS or GC/MS. 
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8.4.1.2 Pentafluoropropionic anhydride (PFPA) 
PFP derivatives of MDMA and its metabolites were prepared using 
pentafluoropropionic anhydride (PFPA). 50 µl of PFPA:ethyl acetate (2:1, v:v) 
was added to each dried extract in a screw-capped vial, and heated at 60oC for 
30 min. All samples were then evaporated to dryness at room temperature under 
a stream of nitrogen and residues were reconstituted in 100 µl of ethyl acetate 
or dry toluene and transferred to labelled 1.5 ml screw-capped autosampler vials 
with inserts before analysis by GC/MS. 
 
8.4.1.3 N-Methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) 
Trimethylsilyl derivatives of MDMA and its metabolites were prepared using N-
methyl-N-(trimethylsilyl)-trifluoroacetamide. 50 µl of MSTFA was added to each 
dried extract in a screw-capped vial, and heated at 60oC for 30 min. All samples 
were transferred to labelled 1.5 ml screw-capped autosampler vials with inserts 
before analysis by GC/MS. 
 
8.4.2 Identification method 
8.4.2.1 Gas chromatography/mass spectrometry conditions 
GC/MS analysis was carried out using an Agilent 7890A gas chromatograph 
equipped with an Agilent 7693 autosampler and connected to an Agilent 5975C 
InertXL MSD with Triple-Axis mass selective detector, operated in the EI positive 
ion mode. Chromatographic separation was performed on an HP-5MS fused silica 
capillary column (30 m × 0.25 mm i.d., film thickness, 0.25 μm, Agilent 
Technologies Inc.). Helium gas at a constant ﬂow of 1 ml/min was used as the 
carrier gas. The injection port temperature was 225oC, and the transfer line 
temperature was 280oC. The injection volume was set at 1 µl in the splitless 
mode. 
 
The mass-selective detector was operated in the full scan mode with a mass 
range between m/z 40 and 500 and was tuned and calibrated with 
perfluorotributylamine. The ion source and quadrupole temperatures were 250oC 
and 150oC, respectively. A solvent delay was set at 6 min to protect the 
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filament. All compounds were identified by their retention times (tR) and mass 
spectral fragmentation patterns. 
 
8.4.2.2 GC/MS method for TMS-derivatives 
The initial column temperature of 90oC was held for 1 min, followed by a 
temperature ramp of 10oC/min to 280oC, which was held for 2 min. The total 
separation run time was 22 min. The ion source was maintained at 250oC and 
quadrupole at 150oC. The MS detector was operated in the full scan mode with a 
mass range between m/z 40 to 700 and in the selected ion monitoring (SIM) 
mode with the ions summarised in Table 8-2. 
 
Table 8-2: SIM conditions for TMS-derivatives of MDMA and its metabolites. 
Compound Retention Time Selected Ions 
MDA-TMS 11.66 116,  135,  236 
MDMA-TMS 12.65 130,  250,  264 
HMA-2TMS 13.16 116,  179,  209,  310 
HMM-2TMS 14.07 130,  179,  324 
HHMA-3TMS 14.59 130,  179,  382 
 
8.4.2.3 GC/MS method for PFPA-derivatives  
The initial column temperature of 90oC was held for 1 min, followed by a 
temperature ramp of 10oC/min to 280oC. After that, the temperature ramp was 
hold at 280oC for 2 min. The total separation run time was 22 min. The ion 
source was maintained at 250oC and quadrupole at 150oC. The MS detector was 
operated in the full scan mode with a mass range between m/z 40 to 700 and in 
the selected ion monitoring mode (SIM) with the ions summarised in Table 8-3. 
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Table 8-3: SIM conditions for PFPA-derivatives of MDMA and its metabolites. 
 
               Bold = M+ 
 
8.4.2.4 GC/MS method for Ac-Derivatives  
The initial column temperature of 90oC was held for 1 min, followed by a 
temperature ramp of 10oC/min to 250oC. After that, the temperature ramp was 
increased to 20oC/min to 300oC. The total run time was 19.5 min. The ion source 
was maintained at 250oC and quadrupole at 150oC. The selected ion monitoring 
mode was used and the ions were as summarised in Table 8-4. 
 
Table 8-4: SIM conditions for Ac-derivatives of MDMA and its metabolites. 
Compound Retention Time Selected Ions 
MDA-Ac 14.16 44,  162,  135,  221 
MDMA-Ac 15.10 58,  100,  135,  162,  235 
HMA-2Ac 15.83 86,  137,  164,  206  
HMM-2Ac 16.60 58,  100,  164,  206 
HHMA-3Ac 17.57 58,  100,  150,  234 
               Bold = M+ 
 
8.4.3 Results of derivatisation with GC/MS analysis 
8.4.3.1 Optimised GC/MS conditions for trimethylsilyl derivatives 
To optimise the GC/MS conditions and to select ions for use in the SIM mode, 
standards of MDA, MDMA, HMA, HMMA and HHMA were derivatised with MSTFA 
and analysed by GC/MS following the method previously described (Section 
Compound Retention Time Selected Ions 
HMA-2PFP 8.5 190,  283,  310 
MDA-PFP 9.6 135,  162,  190,  325 
HHMA-3PFP 9.6 160,  204,  442 
HMM-2PFP 10.5 160,  204,  310  
MDMA-PFP 11.2 135,  162,  204,  339 
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8.4.2.2) in full scan MS mode over the mass range from m/z 40-700. The EI mass 
spectra of the TMS-derivatives are shown in Figure 8-1. 
 
The TMS-derivatives of MDA, MDMA, HMA, HMMA and HHMA were eluted at 11.66, 
12.65, 13.16, 14.07 and 14.59 min, respectively. However, the ion at m/z 73, 
corresponding to the TMS group, is prominent in all TMS spectra and is not 
selective for a SIM method. Two large peaks in the mass spectra of MDMA-TMS, 
HMMA-2TMS and HHMA-3TMS were at m/z 73 and 130 and for MDA-TMS and HMA-
2TMS were at m/z 73 and 116. The mass spectra of MDA-TMS, MDMA-TMS and 
HHMA-3TMS had only a few characteristic peaks - two large peaks and small 
fragment ion peaks which were insufficient for quantification. 
 
 
 
Figure 8-1: Mass spectral patterns of TMS-derivatives of MDMA and its 
metabolites. 
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Figure 8-1 (cont.): Mass spectral patterns of TMS-derivatives of MDMA and its 
metabolites.  
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8.4.3.2 Optimised GC/MS conditions for acetate derivatives 
To optimise the GC/MS conditions and select ions for use in the SIM mode, 
standards of MDA, MDMA, HMA, HMMA and HHMA were derivatised with acetic 
anhydride: pyridine (3:2, v:v) and analysed by GC/MS following the method 
previously described (Section 8.4.2.4) in full scan MS mode over the mass range 
from m/z 40-700. Acetate derivatives of MDA, MDMA, HMA, HMMA and HHMA 
were well separated at 14.16, 15.10, 15.83, 16.60 and 17.57 min, respectively. 
However, the ions at m/z 44 and 58 that were prominent in nearly all acetate 
mass spectra of MDMA and its metabolites are not sufficiently selective for use in 
a SIM method. The EI mass spectra of Ac derivatives are shown in Figure 8-2. 
 
Two large peaks in the mass spectra of MDMA-Ac, HMMA-2Ac and HHMA-3Ac were 
at m/z 58 and 100 and the largest peak for MDA-Ac and HMA-2Ac was at m/z 44. 
The mass spectrum of HHMA-3Ac had only a few characteristic peaks, large 
peaks at m/z 58 and 100 and small fragment ion peaks at m/z 123, 150, 192 and 
234.  
 
 
 
 
Figure 8-2: Mass spectral patterns of Ac-derivatives of MDMA and its 
metabolites. 
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Figure 8-2 (cont.): Mass spectral patterns of Ac-derivatives of MDMA and its 
metabolites. 
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8.4.3.3 Optimised GC/MS conditions for PFPA derivatives 
To optimise the GC/MS conditions and select ions for use in the SIM mode, 
standards of MDA, MDMA, HMA, HMMA and HHMA were derivatised with PFPA: 
ethyl acetate (2:1, v:v) and analysed by GC/MS following the method previously 
described (Section 8.4.2.3) in full scan MS mode over the mass range from m/z 
40-1000. PFP-derivatives of HMA, HHMA, MDA, HMMA and MDMA were eluted at 
8.5, 9.6, 9.6, 10.5 and 11.2 min, respectively. The perfluoroacyl derivatives had 
mass spectra containing ions at high m/z values which were more selective than 
those for the TMS and Ac derivatives. However, the GC method needs to be 
further developed to separate HMA, HHMA and MDA. The EI mass spectra of the 
PFP-derivatives are shown in Figure 8-3. 
 
 
 
 
Figure 8-3: Mass spectral patterns of PFP-derivatives of MDMA and its 
metabolites. 
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Figure 8-3 (cont.): Mass spectral patterns of PFP-derivatives of MDMA and its 
metabolites. 
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MDA-PFP had two large peaks at m/z 135 and 162, small fragment ion peaks at 
m/z 119 and 190 and a small molecular ion peak at m/z 325. The mass spectrum 
of HMMA-2PFP had three large peaks at m/z 160, 204 and 310 and a small 
fragment ion peak at m/z 119. The mass spectrum of MDMA-PFP had three large 
peaks at m/z 135, 162 and 204, small fragment ion peaks at m/z 77 and 119 and 
a small molecular ion peak at m/z 339. Therefore, the PFP-derivatives of MDMA 
and its metabolites were suitable for quantification. 
 
8.4.3.4 Comparison of derivatisation methods 
To evaluate the response intensity of the three derivatisation methods, 5 µg 
standards of HHMA, HMMA, HMA and MDMA were derivatised with MSTFA, PFPA 
and acetic anhydride and analysed by GC/MS. Response factors (RF) for each 
analyte were calculated following the equation below. 
 
 
Response Factor (RF) = Peak Area / weight injected (µg) 
 
 
To compare the response intensity between TMS and PFP-derivatives and Ac-
derivatives, relative response factors (RRFs) were calculated following the 
equation below. 
 
 
Relative Response Factor (RRF) = Response Factor A / TMS Response Factor 
 
Table 8-5: Comparison of response intensity of the three derivatisation 
methods. 
 
Compound 
Ac-derivative PFP-derivative TMS-derivative 
RF RRFAc RF RRFPFP RF 
HHMA 5.88 x 106 0.85 3.56 x 106 0.51 6.93 x 106 
HMA 3.77 x 106 0.56 7.24 x 106 1.08 6.69 x 106 
HMM 6.16 x 106 0.89 9.12 x 106 1.32 6.89 x 106 
MDMA 5.70 x 106 0.79 6.68 x 106 0.93 7.20 x 106 
 
*Response Factor (RF)  
**Relative Response Factor (RRFx)  
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The results showed that TMS-derivatives gave a good response for all analytes. 
This is why they were chosen for the denominator. However, the mass spectra 
obtained from TMS-derivatives were unsuitable for the development of a 
quantitative method. PFP-derivatives were selected after comparing their 
responses with Ac-derivatives due to their good response factors and the 
availability of peaks which had high m/z values in their mass spectra. However, 
this GC/MS method could not separate HHMA and MDA which are major and 
minor MDMA metabolites. 
 
In an attempt to improve the separation of PFP-derivatives of HMA, HHMA and 
MDA, the initial GC column temperature was decreased to 80oC and held for 1 
min, followed by a temperature ramp of 20oC/min to 170oC. Because the PFP-
derivatives of MDMA and its metabolites were eluted from the GC column at 
temperatures in the range 170oC to 200oC, temperature ramps of 3oC, 4oC, and 
4.5oC/min were applied over this range followed by a ramp of 20oC/min to 
300oC. The MS detector was operated in the full scan mode with a mass range 
between m/z 40 to 700. 
 
With temperature ramps of 4oC, and 4.5oC/min, HHMA-3PFP and MDA-PFP co-
eluted at 9.88 and 9.76 min, respectively. With a temperature ramp of 3oC/min, 
HHMA-3PFP and MDA-PFP were partially separated, eluting at 9.27 and 9.31 min. 
The chromatograms of PFP-derivatives under these conditions are shown in 
Figure 8-4. 
 
In conclusion, because HHMA-3PFP derivative still overlapped with MDA-PFP 
derivative even with a decreased oven temperature ramp of 3oC/min, acetate 
derivatives were judged to be potentially the most useful for a GC/MS method. 
However, in parallel, an LC/MS method was also developed to identify and 
quantitate MDMA and its metabolites in urine samples which ultimately was 
found to be superior to the GC/MS method. Finally, the LC/MS method was 
chosen and validated. The GC-MS method was not further developed, for 
example by using lower temperature programme rates or by evaluating other GC 
columns, and was not subsequently validated for the purposes of this study. 
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Figure 8-4: TIC chromatograms of PFP-derivatives of MDMA and its metabolites 
with temperature ramps of 3, 4 and 4.5oC/min. 
 
 
8.5 LC/MS method development 
8.5.1 Optimisation of LC/MS conditions 
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chromatography to gain a physical separation of the compounds. Separation by 
LC of bases on the stationary phase (column) depends on the mobile phase and 
the physical properties of the molecules, such as hydrophobicity. The 
investigation of MDMA and its metabolites depends on the ability of the method 
to separate all analytes including hydrophobic (MDMA and MDA), less 
hydrophobic (HMA and HMMA) and hydrophilic compounds (HHMA). Physico-
chemical properties of MDMA and its metabolites are listed in Table 8-6. 
 
Table 8-6: Physico-chemical properties of MDMA and its metabolites. 
Compound  Formula MW Log P 
octanol/water 
pKa 
MDMA  C11H15NO2 193.24 1.806 10.32 
MDA C10H13NO2 179.22 1.667 9.94 
HMMA C11H17NO3 195.26 0.913 9.84 & 10.63 
HMA  C10H15NO2 181.23 0.774 9.70 & 10.05 
HHMA  C10H15NO2 181.23 0.606 9.70 & 10.34 
 
8.5.1.1 LC separation 
To separate MDMA and its metabolites, standards of MDMA, MDA, HHMA, HMMA 
and MDA were analysed by LC/MS using a Gemini C18 column. LC separation 
started with isocratic elution using a low concentration of organic solvent (9% 
acetonitrile containing 0.1% formic acid in water) at flow rate of 0.35 ml/min. 
HHMA, HMMA and HMA split into two peaks with retention (capacity) factors (k′) 
in the range 0.7 to 1.26. Figure 8-5 shows the poor separation of HHMA, HMMA 
and HMA that was obtained on the Gemini C18 column. 
 
A HILIC column or normal phase liquid chromatography was considered for the 
analysis of hydrophilic compounds such as HHMA. However, the aim of this study 
was to develop an LC/MS method using a conventional C18 HPLC column that is a 
routinely-available column in all laboratories that perform HPLC and/or LC/MS 
analysis. 
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Figure 8-5: LC/MS chromatograms of underivatised MDMA and its metabolites 
using a Gemini C18 column. 
 
 
To improve the LC separation, acylation with acetic anhydride was used to 
derivatise MDMA and its metabolites that contain active functional groups (OH 
and NH) to form larger, more hydrophobic, compounds. Derivatives have the 
potential to improve LC separations by reverse-phase HPLC and increase 
sensitivity in mass spectrometry. Moreover, HHMA and HMA have different 
chemical structures but the same molecular weights, whereas their Ac-
derivatives have different molecular weights because HHMA accepts three acyl 
groups whereas HMA only accepts two. The structures of HHMA, HMA and their 
Ac-derivatives are shown in Figure 8-6. 
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Figure 8-6: Structures of HHMA, HMA and their Ac-derivatives. 
 
A mobile phase containing 33% of 0.1% formic acid in methanol and 67% of 0.1% 
formic acid in water was tried for separation of the Ac-derivatives of MDMA and 
its metabolites but was found to have a significant adverse effect on the column 
pressure. However, good chromatography was obtained using an isocratic mobile 
phase containing 33% of 0.1% formic acid in acetonitrile and 67% of water 
containing 0.1% formic acid with a flow rate of 0.35 ml/min. All analytes were 
separated using this mobile phase on a conventional C18 column with 
satisfactory retention factors (k′) in the range 3.3 to 5.6. The retention factor 
was 3.3 for HMA-2Ac (the most hydrophilic), 3.5 for MDA-Ac, 4.7 for HHMA-3Ac, 
4.9 for HMMA-2Ac, 5.4 for MDMA-d5-Ac and 5.6 for MDMA-Ac (the least 
hydrophilic), see Figure 8-7. The hold-up time (t0 = 0.8 min) was determined by 
injecting pure methanol. It was concluded that acetylation improved the peak 
shapes and retention factors of MDMA and its metabolites in reverse-phase 
LC/MS. 
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Figure 8-7: LC/MS/MS MRM chromatograms for MDMA-Ac and its metabolites 
following extraction from urine (concentration 0.25 µg/ml). 
8.5.1.2 MRM optimisation 
Liquid chromatography coupled with tandem mass spectrometry in multiple 
reaction monitoring (MRM) mode is a highly sensitive and selective detection 
method for targeted analysis. The sensitivity of MRM-MS depends critically on 
the appropriate tuning of instrument parameters such as fragmentor voltage 
(FV), collision energy (CE) and/or cone voltage in order to generate optimal 
precursor and product ions. Precursor ions, product ions, FVs and CEs for MDMA-
Ac, MDA-Ac, HHMA-3Ac, HMMA-2Ac, HMA-2Ac and MDMA-d5-Ac were obtained 
from direct injection of Ac-derivatives of standards in methanol into the mass 
spectrometer interface using a syringe pump with positive ESI and the optimised 
parameters are summarised below in Table 8-8. To obtain a high degree of 
certainty in the identification method, 4 identification points (IPs) are 
required166. One quantifier and two qualifier ions were applied for MDMA and its 
metabolites.  
 
The fragmentation patterns of the acetate derivatives of MDMA and its 
metabolites in LC/MS are rather different from the type of ion reactions found in 
GC/MS. Mass spectral data for all analytes were obtained in the positive ESI 
mode. Representative fragmentation reactions of derivatives of MDMA and its 
metabolites at a CE of 20 eV are illustrated in Figure 8-8. Under optimised 
conditions, most ion reactions had different optimum CEs and a CE of 20 eV was 
chosen for Figure 8-8 as a mid-range value which demonstrates the patterns, 
although ion ratios under optimised conditions are different. 
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Figure 8-8: Mass spectra of Ac-derivatives of MDMA and its metabolites at a CE 
of 20 eV in product ion scan mode. Under optimised conditions, most ion 
reactions have different optimum CEs. The spectra illustrated here demonstrate 
typical patterns, although the ion ratios under optimised conditions may be 
different. 
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The protonated molecular ion (M-H)+ of MDMA-Ac at m/z 236 was used as 
precursor ion and its fragment ions at m/z 105, 135 and 163 were selected as 
product ions. The fragment ion at m/z 163, the most intense peak in the mass 
spectrum of MDMA-Ac, was used as the quantifier ion and the ions at m/z 105 
and 135 were used as qualifiers ions.  
 
The protonated molecular ion of MDA-Ac at m/z 222 was used as precursor ion 
and its fragment ions at m/z 105, 135 and 163 were selected as product ions. 
The ion at m/z 163, the most intense peak of MDA-Ac, was used as the quantifier 
ion and the ions at m/z 105 and 135 were used as qualifiers ions.  
 
The protonated molecular ion of HHMA-3Ac at m/z 308 was used as precursor ion 
and its fragment ions at m/z 151, 224 and 266 were selected as product ions. 
The product ions of the Ac-derivative of HHMA at m/z 266 and m/z 244 resulted 
from loss of ketene groups (COCH2, 42 Da) from the protonated molecular ion. 
The ion at m/z 151, the most intense peak in the mass spectrum of HHMA-3Ac, 
was used as the quantifier ion and the ions at m/z 224 and 266 were used as 
qualifiers ions.  
 
The protonated molecular ion of HMMA-2Ac at m/z 280 was used as precursor ion 
and its fragment ions at m/z 137, 165 and 238 were selected as product ions. 
The product ion of the Ac-derivative of HMMA at m/z 238 resulted from loss of a 
ketene group (COCH2, 42 Da) from the protonated molecular ion. The ion at m/z 
165, the most intense peak of HMMA-2Ac, was used as the quantifier ion and the 
ions at m/z 137 and 238 were used as qualifier ions.  
 
The protonated molecular ion of HMA-2Ac at m/z 266 was used as precursor ion 
and its fragment ions at m/z 105, 137 and 165 were selected as product ions. 
The ion at m/z 165, the most intense peak of HMA-2Ac, was used as a 
quantitative ion and ion at m/z 105 and 137 were used as qualifier ions.  
 
The protonated molecular ion of MDMA-d5-Ac at m/z 241 was used as precursor 
ion and its fragment ions at m/z 107, 135 and 165 were selected as product ions. 
The ion at m/z 165, the most intense peak in the mass spectrum of MDMA-d5-Ac, 
was used as the quantifier ion. 
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In conclusion, because the mass spectra of acetate derivatives of MDMA and its 
metabolites were not sufficiently selective for use in a GC/MS SIM method, 
acetylation with LC/MS analysis was chosen for further in vitro and in vivo 
metabolite studies. 
 
8.5.2 Solid phase extraction  
Liquid-liquid extraction is not suitable for the extraction of hydrophilic 
compounds such as HHMA and, to decrease the matrix background from 
biological samples, solid phase extraction methods were developed. The SPE 
cartridges involved in this study were chosen for evaluation from amongst those 
used in previous studies and also included the one used in the routine method 
for MDMA analysis in the forensic toxicology laboratory, University of Glasgow.  
 
Three types of SPE cartridge (Oasis® MCX, Oasis® WCX and Clean Screen® DAU) 
were compared for the extraction of MDMA and its hydrophilic metabolites, 
focussing on HHMA, HMMA and HMA. MDA was not included in this study, which 
was primarily concerned with obtaining good recoveries of polar metabolites, as 
its polarity is similar to that of MDMA: Log P values for MDMA and its metabolites 
are listed in Table 8-6. 
 
8.5.2.1 Extraction method 
8.5.2.1.1 Oasis® MCX and Clean Screen® DAU  
The SPE cartridges were sequentially conditioned with 3 ml methanol, 3 ml 
deionised water and 2 ml 0.1 M phosphate buffer pH 6. After transferring 
samples (n = 2) to the column and passing them through the cartridge 
completely, the cartridges were washed with 3 ml deionised water, 2 ml 0.1 M 
acetate buffer pH 4.5 and 3 ml methanol and dried under full vacuum for 10 
min. New labelled 4 ml glass vials were placed in a rack within the vacuum work 
station.  Analytes were eluted with 3 ml of dichloromethane/ isopropanol/NH3 
(78:20:2 v:v:v) and the eluent were transferred to labelled 3.5 ml vials and 
evaporated to dryness by a gentle flow of nitrogen gas at ambient temperature 
before performing derivatisation. 
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8.5.2.1.2 Oasis® WCX 
The SPE cartridges were sequentially conditioned with 3 ml methanol and 3 ml 
deionised water. After transferring samples (n = 2) to the column and passing 
them through the cartridge completely, the cartridges were washed with 3 ml of 
deionised water and 3 ml of methanol. New labelled 4 ml glass vials were placed 
in a rack within the vacuum manifold.  Analytes were eluted with 3 ml of 
acetonitrile/methanol/10% NH3 (63:27:10 v:v:v) and the eluent were transferred 
to labelled 3.5 ml vials and evaporated to dryness by a gentle flow of nitrogen 
gas at ambient temperature before performing derivatisation. 
 
8.5.2.2 Results of solid phase extraction 
8.5.2.2.1 Clean Screen® DAU 
Clean Screen DAU was tested according to the method described in Section 
8.5.2.1.1 which was developed for routine analysis of amphetamines in blood 
and urine in the forensic toxicology laboratory, University of Glasgow. Clean 
Screen DAU is a mixed-mode column exhibiting both hydrophobic and cation 
exchange characteristics which was designed for forensic work. The cartridges 
were tested using a mixture of standards of MDMA, HHMA, HMMA, HMA and 
MDMA-d5, each at a concentration of 1 µg/ml in blank HLM incubation matrix. 
The extracted samples were analysed using LC/MS/MS. The results showed that 
HHMA-3Ac was not retained on the column although the other analytes were 
retained strongly (recoveries higher than 85% for HMMA-2Ac and higher than 90% 
for MDMA-Ac, HMA-2Ac and MDMA-d5-Ac). Figure 8-9 displays LC/MS/MS MRM 
chromatograms for the HHMA ions, with a complete absence of a peak at 3.6 
min, the retention time of HHMA-3Ac. Figure 8-10 displays the corresponding 
chromatograms for HMA, HMMA and MDMA, with satisfactory peak shapes and 
peak separations. 
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Figure 8-9: LC/MS/MS MRM chromatograms of HHMA-3Ac ions after extraction 
with Clean Screen® DAU. The retention time of HHMA-3Ac is 3.6 min on Gemini 
column (arrowed).  
 
 
 
Figure 8-10: LC/MS/MS MRM chromatograms for HMA-2Ac, HMMA-2Ac and MDMA-
Ac after extraction with Clean Screen® DAU. 
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8.5.2.2.2 Oasis® MCX 
Oasis® MCX was also tested using the method described in Section 8.5.2.1.1. 
Oasis® MCX is a mixed-mode reversed-phase/strong cation-exchange polymer 
column designed for basic compounds. The cartridges were tested using a 
mixture of standards of MDMA, HHMA, HMMA and HMA, each at a concentration 
of 1 µg/ml in blank HLM incubation matrix. The extracted samples were analysed 
using LC/MS/MS. The results showed that HHMA-3Ac was not retained on this 
column either (see Figure 8-11) although the recovery of MDMA-Ac was 63% and 
HMMA-2Ac and HMA-2Ac were retained strongly (recoveries higher than 100%, 
Figure 8-12). Previous work by Menet et al.167 has shown that HHMA and HMA 
were poorly retained on mixed-mode and strong cation exchange cartridges 
(Bond Elut Certify® and Chromabond SCX®). The efficiency of mixed-mode SPE 
columns in retaining hydrophilic compounds by ionic interaction is dependent on 
the relative number of SCX moieties compared to C18 moieties. 
 
 
 
 
Figure 8-11: LC/MS/MS MRM chromatograms of HHMA-3Ac ions after extraction 
with Oasis® MCX. The retention time of HHMA-3Ac is 3.6 min on Gemini column 
(arrowed). 
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Figure 8-12: LC/MS/MS MRM chromatograms for HMA-2Ac, HMMA-2Ac and MDMA-
Ac after extraction with Oasis® MCX. 
 
8.5.2.2.3 Oasis® WCX 
Oasis® WCX was tested using the method described in Section 8.5.2.1.2 
according to Fonsart et al.163 with some modifications. Oasis® WCX is a mixed-
mode reversed-phase/weak cation-exchange polymer column designed to retain 
and release quaternary amines and strongly basic compounds. The cartridges 
were tested using standards of MDMA, HHMA, HMMA and HMA at a concentration 
of 1 µg/ml in blank HLM incubation matrix. The extracted samples were analysed 
using LC/MS/MS. The results for this cartridge also showed that HHMA was poorly 
retained on the column (recoveries lower than 15%, Figure 8-13) whereas the 
recovery of MDMA was 57% (Figure 8-14). HMMA and HMA were retained strongly 
(recoveries higher than 70%) on the column. It shows that hydrophilic analytes 
were not completely retained by the WCX column. However, this result is in 
contrast with a previous study by Menet et al.167 which found that Oasis® WCX 
gave good recoveries for MDMA and its five metabolites in a comparison of three 
SPE types (Bond Elut® Certify, Chromabond® SCX and Oasis® WCX). The most 
likely explanation of these differences is that the eluent used in this study was 
different from that used in the previous study by Menet et al., which would have 
affected the recovery of HHMA. In that study, the recovery of HHMA was 63.3% 
at a low concentration (250 ng/ml) and 69.0% at a high concentration (1 µg/ml). 
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Figure 8-13: LC/MS/MS MRM chromatograms of HHMA-3Ac, HMMA-2Ac and HMA-
2Ac after extraction with SPE Oasis® WCX. 
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Figure 8-14: LC/MS/MS MRM chromatograms of MDMA-Ac after extraction with 
SPE Oasis® WCX. 
 
8.5.2.3 Comparison of SPE methods 
Oasis® WCX columns were considered to be the best compromise after comparing 
them with Oasis® MCX (Waters) and Clean Screen DAU (UCT Inc.) columns. Oasis® 
MCX and Clean Screen® DAU were excluded due to significant losses of HHMA 
during extraction although MDMA and other metabolites were retained with good 
recoveries. The Oasis® WCX columns gave the best recovery of HHMA amongst 
the three types of SPE cartridges evaluated, see Table 8-7. 
 
Table 8-7: SPE recoveries of MDMA and its metabolites. 
 
Drug Average recovery % (n = 2) 
Oasis® MCX Clean Screen® DAU Oasis ®WCX 
HHMA ND ND 13% 
HMMA 115% 100% 74% 
HMA 100% 87% 97% 
MDMA 63% 113% 57% 
ND = Not detected 
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However, although SPE methods can reduce the matrix background from 
biological samples, HHMA was poorly retained on the Oasis® WCX column 
(recovery was 13%). The analyst’s time to perform SPE of 24 samples and dry the 
extracts was approximately 2-3 h while the sample preparation time for protein 
precipitation was only 1 h for 24 samples. In addition, the major financial 
difference between SPE and liquid-liquid extraction or protein precipitation 
methods was the purchase of SPE columns for each extraction (£2.45 per 
cartridge for Oasis® WCX).  
 
In the end, protein precipitation with acetonitrile was developed and used 
subsequently as the extraction method for MDMA and its metabolites in 
incubation medium and in urine samples (see Sections 8.6.2 and 8.6.3). 
 
8.6 Methods and materials 
8.6.1 Reagents and standards 
Acetonitrile, ethyl acetate and methanol (HPLC grade) were obtained from VWR 
International Ltd (UK).  Acetic anhydride, formic acid, anhydrous pyridine, N-
methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA), pentafluoropropionic acid 
anhydride (PFPA), sodium chloride and anhydrous toluene were obtained from 
Sigma-Aldrich Co, LLC (UK). Ammonia solution 28% w/v, dichloromethane, 2-
propanol, potassium chloride, sodium acetate trihydrate, sodium phosphate 
dibasic, potassium dihydrogen phosphate, disodium hydrogen orthophosphate 
anhydrous (Na2HPO4) and sodium dihydrogen orthophosphate monohydrate 
(NaH2PO4.H2O) were obtained from BDH (UK).  
 
3,4-Methylenedioxymethamphetamine-HCl (MDMA), 3,4-methylenedioxy-
methamphetamine-d5 (MDMA-d5), 3,4-methylenedioxyamphetamine (MDA), 
human liver microsomes (HLM), β-Nicotinamide adenine dinucleotide phosphate 
hydrate (β-NADP), D-glucose 6-phosphate dipotassium salt hydrate (G6P), β-
glucuronidase from Helix pomatia and glucose-6-phosphate dehydrogenase 
(G6PD) from baker's yeast (S. cerevisiae) were purchased from Sigma-Aldrich Co, 
LLC (UK). 4-Hydroxy-3-methoxymethamphetamine-HCl (HMMA), 3,4-dihydroxy-
methamphetamine-HCl (HHMA), and 4-hydroxy-3-methoxyamphetamine-HCl 
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(HMA) were purchased from Lipomed (supplied by Kinesis, Ltd UK). HLM was 
subdivided on receipt into 50 µl aliquots and were stored at -80oC until used. 
 
Stock standard solutions were prepared by dissolving each compound in 
methanol to achieve a concentration of 1 mg/ml of drug substance. Working 
standard solutions were prepared by serial dilution of stock standard solutions 
with methanol. All stock and working standard solutions were stored at 4oC.  
 
8.6.1.1 Preparation of 0.1 M phosphate buffer pH 6 
1.7 g of disodium hydrogen orthophosphate anhydrous (Na2HPO4) and 12.14 g of 
sodium dihydrogen orthophosphate monohydrate (NaH2PO4) were weighed out 
and added to a 1 L volumetric flask and 800 ml of deionised water was added. 
The pH was adjusted to pH 6 using 0.1 M monobasic sodium phosphate or 0.1 M 
dibasic sodium phosphate. The volume was then made up to 1 L with deionised 
water. 
 
8.6.1.2 Preparation of 0.1 M acetate buffer pH 4.5 
5.86 g of sodium acetate trihydrate was weighed out and added to a 1 L 
volumetric flask and 800 ml of deionised water and 3.24 ml of glacial acetic acid 
were added. The pH was adjusted to pH 4.5 using 0.1 M acetic acid or 0.1 M 
sodium acetate. The volume was then made up to 1 L with deionised water. 
 
8.6.1.3 Preparation of phosphate buffer saline (PBS) pH 7.4 
4.00 g of sodium chloride (NaCl), 0.10 g of potassium chloride (KCl), 0.72 g of 
sodium phosphate dibasic (Na2HPO4) and 0.12 g of potassium dihydrogen 
phosphate (KH2PO4) were weighed out and added to a 500 ml volumetric flask. 
The volume was then made up to 500 ml with deionised water. 
 
8.6.1.4 Preparation of 0.1 M sodium acetate buffer pH 5 
13.6 g of sodium acetate was weighed out and added to a 1 L volumetric flask 
and 800 ml of deionised water and 6 ml of glacial acetic acid were added. The 
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pH was adjusted to pH 5 using acetic acid. The volume was then made up to 1 L 
with deionised water. 
 
8.6.1.5 Preparation of NADPH generating system 
β-NADP was prepared as a 10 mg/ml solution in water and G6P as a 0.1 M 
solution in water; both were stored at -20oC until used. The G6PD was dissolved 
in buffer to achieve an activity of 1,000 IU/ml and was stored at -20oC until 
used. 
  
8.6.1.6 Preparation of MDMA in phosphate buffer pH 7.4 
Stock solutions of MDMA for use in metabolism studies were freshly prepared at 
10 µg/ml in pH 7.4 phosphate buffer and stored at -20 oC until used. 
 
8.6.1.7 Preparation of 0.1 M acetic acid 
800 ml of deionised water was measured into a 1L volumetric flask and 5.7 ml of 
glacial acetic acid was added. The volume was then made up to 1 L with 
deionised water. 
 
8.6.1.8 Preparation of 0.1 M sodium acetate   
1.36 g of sodium acetate trihydrate was weighed out and added to a beaker and 
dissolved in 80 ml of deionised water. This was then transferred to a 100 ml 
volumetric flask and the volume was made up to 100 ml with deionised water. 
 
8.6.1.9 Preparation of 0.1 M monobasic sodium phosphate   
2.76 g of sodium dihydrogen orthophosphate was weighed out and added to a 
beaker and dissolved in 100 ml of deionised water. This was then transferred to 
a 200 ml volumetric flask and the volume was made up to 200 ml with deionised 
water. 
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8.6.1.10 Preparation of 0.1 M dibasic sodium phosphate 
2.84 g of disodium hydrogen orthophosphate (anhydrous) was weighed out and 
added to a beaker and dissolved in 100 ml of deionised water. This was then 
transferred to a 200 ml volumetric flask and the volume was made up to 200 ml 
with deionised water. 
 
8.6.1.11 Preparation of quality control samples 
The quality control samples were prepared by spiking mixed standard HHMA, 
HMA, HMMA, MDA, MDMA and MDMA-d5 in blank urine samples to obtain the 
concentrations of 0.1 µg/ml (low), 0.5 µg/ml (medium) and 1 µg/ml (high). 
 
8.6.2 In vitro assay (human liver microsomes) 
The method used was adapted from previous work by Mueller and Rentsch127. All 
reagents were held at room temperature to thaw. 50 µl HLM were used in the 
incubation mixture with 400 µl of drug substance at 10 µg/ml (i.e. 4 µg) in pH 
7.4 phosphate buffer per incubation. The NADPH generating system (NGS) was 
used to generate the NADPH for the reaction. It consisted of 50 µl of 0.1M G6P, 
25 µl of 10 mg/ml β-NADP and 2 µl of 40 IU/ml G6PD. The NGS mixture was pre-
incubated for 3 min at 37oC before being added to the incubation mixture to 
start the reaction. The mixture was incubated in a shaking incubator at 37oC, 30 
rpm for 90 min. To maintain the reaction, 77 µl more NGS system was added to 
the incubation mixture after 30 min.  The reaction was stopped at 90 min by the 
addition of 600 µl of ice-cold acetonitrile to the incubation mixture. After 
vortexing and centrifuging at 13,000 x g for 10 min, the supernatant was 
transferred to a 3.5 ml glass vial before performing the extraction of 
metabolites. 
 
8.6.3 In vivo assays (MDMA positive urine samples)  
Human urine samples which were known to be positive for MDMA were obtained 
from Glasgow Royal Infirmary for routine toxicology service analysis and the 
results of the analyses described below were reported as part of the case 
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investigation. The West of Scotland Research Ethics Committee confirmed that 
separate ethical permission was not required as the work was related to hospital 
service development. All samples were stored at 4oC prior to processing. Each 
urine sample was analysed for MDMA and its metabolites (MDA, HHMA, HMMA and 
HMA) using the two methods described below. 
 
8.6.3.1 Non-hydrolysed extraction method  
A 0.4 ml portion of each urine sample was mixed with 0.8 ml of acetonitrile and 
centrifuged at 13,000 rpm for 10 min. 400 µl of the top organic layer was 
transferred to a 3.5 ml glass vial and evaporated to dryness by a gentle flow of 
nitrogen gas at ambient temperature before performing derivatisation. Residues 
were reconstituted in 1 ml of 10% acetonitrile in deionised water containing 0.1% 
formic acid. 
 
8.6.3.2 Enzymatically hydrolysed extraction method 
A 0.4 ml portion of each urine sample was mixed with 70 µl of 0.1M sodium 
acetate buffer pH 5 and 40 µl of β-glucuronidase. The mixture was incubated in 
a shaking incubator at 56oC, 10 rpm for 60 min. 0.8 ml of acetonitrile was added 
before vortexing and centrifuging at 13,000 x g for 10 min. 400 µl of the top 
organic layer was transferred a 3.5 ml glass vial and evaporated to dryness by a 
gentle flow of nitrogen gas at ambient temperature before performed 
derivatisation. Residues were reconstituted in 1 ml of 10% acetonitrile in 
deionised water containing 0.1% formic acid. 
 
8.6.4 Derivatisation 
8.6.4.1 Acetic anhydride derivatisation (AA) 
This was as described in Section 8.4.1.1. 
 
8.6.4.2 Stability of derivatives of standards 
The stability of derivatives in LC mobile phase was determined using acetyl 
derivatives of MDMA, MDA, HHMA, HMMA and HMA standards in the concentration 
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range from 0.01-2 µg/ml (0.01, 0.25, 0.50, 0.1, 0.25, 0.5, 1 and 2 µg/ml). The 
derivatives were investigated for short-term stability using the LC/MS method 
described below. Derivatised samples were stored in the LC/MS autosampler at 
room temperature after derivatisation and were analysed at 6, 12, 18, 24, 30 
and 96 h. 
 
8.6.5 Liquid chromatography/mass spectrometry conditions 
Chromatographic separation was performed using an Agilent Binary SL 1200 LC 
from Agilent Technologies Inc. Isocratic elution was performed on a Gemini C18 
column (150 x 2.0 mm, 5 μm) protected by a Gemini C18 Security Guard Pre-
Column (4 x 2.0 mm, 5 μm) from Phenomenex Inc., which was maintained at 
40ºC with a ﬂow rate of 0.35 ml/min. The injection volume was 20 µl and the 
mobile phase was composed of 0.1% formic acid in water and 0.1% formic acid in 
acetonitrile (67:33 v:v) and the run time was 10 min per injection. 
 
Analysis of MDMA and its metabolites was performed using an Agilent 6410 Triple 
Quad LC/MS/MS instrument (Agilent Technologies Inc.) equipped with an Agilent 
Binary SL 1200 LC system interface. Nitrogen was from a nitrogen generator (In 
House Gas (Manufacturing) Ltd, UK). 
 
Ionisation of analyses of interest was carried out using ESI. The mass 
spectrometer was operated in the positive ion multiple reaction monitoring 
(MRM) mode. Nitrogen was used as nebuliser gas at 30 psi. The gas temperature 
was set to 350oC and the gas flow to 11 ml/min. The MRM transitions, FVs and 
CEs for derivatised MDMA and MDMA metabolites were optimised separately by 
direct infusion into the MS of each derivatised standard solution at a 
concentration of 5 μg/ml in mobile phase (50:50 v:v). All analytes were 
identified and quantified based on their retention time and quantifier and 
qualifier ion ratios that were obtained from MRM transitions. The MRM 
transitions, FVs and CEs used for the measurement of MDMA and its metabolites 
are summarised in Table 8-8. 
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Table 8-8: MRM conditions for derivatives of MDMA and metabolites. 
Name Precursor 
Ion (m/z) 
Fragmentor 
Voltage (eV) 
Product 
Ion*  
(m/z) 
Collision 
Energy 
(eV) 
Qualifier/
quantifier 
ion ratio 
MDA-Ac 222.2 90 163 10 - 
135 20 60% 
105 25 91% 
MDMA-Ac 236.2 90 163 10 - 
135 30 44% 
105 30 83% 
MDMA-d5-
Ac 
 
241.3 90 165 10 - 
135 20 - 
107 30 - 
HMA-2Ac 266.3 90 165 20 - 
137 30 66% 
105 40 70% 
HMMA-2Ac 280.3 115 238 10 27% 
165 20 - 
137 30 51% 
HHMA-3Ac 308.3 115 266 10 53% 
224 20 18.5% 
151 30 - 
*m/z values in bold were used as quantifier ions 
 
8.6.6 Method validation 
8.6.6.1 Blank urine samples 
Existing blank urine samples from a previous research project, obtained with 
informed consent and appropriately stored at -20oC in Forensic Medicine and 
Science, were used. The chair of the University Medical Research Ethics 
Committee confirmed that approval would not be needed for these samples.  
 
8.6.6.2 Selectivity/specificity 
The selectivity of the described method was evaluated using 10 different sources 
of blank urine. The specificity of the described method was evaluated using 
blank urine spiked with a mixture of drugs that are routinely detected in forensic 
toxicology cases (amphetamine, methamphetamine, mephentermine, 
paramethoxyamphetamine, alprazolam, diazepam, flunitrazepam, midazolam, 
codeine, morphine, hydrocodone, hydromorphone, oxycodone, butylone and 
methylone) at a concentration of 1 µg/ml. Blank and spiked samples were 
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extracted and analysed by LC/MS to determine if there were any signals 
interfering with the signals of the analytes or the internal standard from blank 
matrix or other common drugs. 
 
8.6.6.3 Linearity 
Calibration curves for MDMA, MDA, HHMA, HMMA and HMA were prepared in 
blank urine which was extracted by the described method, covering low and high 
concentrations in the range from 0.025 to 1.5 µg/ml (0.025, 0.050, 0.1, 0.25, 
0.50, 0.75, 1 and 1.5 µg/ml). MDMA-d5 at a concentration of 0.25 µg/ml was 
spiked in all samples as internal standard. Blank urine with internal standard was 
included with each run as zero concentration standard samples. Calibration 
curves were plotted of the resulting response (the area ratio of analytes versus 
internal standard) versus the corresponding concentrations. The linear 
correlation coefficient (R2) was obtained for each regression curve. 
 
8.6.6.4 Lower limit of quantitation 
The sensitivity of the method was assessed by determining the Lower Limit of 
Quantitation (LLOQ) of each analyte. Spiked urine samples at a concentration of 
0.025 µg/ml (the lowest concentration standard in the calibration curves) and 
blank spiked with internal standard (n = 6) was analysed for this purpose. The 
signal-to-noise (S/N) ratio of LLOQ, calculated by comparing the peak area of 
analyte with the baseline (noise), is required to be equal or greater than 10. The 
lowest concentration standard in the calibration curve was used as a lower limit 
of quantitation for the described method. 
 
8.6.6.5 Accuracy and precision 
Three different concentrations of the quality control samples (QCs) were used to 
evaluate the intra-assay and inter-assay precision. The concentration of 0.1 
µg/ml was used as low QC, 0.5 µg/ml as medium QC and 1 µg/ml as high QC. 
Intra-assay precision of the method for MDMA and its metabolites was 
determined using QCs (n = 3) in one day. The calibration curve of each analyte 
of interest was prepared using the concentration ranges mentioned previously. 
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Inter-assay precision was assessed using a similar procedure to the intra-assay 
precision but over six different days. Accuracy was estimated in terms of bias 
and was calculated using the equation described in Chapter 4. 
 
8.6.6.6 Matrix effects 
Matrix effects were measured using the method described by Matuszewski et 
al.46 Neat standards at concentrations of 0.1 and 1 µg/ml were obtained by 
diluting 10 µg/ml and 100 µg/ml stock standards in 10% of acetonitrile plus 0.1% 
formic acid in deionised water. Blank urine samples were obtained from five 
different sources and spiked after un-hydrolysed extraction with analytes of 
interest at 0.1 and 1 µg/ml. Matrix effects of endogenous compounds were 
calculated by comparing the peak areas of spiked samples with the peak areas of 
neat standards. 
 
8.6.7 Post mortem case materials 
Three post mortem urine samples known to be positive for MDMA were analysed 
and reported as part of the medico-legal investigation of the three cases. Ethical 
approval and consent are not required if the analytical results are reported to 
the Procurator Fiscal. In addition, the Head of the Scottish Fatalities 
Investigation Unit was informed and his permission was obtained in an email to 
publish the analytical results in this thesis. All samples were stored at 4oC prior 
to processing. Urine samples were analysed for MDMA and its metabolites (MDA, 
HHMA, HMMA and HMA) using the method described earlier 
 
8.7 Results and discussion 
8.7.1 Stability of Ac-derivatives 
To develop a quantitative LC/MS method using chemical derivatisation, one 
parameter that needed to be assessed was the stability of the derivatives in the 
mobile phase. Standards of MDMA-Ac, HHMA-3Ac, HMMA-2Ac and HMA-2Ac at 
0.01, 0.025, 0.050, 0.1, 0.25, 0.5, 1 and 2 µg/ml were analysed by LC/MS and 
then maintained at room temperature on the autosampler for re-analysis. For 
routine analysis, samples should be stable before analysis in the autosampler for 
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24 h. Analytes were evaluated at 0, 6, 12, 18, 24, 30 and then at 96 h. Area 
ratios of analytes and internal standard were calculated and compared with that 
obtained with freshly prepared standards. 
The stability of underivatised and derivatised MDMA and its metabolites, 
including MDA, HMMA and HMA has been studied and data is available in the 
literature93,159,164,168,169. Pirnay et al.93 reported that HFBA-derivatives of MDMA, 
MDA, HMMA and HMA were stable for 3 freeze/thaw cycles, 14 h at room 
temperature before analysis, 72 h in the refrigerator before analysis and 72 h at 
ambient temperature on the GC/MS autosampler. Moreover, only one study on 
the stability of HHMA has been reported. Mueller et al.159 found less than a 10% 
loss of underivatised HHMA in mobile phase after 14 h in the autosampler at 
room temperature. However, this is the first time that the stability of acetate 
derivatives of MDMA, MDA, HHMA, HMMA and HMA in LC mobile phase has been 
reported. 
Plots of analyte concentration versus storage time in the autosampler are shown 
in Figure 8-15. Acetates of MDMA, HHMA, HMMA and HMA were stable in the 
HPLC mobile phase for 30 h at room temperature at all concentrations, which 
was acceptable for a regular analytical run. Additional measurements were 
made at 96 h to determine if any decomposition occurred over an extended 
period. These analyses indicated that analyte concentrations decreased by up to 
almost 50% over 96 h. Further work on stability would be necessary if samples 
were likely to be left routinely in the autosampler for more than 30 h. These 
results have shown that derivatisation with acetic anhydride is suitable for the 
development of a routine method for quantitation of MDMA and its metabolites 
in urine samples. 
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Figure 8-15: Stability of Ac-derivatives of standards of MDMA and its metabolites 
in the HPLC mobile phase at low and high concentrations over a 96 h period. A 
non-linear scale has been applied to the x-axis to improve visibility of the points 
up to 30 h. 
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8.7.2 Method validation 
8.7.2.1 Selectivity/specificity 
Specificity of the method was evaluated using blank urine spiked with a mixture 
of the most common drugs detected in forensic cases such as amphetamines, 
benzodiazepines and opiates. To investigate the selectivity of the method from 
endogenous compounds, 10 blank urine specimens from different individuals 
were analysed to evaluate chromatographic interference. Blank urine spiked 
with internal standard was also included with each batch. The absence of 
analyte ions in blank urines spiked with internal standard proved that internal 
standard did not contain relevant amounts of unlabelled analytes (Figure 8-16). 
Also, no interference peaks were detected for any of the analytes in extracts of 
spiked urine samples (Figure 8-17). 
 
 
 
Figure 8-16: MRM chromatograms obtained by LC/MS/MS analysis of an 
acetylated extract of blank urine spiked with internal standard MDMA-d5, 
showing absence of interferences at the retention times of MDMA and its 
metabolites (selectivity). 
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Figure 8-17: MRM chromatograms obtained by LC/MS/MS analysis of a spiked 
urine sample. Retention times of analytes are indicated (arrowed). 
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Figure 8-17 (cont.): MRM chromatograms obtained by LC/MS/MS analysis of a 
spiked urine sample. Retention times of analytes are indicated (arrowed). 
 
8.7.2.2 Linearity 
The concentration range for calibration curves was chosen based on previous 
studies of urine concentrations of MDMA and its metabolites in humans90,148,152. 
Calibration curves using eight concentration levels with six replicates each were 
constructed to assess the calibration model. A weighted (1/x2) calibration model 
was used to allow for unequal variances across the calibration range (0.025 to 
1.5 µg/ml). Regression equations and linear correlation coefficients (R2) are 
given in Table 8-9. The linear regression equations for MDMA and MDA had linear 
correlation coefficient (R2) values greater than 0.999, which is very satisfactory, 
and for HHMA, HMMA and HMA had values greater than 0.98, which is sufficient. 
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Table 8-9: Regression models, correlation coefficients (R2) and LLOQs for 
LC/MS/MS analysis of acetate derivatives of MDMA and its metabolites in urine. 
 
Analytes Regression R2 LLOQ* 
(µg/ml) 
MDMA-Ac y = 1.040x - 0.0284 0.999 0.025 
MDA-Ac y = 0.730x - 0.0120 0.999 0.025 
HHMA-3Ac y = 0.957x - 0.0126 0.980 0.025 
HMMA-2Ac y = 1.149x - 0.0070 0.982 0.025 
HMA-2Ac y = 0.680x - 0.0070 0.985 0.025 
*LLOQ was set at the concentration of the lowest standard in the calibration 
curve (0.025 µg/ml). 
 
 
    Control samples 
Figure 8-18: Calibration curves (0.025-1.5 µg/ml) for LC/MS/MS analysis of 
acetate derivatives of MDMA and its metabolites in urine. LLOQs are indicated 
(arrowed). Concentrations of standards are 0.025, 0.050, 0.1, 0.25, 0.50, 0.75, 1 
and 1.5 µg/ml. 
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Figure 18-18 (cont.): Calibration curves (0.025-1.5 µg/ml) for LC/MS/MS 
analysis of acetate derivatives of MDMA and its metabolites in urine. LLOQs are 
indicated (arrowed). Concentrations of standards are 0.025, 0.050, 0.1, 0.25, 
0.50, 0.75, 1 and 1.5 µg/ml. 
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8.7.2.3 Lower limit of quantitation 
Calculation of the lower limit of quantification (LLOQ) has been carried out by 
different methods but in the present study the lower point of the calibration 
curve at 0.025 µg/ml was used as the LLOQ. It can be seen from Figure 8-19 that 
the signal-to-noise ratios at that concentration are higher than 10, the minimum 
value. The signal-to-noise (S/N) ratio of MDMA-Ac was 39, MDA-Ac was 34, 
HHMA-3Ac was 44, HMMA-2Ac was 64 and HMA-2Ac was 49, which suggest that 
the LLOQs are actually lower than 0.025 µg/ml.  The LLOQs of the method were 
in the same range as in previously published methods91,93. However, the urine 
sample volume used in this method was significantly lower (400 µl) than in those 
studies. Based on the Substance Abuse and Mental Health Services 
Administration (SAMHSA) confirmatory test cut-offs at 250 ng/ml for MDMA and 
MDA in urine, the detection limits and the linearity ranges of this method are 
suitable for routine analysis of MDMA and its metabolites in urine samples.  
 
 
 
 
 
Figure 8-19: LC/MS/MS MRM chromatograms for the analysis of acetate 
derivatives of MDMA metabolites from urine at a concentration of 0.025 µg/ml 
(LLOQ). The S/N ratios are greater than 10 in each chromatogram. 
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Figure 8-19 (cont.): LC/MS/MS MRM chromatograms for the analysis of acetate 
derivatives of MDMA metabolites from urine at a concentration of 0.025 µg/ml 
(LLOQ). The S/N ratios are greater than 10 in each chromatogram. 
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Figure 8-19 (cont.): LC/MS/MS MRM chromatograms for the analysis of acetate 
derivatives of MDMA metabolites from urine at a concentration of 0.025 µg/ml 
(LLOQ). The S/N ratios are greater than 10 in each chromatogram. 
 
8.7.2.4 Accuracy and precision 
Precision and accuracy for intra-day and inter-day assay were examined by 
analysing urine quality control samples (QCs) containing the analytes at three 
concentrations (LOW, MED and HIGH, n = 6 in each case). The measured 
concentrations of QCs were determined from daily calibration curves. The 
precision of the method was assessed as the percentage relative standard 
deviation (%RSD) and accuracy was assessed as the percentage deviation from 
the accepted reference value (%bias). Good values for intra-day precision (%RSD) 
were obtained for all analytes in the range of 0.8 to 5.7%, which were inside the 
acceptance criteria of ±15%. Values for inter-day precision (%RSD) were 6.1 to 
18.5% and for accuracy (bias) were -14.5 to 17.2%. The higher values of %RSD 
and bias were due to the measured concentrations of HHMA-3AC and HMA-2Ac in 
MED QCs, that were above the acceptance criteria, while other QCs were inside 
the acceptance limits. However, the method was sufficiently accurate and 
precise for forensic toxicology analysis of MDMA and its metabolites in authentic 
urine samples. Inter-day precision and accuracy for all analytes are listed in 
Table 8-10. 
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Good precision and accuracy were obtained at the LLOQ for all analytes, in the 
range of 1.6 to 3.2 %RSD and -3.2 to -14.7 %bias respectively, which were inside 
the acceptance criteria of ± 20%. Accuracy and precision data for each 
compound at the LLOQs are listed in Table 8-11. 
 
Table 8-10: Inter-day assay precision and accuracy for determination of MDMA 
and its metabolites in urine (n = 6). 
 
Analyte QC 
Sample 
Expected 
Concentration, 
ng/ml 
Observed 
Concentration, 
ng/ml 
Accuracy 
(%Bias) 
Precision 
(%RSD) 
MDMA-Ac LOW 100 97.4 -2.6 7.0 
 MED 500 506 1.2 9.6 
 HIGH 1000 1066 6.6 12.0 
MDA-Ac LOW 100 97.7 -2.3 7.3 
 MED 500 514 2.8 9.5 
 HIGH 1000 1089 8.9 13.5 
HHMA-3Ac LOW 100 92.7 -7.3 6.1 
 MED 500 586 17.2 18.5 
 HIGH 1000 885 -14.5 11.8 
HMMA-2Ac LOW 100 97.1 -2.9 6.9 
 MED 500 567 13.4 14.9 
 HIGH 1000 932 -6.8 10.0 
HMA-2Ac LOW 100 95.0 -5.0 9.8 
 MED 500 581 16.3 14.6 
 HIGH 1000 970 -3.0 11.6 
 
Table 8-11: Inter-day assay accuracy and precision at the LLOQs (n = 6). 
 
Analyte Expected 
Concentration, 
ng/ml 
Observed 
Concentration, 
ng/ml 
Accuracy 
(%Bias) 
Precision 
(%RSD) 
MDMA-Ac 25 24.2 -3.2 1.9 
MDA-Ac 25 24.1 -3.5 1.6 
HHMA-3Ac 25 21.3 -14.7 3.2 
HMMA-2Ac 25 21.7 -13.0 1.9 
HMA-2Ac 25 22.2 -11.4 2.1 
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8.7.2.5 Matrix effects 
The assessment of matrix effects showed the occurrence of ion suppression or 
ion enhancement of each analyte in extracts of urine from 5 different sources. A 
matrix effect value of <100% demonstrates ion suppression whereas a value of 
>100% indicates ion enhancement. The matrix slightly inhibited the ionisation of 
all derivatised analytes at low concentrations. However, no remarkable matrix 
effects were observed for any of the analytes at high concentrations. Matrix 
effects data are listed in Tables 8-12 and 8-13. 
 
Table 8-12: Urine matrix effects at low analyte concentrations (0.1 µg/ml) as 
percent of signal obtained with pure reference standards. 
 
Drug Source 
1 
Source 
2 
Source 
3 
Source 
4 
Source 
5 
Mean %CV 
HHMA 98 91 98 87 66 88 13 
HMMA 95 91 91 88 70 87 10 
HMA 96 87 79 80 62 81 14 
MDMA 106 87 91 85 68 88 14 
MDA 105 90 82 89 61 86 17 
 
Table 8-13: Urine matrix effects at high analyte concentrations (1 µg/ml) as 
percent of signal obtained with pure reference standards. 
 
Drug Source 
1 
Source 
2 
Source 
3 
Source 
4 
Source 
5 
Mean %CV 
HHMA 98 97 98 103 103 100 2 
HMMA 99 98 97 102 102 100 2 
HMA 99 98 90 100 103 98 4 
MDMA 101 97 95 99 103 99 3 
MDA 100 98 88 107 103 99 7 
 
 
8.7.3 In vitro metabolism studies 
Pooled human liver microsomes (HLM) were incubated with MDMA standard and 
extracted and analysed using the LC/MS/MS method described previously. 3,4-
Dihydroxymethamphetamine (HHMA) and 3,4-methylenedioxyamphetamine 
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(MDA), the two key metabolites of MDMA, were expected to be produced by 
human liver microsomes in the in vitro metabolism procedure described earlier. 
Derivatives of standards were identified at the following retention times: MDMA-
Ac at 4.7 min, HMMA-2Ac at 4.2 min, HHMA-3Ac at 4.0 min, MDA-Ac at 3.2 min 
and HMA-2Ac at 3.0 min. Slight variations in retention times occur in HPLC 
depending on a number of factors, for example, history of column use by other 
researchers and aging of mobile phase. Each analyte was confirmed by assessing 
the qualifier/quantifier ion ratios, with ± 20% tolerance compared to the un-
extracted standards. 
 
Three phase I metabolites (both major and minor metabolites) of MDMA were 
detected in HLM samples. The retention times and the mass ratios of MDMA and 
its metabolites obtained from HLM samples were consistent with those that were 
observed with the standards. MDMA derivative (MDMA-Ac) was eluted at 4.7 min 
and was identified and confirmed by quantifier and qualifier ions at m/z 
236>163, 236>135 and 236>105. The qualifier/quantifier ion ratio was 39% for 
m/z 135 and was 73% for m/z 105 which were in the acceptable range, see 
Figure 8-20. 
 
3,4-Dihydroxymethamphetamine derivative (HHMA-3Ac) was eluted at 4.0 min 
and was identified and confirmed by MRM transitions at m/z 308>266, 308>224 
and 308>151. The ratio of qualifier/quantifier ions was 55% for m/z 266 and 21% 
for m/z 224 which were in the acceptable range. 
 
3,4-Methylenedioxyamphetamine derivative (MDA-Ac) was eluted at 3.2 min and 
was identified and confirmed by MRM transitions at m/z 222>163, 222>135 and 
222>105. The ratio of qualifier/quantifier ions was 54% for m/z 135 and was 83% 
for m/z 105 which were in the acceptable range. 
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Figure 8-20: LC/MS/MS MRM chromatograms of MDMA metabolites in HLM samples compared with Ac-derivatives of reference standards. 
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A small peak of 4-hydroxy-3-methoxymethamphetamine derivative (HMMA-2Ac) 
was detected in HLM samples at 4.2 min and was identified and confirmed by 
MRM transitions at m/z 280>238, 280>165 and 280>137. The ratio of qualifier/ 
quantifier ion was 23% for m/z 238 which was in the acceptable range. However, 
the ratio of qualifier/quantifier ion for m/z 137 was 37%, which was out of the 
acceptable range (±20%) probably because the chromatographic peaks 
corresponding to HMMA-2Ac were small in size, which can affect the ion ratios. 
 
A small peak of 4-hydroxy-3-methoxyamphetamine derivative (HMA-2Ac) was 
detected in HLM samples at 3.0 min and was identified and confirmed by MRM 
transitions at m/z 266>105, 266>137 and 266>165. The ratio of qualifier/ 
quantifier ions was 57% for m/z 137 and was 63% for m/z 105 which were in the 
acceptable range. LC/MS MRM chromatograms of MDMA metabolites in an HLM 
sample are shown in Figure 8-21. 
 
 
 
 
Figure 8-21: LC/MS MRM chromatograms of MDMA metabolites in an HLM 
sample. 
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In vitro results have shown that HHMA appears to be a major MDMA metabolite 
in HLM samples whereas MDA was found as a minor metabolite. This result is in 
agreement with previously published data about MDMA metabolites in humans 
and confirmed that HHMA is an intermediate metabolite of MDMA in 
humans90,91,162,164,170.  
 
Because HMMA and HMA are produced from HHMA and MDA, small peaks of HMMA 
and HMA were also found in HLM samples. Finally, this experiment confirmed 
that human liver microsomes can be used to simulate drug metabolism in 
humans. 
 
8.7.4 In vivo metabolism studies 
8.7.4.1 Non-hydrolysed urine analysis 
Ten positive human urine samples obtained from Glasgow Royal Infirmary for 
routine toxicology service analysis were analysed for MDMA and its metabolites 
(MDA, HHMA, HMMA and HMA) using the method described previously without a 
hydrolysis procedure in the sample preparation step. MDMA, MDA, HHMA and 
HMMA were detected in all samples. The concentrations were reported as µg/ml 
urine. Concentrations outside the calibration range were estimated by 
extrapolation and are reported here for research comparison purposes only. 
Concentrations of MDMA and its metabolites in non-hydrolysed urine samples are 
summarised in Table 8-14. 
 
MDMA, MDA, HHMA and HMMA concentrations were found in the ranges 9.2-89.2 
µg/ml, 0.23-5.4 µg/ml, 0.12-2.90 µg/ml and 0.15-4.25 µg/ml, respectively. HMA 
was found at concentrations greater than the method LLOQ in only one of ten 
non-hydrolysed urine specimens (U-01) and at concentrations lower than the 
calibration range in six of ten non-hydrolysed urine samples. 
 
The concentrations of free HHMA were found to be higher than MDA in three 
samples (U-02, U-03 and U-08) and the concentrations of free-HMMA were also 
found to be higher than MDA in three samples (U-02, U-07 and U-08). Moreover, 
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the concentration of MDA was found to be lower than the combined 
concentrations of free HHMA and free HMMA in seven samples. 
 
Table 8-14: Concentrations of analytes in non-hydrolysed urine samples (µg/ml). 
 
Name HMA-2Ac MDA-Ac HHMA-3Ac HMMA-2Ac MDMA-Ac** 
U-01 0.052 5.41** 2.32** 1.39 76.1 
U-02 <0.025 0.67 2.90** 4.25** 45.4 
U-03 ND* 0.60 0.65 0.47 89.2 
U-04 <0.025 1.27 0.49 0.53 21.5 
U-05 ND 0.23 0.21 0.23 9.20 
U-06 <0.025 1.68** 1.24 1.11 53.2 
U-07 <0.025 0.32 0.16 1.84** 14.2 
U-08 <0.025 0.35 1.46 1.38 12.6 
U-09 ND 0.51 0.12 0.15 10.8 
U-10 <0.025 1.52 1.22 0.87 69.5 
*ND = not detected 
**Concentrations outside the calibration range were estimated by extrapolation for research 
comparison purposes only. 
 
The concentrations of MDA, free HHMA and free HMMA in ten urine samples were 
found to be within the expected ranges with the exception of U-01 and U-02, 
which had concentrations of MDA and HMMA which were higher than the 
expected ranges. Moreover, the concentration of free HMA was found to be 
lower than expected and in all samples MDMA concentrations were higher than 
the calibration range. 
 
8.7.4.2 Hydrolysed urine analysis 
Some of the MDMA metabolites, such as HHMA, HMMA and HMA, were expected 
to be excreted in conjugated forms (mostly glucuronide or sulphate conjugates). 
To evaluate the conjugated forms of MDMA metabolites, a hydrolysis procedure 
was required in order to release HHMA, HMMA and HMA from their conjugates. 
Ten positive human urine samples, the same samples as used in Section 8.7.4.1, 
were analysed for MDMA and its metabolites (MDA, HHMA, HMMA and HMA) using 
the method described previously with the addition of an enzymatic hydrolysis 
108 
 
method in the sample preparation step. Total MDMA, MDA, HHMA, HMMA and 
HMA concentrations (µg/ml) in hydrolysed urine samples are summarised in 
Table 8-15. Concentrations outside the calibration range were estimated by 
extrapolation and are reported here for research comparison purposes only. 
 
Total MDMA, MDA, HHMA, HMMA and HMA concentrations were found in the 
ranges 8.8-87.3 µg/ml, 0.20-5.47 µg/ml, 0.16-2.91 µg/ml, 0.56-5.27 µg/ml and 
0.025-0.27 µg/ml, respectively. HMA was found at concentrations greater than 
the method LLOQ in six of ten hydrolysed samples (U-01, U-02, U-04, U-06, U-08 
and U-10) and at concentrations lower than the calibration range in the other 
urine samples. 
 
The concentrations of total HMMA were found to be higher than MDA in eight 
samples (U-02, U-03, U-05, U-06, U-07, U-08, U-09 and U-10). Moreover, the 
concentration of MDA was found to be lower than the combined concentrations 
of total HHMA and HMMA in all samples, suggesting that HHMA and HMMA are 
major metabolites of MDMA in human. 
 
Table 8-15: Concentration of analytes in hydrolysed urine samples (µg/ml). 
 
Name HMA-2Ac MDA-Ac HHMA-3Ac HMMA-2Ac MDMA-Ac** 
U-01 0.269 5.47** 2.91** 3.19** 67.5 
U-02 0.044 0.77 2.22** 5.27** 43.6 
U-03 <0.025 0.52 0.72 0.93 87.3 
U-04 0.063 1.21 0.46 0.87 20.8 
U-05 <0.025 0.20 0.57 0.56 8.84 
U-06 0.078 1.48 1.38 4.12** 59.7 
U-07 <0.025 0.33 0.16 1.81** 14.7 
U-08 0.053 0.48 0.95 1.73 12.3 
U-09 <0.025 0.34 0.24 0.96 11.4 
U-10 0.025 1.13 0.92 1.60** 74.0 
**Concentrations outside the calibration range were estimated by extrapolation for research 
comparison purposes only. 
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Concentrations of MDA, total HHMA and total HMMA in ten urine samples were 
found to be within the expected range with the exception of U-01, which had 
high concentrations of MDA, HHMA and HMMA, U-02 which had high 
concentrations of HMMA and HHMA and U-06 which had a high concentration of 
HMMA above the calibration range. Moreover, the concentration of MDMA in all 
urine samples was found to be higher than the expected range while the 
concentration of total HMA was found to be lower than expected. 
 
No information was available concerning the dose(s) or time(s) of MDMA 
administration in these cases, although given the circumstances that the 
patients were admitted to the hospital emergency department because of acute 
intoxication, it is likely that the samples were collected proximal to the last 
administration of MDMA. In each case, MDMA was the main analyte detected, 
with the maximum metabolite/MDMA ratio being 0.14 for HMMA in case U-08 and 
the ratio of free (MDA+HHMA+HMMA+HMA)/MDMA ranging from 0.02-0.26. These 
findings contrast with results published by Segura et al. who found that, after a 
single administration of 100 mg MDMA to four volunteers, both HMMA and HHMA 
exceeded MDMA in urine at all intervals up to 24 h after administration91. The 
percentages of administered dose excreted over the first 24 h in the form of 
MDMA, MDA, HMMA and HHMA were 15.0%, 1.5%, 22.7% and 17.7% respectively. 
However, no data is given for the ratios of metabolites to MDMA after the first 
24 h. 
 
One possible explanation for the differences between this study and that of 
Segura et al.91 is that repeated or multiple doses were taken by the users in the 
present study. Metabolite/MDMA ratios may decrease following administration of 
more than one dosing. Farré et al.171 found that metabolic ratios in plasma of 
MDA/MDMA, (MDA+HMA+HMMA)/MDMA, (HMMA+HMA)/(MDA+MDMA) and 
(HMA+HMMA)/MDMA after a single dose were 0.05, 1.67, 1.54 and 1.52 but after 
repeated dose were 0.05, 0.86, 0.77 and 0.81, respectively. The lower ratios 
after the second dose were due to lower conversion of MDMA to HMMA and HMA, 
which was attributed to autoinhibition of CYP2D6 by MDMA. However, Farré’s 
ratios were for plasma and may not be reliable indicators of ratios in urine.  
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An alternative explanation of the differences is that the method used in this 
study is different from that of Segura et al.91 and resulted in different relative 
amounts of MDMA and its metabolites, for example as a result of differences in 
the efficiency of the hydrolysis procedure. In the absence of commercially-
available standards of metabolite conjugates, this would need to be resolved by 
comparative analysis of samples by the two methods. 
 
8.7.4.3 Comparison of hydrolysed and non-hydrolysed urine 
samples 
The same urine samples were analysed before and after hydrolysis, allowing 
direct comparison of analyte concentrations under the two conditions. As shown 
in Table 8-16, the urinary concentrations of HMMA and HMA dramatically 
increased after enzymatic hydrolysis using the β-glucuronidase and sulphatase 
derived from Helix pomatia, see Figure 8-22. Compared to non-hydrolysed urine 
samples, HMMA and HMA concentrations were significantly higher (p<0.05) after 
enzymatic hydrolysis (139% ± 84.5% and 783% ± 112%, respectively). There were 
no significant differences in MDMA, MDA and HHMA concentrations between non-
hydrolysed and hydrolysed samples. The differences in concentrations of MDMA 
and its metabolites found in this study between hydrolysed and non-hydrolysed 
urine samples are in agreement with previously reported data158. 
 
Pirnay et al.158 found that HMMA and HMA recoveries were significantly increased 
by 4768% ± 1128% and 1310% ± 366% following acid hydrolysis (n = 5). MDA 
recoveries were significantly increased by E coli β-glucuronidase by 33.0% ± 8.4% 
whereas no significant differences were detected for either MDMA or MDA 
between non-hydrolysed urine samples and acid and H. pomatia enzymatically 
hydrolysed specimens. Acid hydrolysis was recommended in that study as the 
hydrolysis method to evaluate HMMA, HMA and MDA in urine samples based on 
recoveries, time efficiency, and cost. 
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Table 8-16: Percentage differences in analyte concentrations between 
hydrolysed and non-hydrolysed urine samples (µg/ml). 
 
Sample % differences in analyte concentrations between hydrolysed and 
non-hydrolysed urine samples 
HMA-2Ac MDA-Ac HHMA-3Ac HMMA-2Ac MDMA-Ac 
U-01 416 1.01 25.7 130 -11.3 
U-02 264 14.1 -23.3 23.9 -4.05 
U-03 0 -13.7 10.5 98.7 -2.15 
U-04 245 -4.26 -6.3 64.89 -3.55 
U-05 0 -9.94 166 144 -3.98 
U-06 1790 -11.7 12.0 271 12.1 
U-07 350 1.04 1.24 -1.55 3.01 
U-08 520 38.3 -35.1 24.9 -2.57 
U-09 0 -34.1 92.8 551 5.27 
U-10 1580 -25.6 -24.3 85.1 6.47 
Mean 738% -4.49% 22.0% 139.2% -0.08% 
 
 
Mueller et al.162 found that recoveries of HHMA and HMMA after acid hydrolysis 
were significantly higher compared to enzymatic hydrolysis (glucuronidase and 
sulphatase). They also suggested that acid hydrolysis proved less efficient in 
cleaving glucuronides than sulphates whereas enzymatic hydrolysis proved less 
efficient in cleaving sulphates than glucuronides. 
 
Schwaninger et al.21 reported that HHMA, HHMA-sulphates, HMMA, HMMA-
sulphates and HMMA-glucuronides were excreted in human urine. Moreover, 
Shima et al.160,172 found that in phase II metabolism of MDMA, sulphation is 
quantitatively more significant than glucuronidation for HMMA in humans. 
 
Enzymatic hydrolysis in this study used β-glucuronidase from Helix pomatia 
which contained ≥100,000 units/ml of β-glucuronidase and ≤7,400 units/ml of 
sulphfatase. The results showed no significant differences in HHMA 
concentrations between non-hydrolysed and H. pomatia enzymatically 
hydrolysed samples.  One possible explanation for this is that sulphation of 
HHMA may predominate in humans in phase II metabolism. 
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Figure 8-22: LC/MS/MS MRM chromatograms of hydrolysed and non-hydrolysed 
urine, showing increased concentrations of free HMA and HMMA after hydrolysis. 
 
8.7.5 Post mortem case samples 
Three urine samples which were known to be positive for MDMA by ELISA 
screening were obtained from Forensic Medicine and Science, University of 
Glasgow as part of the investigation of post mortem medico-legal cases. All 
samples were analysed for MDMA and their metabolites in un-hydrolysed urine 
using the LC/MS method described above. Concentrations outside the calibration 
range were estimated by extrapolation and are reported here for research 
comparison purposes only. 
 
MDMA and its metabolites were detected in all case samples (see Table 8-17). 
MDMA, MDA, HHMA and HMMA concentrations were found in the ranges 9.13-32.6 
µg/ml, 0.20-1.25 µg/ml, 0.55-1.50 µg/ml and 0.29-0.50 µg/ml, respectively. The 
concentrations of MDMA in the urine samples were found to be higher than the 
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calibration range.  However, the concentrations of HHMA, HMMA and MDA in 
urine were found to be within the expected ranges (see Figure 8-23). 
 
Table 8-17: Concentrations of MDMA and its metabolites in non-hydrolysed urine 
from MDMA-positive post mortem cases. 
 
Sample MDMA** 
(µg/ml) 
MDA 
(µg/ml) 
HHMA 
(µg/ml) 
HMMA 
(µg/ml) 
HMA 
(µg/ml) 
Case 1 9.13 0.20 0.90 0.50 <0.025 
Case 2 32.6 1.25 1.50 0.38 <0.025 
Case 3 23.6 0.72 0.55 0.29 ND 
*ND = not detected 
**Concentrations outside the calibration range were estimated by extrapolation for research 
comparison purposes only. 
 
 
As noted earlier for hospital samples (Section 8.7.4.2), MDMA was present in 
these post mortem urine samples at much higher concentrations than any of its 
metabolites, in contrast to the findings of Segura et al. 91 However, the ratio of 
MDA/MDMA in the present study, in both clinical and post mortem cases is in 
agreement with those reported by Segura et al.91 and others, for example, 
Kunsman et al148 reported MDMA and MDA concentrations in randomly collected 
urine specimens from active-duty military members ranging from 0.38 to 96.2 
µg/ml and from 0.15 to 8.6 µg/ml respectively. The ratio of MDA/MDMA in urine 
is therefore not reliable as an indicator of an acute sudden death due to 
administration of MDMA. 
 
The method developed and validated in this chapter was successfully applied to 
routine post mortem case samples. However, dilution of samples or a higher 
calibration range should be considered for MDMA. 
 
114 
 
 
 
Figure 8-23: LC/MS/MS chromatograms of acetate derivatives of MDMA and its 
metabolites extracted from a post mortem human urine case sample. 
 
8.8 Conclusions 
This study presents a description of an in vitro metabolism study of MDMA using 
human liver microsomes (HLM) and a comparison of the metabolite pattern with 
that found in human urine. The study has confirmed that HLM can be used to 
simulate drug metabolism in humans and to provide chromatographic and mass 
spectrometric data on metabolites. Protein precipitation plus derivatisation 
coupled with LC/MS/MS provides a highly sensitive and selective assay procedure 
for detecting the dihydroxy metabolite of MDMA (HHMA). An analytical method 
was developed for MDMA and its metabolites in urine and has shown sufficient 
specificity by removing interfering compounds, including endogenous 
compounds. The method was validated and achieved an adequate sensitivity for 
analysis of MDMA and its metabolites in urine samples. Moreover, the method 
has shown adequate accuracy and precision for use in routine analysis. A 
standard enzymatic hydrolysis procedure using β-glucuronidase/sulfatase from 
Helix pomatia was successful for the recovery of total HMMA and total HMA form 
urine samples. 
 
In summary, the results show that HHMA and HMMA are major phase I 
metabolites of MDMA in humans. HHMA has a high reactivity due to its chemical 
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structure. However, chemical derivatisation can decrease the polarities of 
hydrophilic metabolites and improve their analysis on conventional reversed 
phase C18 columns. Acetate derivatives were stable in LC mobile phase up to 30 
h. Finally, this method was found to be suitable for application as a routine 
quantitative method for MDMA and its metabolites in both clinical and post 
mortem urine samples. 
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Chapter 9 In vitro metabolism studies on 
methylenedioxy-substituted amphetamines 
using human liver microsomes and 
LC/MS/MS with chemical derivatisation 
 
9.1 Introduction 
The chemistry and pharmacology of selected phenethylamine derivatives were 
covered in Chapter 7. Analysis of cathinones such as methylone and butylone in 
biological specimens is not a routine procedure in forensic toxicology 
laboratories. Only a few laboratories have identification methods for the 
detection of methylone and butylone but these do not cover their metabolites. 
Kamata et al.125 reported that methylone metabolite (HMMC) was detected in rat 
urine samples longer than methylone after a single dose of 5.0 mg/kg. HMMC 
was detectable up to 48 h post-dosing whereas methylone was detectable only 
up to 36 h post-dosing. This result has shown that analysis of HMMC in urine 
specimens can extend the detectable time of positive urine. 
 
9.2 Aims 
Based on the knowledge of the toxicity of MDMA and its metabolites, previous 
studies120,121,173 reported that β-keto amphetamines (cathinones) have similar 
neurotoxicity to MDMA. Limited data are available on the metabolism of 
methylone and butylone. A significant problem for the forensic toxicologist is a 
lack of information on the pharmacology and toxicology of NPS and a lack of 
reference standards of the metabolites and even of the parent drugs themselves. 
Ethical considerations preclude administration of NPS to human subjects, so any 
advance in the elucidation of NPS metabolism in humans will depend on the 
availability of alternative methods that can simulate human metabolic 
pathways. In vitro studies with human liver microsomes provide one potential 
alternative approach to metabolism studies. Furthermore, some phase I 
metabolites such as dihydroxy-metabolites (HHMA or HHMC) have a high polarity, 
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basicity and high water solubility. As noted in Chapter 8, an additional challenge 
to the forensic toxicologist is the analysis of these polar metabolites using 
conventional C18 HPLC columns, which result in low retention volumes and poor 
resolution of metabolites. Conversion of metabolites to more hydrophobic 
compounds by derivatisation has the potential to improve separations by 
reversed-phase HPLC and increase sensitivity in mass spectrometry, because 
mobile phases with a higher organic solvent content can be used. The need for a 
sensitive technique for detection and identification of methylone, butylone and 
their metabolites is essential. 
 
The initial aim of this work was to apply the in vitro method described in 
Chapter 8 to simulate the human metabolic pathways of methylendioxy-
substituted cathinones, using methylone and butylone as two representative 
examples of this type of drug, see Figure 9-1. The second part was aimed to 
develop a reliable, sensitive, and selective method for identification of 
methylone, butylone and their metabolites using reversed-phase LC/MS/MS. 
 
9.3 Review of previous analytical methods for the 
determination of methylone, butylone and their 
metabolites in biological samples 
Only a few analytical methods have been described and used in forensic 
toxicology for the quantitation of methylone and butylone and their metabolites 
in biological samples and these are reviewed below and summarised in Table 9-
1. 
 
 
 
Figure 9-1: Chemical structures of methylone and butylone. 
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Table 9-1: Previous GC/MS and LC/MS methods for the analysis of methylone, butylone and their metabolites in biological samples. 
Analytes Samples Chromatography Extraction Method Year 
MDMC, 
MDC, 
HMMC, 
3-OH-4-MeO-MC 
Human 
& rat 
urine 
GC/MS 
Column: DB-5MS capillary (30 m x 0.25 mm i.d. x 0.25 µm) 
LC/MS  
Column: L-column ODS (1.5 mm x 150 mm) 
Mobile phase: 10 mM ammonium formate buffer pH 3.5 and methanol 
in gradient mode 
Acid hydrolysis 
LLE: chloroform: 2-propanol (3:1, v/v)  
Derivatised with TFA 
2006125 
bk-MBDB 
bk-BDB 
β-OH-MBDB 
4-OH-3-MeO-Met. 
Urine GC/MS 
Column: DB-5MS capillary (30 m x 0.25 mm i.d. x 0.25 µm) 
LC/MS  
Column: L-column ODS2 (1.5 mm x 150 mm, 5 µm) 
Mobile phase: 10 mM ammonium formate buffer pH 3.5 and methanol 
in gradient mode;  flow Rate: 0.1 ml/min 
GC/MS 
Acid hydrolysis 
LLE: CH2Cl2 /IPA (4:1) 
Derivatised with TFA 
LC/MS 
Acid hydrolysis 
Protein precipitation with DBA MeOH 
2009138 
MDMC, bk-MBDB 
MDC, bk-BDB 
HMMC, HMC 
4-OH-3-MeO-Met. 
Di-OH butylone Met 
Human 
& rat 
urine 
GC/MS 
Column: HP-1 capillary (12 m x 0.2 mm i.d. x 0.33 µm) 
Enzymatic hydrolysis 
SPE: Isolute HCX  
Derivatised with Ac and/or 
Diazomethane 
2010126 
MDMC, MDC 
Dihydro-methylone 
bk-MBDB 
bk-BDB, 
OH-MBDB 
HLM LC/MS  
Column: Betasil phenyl/ hexyl (3 mm x 100 mm, 3 µm) 
Mobile phase: 5 mM ammonium acetate + 0.1% formic acid in water 
and in 5 mM ammonium acetate + 0.5% formic acid methanol  
HLM Incubation 2012127 
MDMC, MDC, 
HHMC, 
N-OH-Met., 
Dihydro-Met. 
HLM, 
human 
liver S9 
UHPLC-MS/MS 
Column: UHPLC BEH C18 (2.1 mm x 100 mm, 1.7 µm) 
Mobile phase: acidic water and acetonitrile + 0.05% formic acid  
Flow Rate: 0.6 ml/min 
HLM Incubation 2013128 
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Table 9-1 (cont.): Previous GC/MS and LC/MS methods for the analysis of methylone, butylone and their metabolites in biological 
samples. 
 
Analytes Samples Chromatography Extraction Method 
 
Year 
MDMC, 
MDC, 
HMMC, 
3-OH-4-MeO-MC, 
3-OH-MDMC 
Rat blood LC-MS 
Column: Luna HST C18 (2 mm x 100 mm, 2.5 µm) 
Mobile phase: 0.1% formic acid in water and MeOH in gradient mode 
Flow Rate: 0.15 ml/min 
Protein precipitation with 
methanol 
2013174 
MDMC, 
MDC, 
HHMC, 
HMMC 
Rat & 
human 
plasma 
LC/MS  
Column: Synergi Polar-RP (2 mm x 100 mm, 2.5 µm) 
Mobile phase: 0.1% formic acid in water and acetonitrile in gradient mode   
Flow Rate: 0.3 ml/min 
Enzymatic hydrolysis 
Protein precipitation: 
Perchloric acid 
SPE: SOLA SCX 
2015130 
MDMC, 
3-OH-4-MeO-MC 
RLM S9 LC/MS  
Column: Gold ODS (2.1 mm x 150 mm, 5 µm) 
Mobile phase: 10 mM ammonium acetate + 0.1% acetic acid in water and 
methanol in gradient mode   
Flow Rate: 0.2 ml/min 
RLM Incubation 2015129 
Met = metabolite 
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Metabolites of methylone in humans and rats were reported and published in 
2006 by Kamata et al.125 using GC/MS with TFA derivatisation and LC-ESI/MS. 
Methylone, 3-hydroxy-4-methoxymethcathinone (3-OH-4-MeO-MC), 4-hydroxy-3-
methoxymethcathinone (HMMC) and 3,4-methylenedioxycathinone (MDC) were 
synthesised and used as analytical standards. Acid hydrolysis was used as a 
sample preparation method for urine samples for LC-ESI/MS and the extracts 
were then derivatised with TFA for GC/MS. The GC/MS method was used to 
differentiate and identify methylone and its metabolites. The ion at m/z 149 and 
the molecular ion (M+) were selected to identify methylone and MDC and ions at 
m/z 154 and 247 were selected for HMMC and 3-OH-4-MeO-MC. LC-ESI/MS was 
additionally performed for the confirmation of methylone and its metabolites 
detected by GC/MS. Protonated molecules with M-H+ at m/z 194 for MDC, 208 
for methylone, 210 for HMMC and 3-OH-4-MeO-MC were selected for LC/MS. 
 
Metabolites of butylone (bk-MBDB) in human urine were reported and published 
in 2009 by Zaitsu et al.138 Butylone, nor-butylone (bk-BDB), bk-MBDB-M1 (4-OH-3-
MeO metabolite), bk-MBDB-M2 (3-OH-4-MeO metabolite), and β-OH-MBDB were 
synthesised and used as analytical standards. Acid hydrolysis and derivatisation 
was used as a sample preparation method for GC/MS. Analytes were separated 
using a fused-silica capillary column DB-5MS and detected with MS in full scan 
mode over the range from m/z 40-500. For LC/MS, deproteinisation with 
dibenzylamine methanol was used as a sample preparation for un-hydrolysed and 
hydrolysed urine. Analytes were separated using an L-column ODS2 semi micro 
column and detected in full scan mode. All butylone metabolites (bk-BDB, bk-
MBDB-M1, bk-MBDB-M2 and β-OH-MBDB) in human urine samples were identified 
by GC/MS and confirmed with LC/MS. 
 
Mayer et al.126 described a detection method for mephedrone, butylone and 
methylone and their metabolites in human and rat urine using GC/MS. Urine 
samples were  hydrolysed with a mixture of glucuronidase and arylsulfatase from 
Helix pomatia before being extracted by solid phase extraction using Isolute 
Confirm HCX cartridges. Analytes were eluted in two separate fractions: a non-
basic compounds fraction was eluted with methanol and a basic compounds 
fraction was eluted with a freshly prepared mixture of methanol: aqueous 
ammonia (98:2, v/v). Both fractions were derivatised by methylation with 
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diazomethane in diethyl ether, acetylation with acetic anhydride: pyridine (3:2, 
v/v), or combined methylation and acetylation. Analytes were separated using a 
cross-linked dimethyl silicone capillary column HP-1 (12 m x 0.2 mm i.d., 0.33 
µm phase thickness) and detected with MS in full scan mode over the mass range 
m/z 50-500 and in the SIM mode. Ions at m/z 149, 114, 72, and 58 were used to 
identify butylone and its metabolites and ions at m/z 149, 100, 86, and 58 were 
used to identify methylone and its metabolites. 
 
In 2012, Mueller and Rentsch127 described an offline and automated online 
metabolism methods using HLM applied to 11 cathinones with analysis by 
LC/MS(n). The offline method consisted of 500 pmol of total CYP substances 
diluted in phosphate buffer pH 7.4 and NADPH generating system. The mixture 
was incubated at 37oC for 3 h and the reaction was stopped by adding ice-cold 
acetonitrile. The online method was performed using an HTC PAL autosampler. 
The incubation mixture was introduced into a 200 µl injection loop and heated 
to 37oC using the column oven for 50 min. After incubation, the mixture was 
transferred to the online extraction columns using Cyclone® and C18 XL columns 
under alkaline conditions. Analytes were separated using a Betasil phenyl/ hexyl 
column (3 mm x 100 mm, 3 µm) and identified using their MS2 and MS3 mass 
spectra and neutral-loss scans. 
 
Pederson et al.128 described a method for the identification of methylone and its 
metabolites using in vitro studies.  Various recombination enzymes (P450 CYP: 
1A2, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4, 3A5 and supermix) and 
different liver fractions (UltraPool HLM and UltraPool human liver S9) were 
applied to the incubation mixture which was incubated at 37oC for 140 min. The 
reaction was stopped with ice-cold acidic acetonitrile containing 0.5% formic 
acid and the supernatant was analysed directly by UPLC-TOF/MS. HHMC was 
synthesised and characterised using 1H-NMR before being applied as a reference 
standard. Analytes were separated using a UHPLC BEH C18 column (2.1 mm x 100 
mm, 1.7 µm), identified using UHPLC-TOF/MS in positive ion scan mode and 
quantified using UPLC-MS/MS with two multiple-reaction-monitoring (MRM) 
transitions. Methylone was determined using the 208>160 (quantifier) and 
208>132 transitions and HHMC using the m/z 196>160 (quantifier) and 196>132 
transitions. 
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In 2015, Ellefsen et al.130 described the quantitative analysis of methylone and 
its metabolites in rat and human plasma using LC/MS. Samples were hydrolysed 
with β-glucuronidase before extraction by protein precipitation. Analytes were 
separated using a Phenomenex Synergi Polar-RP column (2.0 mm x 100 mm, 2.5 
µm) and quantitated with a 3200 QTRAP mass spectrometer. Methylone was 
determined with the m/z 208>160 (quantifier) and 208>132 transitions, MDC 
with the m/z 164>146 (quantifier) and 194>118 transitions, HHMC with the m/z 
196>160 (quantifier) and 196>132 transitions and HMMC with the m/z 210>160 
(quantifier) and 210>132 transitions. 
 
Chen129 described an in vitro method for the determination of four designer 
drugs (MDPV, 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP), methylone and 
methcathinone) and their major metabolites by LC/MS. Rat liver microsomes S9 
fraction was incubated with each target drug and NADPH at 37oC for 120 min. 
The reaction was stopped with acetonitrile and the supernatants were analysed 
by LC/MS. Analytes were separated using a Thermo Gold ODS column (2.1 mm x 
150 mm, 5 µm) and quantitated by an LXQ ion trap mass spectrometer. 
Methylone was identified from its protonated molecular ion, M-H+, at m/z 208 
and from the base peak fragment ion at m/z 190.1, which was chosen as the 
quantitation ion. 3-OH-4-MeO-MC was identified with an M-H+ at m/z 210.1 in 
MS1, at m/z 192.1 in MS/MS and at m/z 160.1 in MS3. 
 
9.4 Methods and materials 
9.4.1 Reagents and standards 
Methylone-HCl was purchased from Sigma-Aldrich Co, LLC (UK). Butylone-HCl 
was purchased from Lipomed (Kinesis, Ltd UK). All other reagents were the same 
as those described in Section 8.6.1. 
 
Individual stock standard solutions were prepared by dissolving each compound 
in methanol to achieve a concentration of 1 mg/ml of drug substance. Working 
standard solutions were prepared by serial dilution of stock standard solutions 
with methanol. All stock and working standard solutions were stored at 4oC. 
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9.4.1.1 Preparation of phosphate buffer saline (PBS) pH 7.4 
This was the same as described in Section 8.6.1.3. 
 
9.4.1.2 Preparation of NADPH generating system 
This was the same as described in Section 8.6.1.5. 
 
9.4.1.3 Preparation of methylone and butylone in phosphate buffer 
pH 7.4 
Stock solution of test standards (methylone and butylone) for use in metabolism 
studies were freshly prepared at 10 µg/ml in pH 7.4 phosphate buffer. 
 
9.4.2 In vitro assay (human liver microsomes) 
This was the same as described in Section 8.6.2. 
 
9.4.3 Derivatisation 
Acetylation of methylone, butylone and their metabolites was carried out using 
acetic anhydride. 50 µl of acetic anhydride: pyridine (3:2, v:v) was added to 
each of the dried HLM sample extracts, and heated at 60oC for 30 min. All 
samples were then evaporated to dryness at room temperature under a stream 
of nitrogen and residues were reconstituted in 200 µl of 10% acetonitrile in 
deionised water containing 0.1% formic acid and transferred to labelled 1.5 ml 
autosampler vials with inserts before analysis by LC/MS/MS. 
 
9.4.4 Liquid chromatography/mass spectrometry conditions 
9.4.4.1 Liquid chromatography conditions 
Chromatographic separation was performed on the same instrument and 
conditions as described in Section 8.6.5. The injection volume was 20 µl and the 
runtime was extended to 15 min per injection to allow butylone to be eluted 
between 9-10 min. 
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9.4.4.2 Mass spectrometry conditions 
Mass spectrometric analysis was performed on the same instrument as described 
in Section 8.6.5. The MRM transitions, FVs and CEs for derivatised methylone and 
butylone were optimised separately by direct infusion of each acetate derivative 
standard solution at a concentration of 5 μg/ml in mobile phase (50:50 v:v) into 
the MS. All analytes were identified and quantified based on their retention 
times and quantifier and qualifier ion ratios that were obtained from the MRM 
transitions. 
 
The MRM transitions, fragmentation voltages and collision energies used for the 
measurement of methylone and its metabolites were developed and are 
summarised in Table 9-2 and for butylone and its metabolites in Table 9-3. 
 
Table 9-2: MRM conditions for acetate derivatives of methylone and its 
metabolites. 
 
Name Precursor 
Ion (m/z) 
Fragmentor  
Voltage (eV) 
Product Ions  
(m/z) 
Collision 
Energy (eV) 
MDC-Ac 236 80 176 15 
146 30 
118 35 
Methylone-Ac 250 90 208 10 
190 20 
160 25 
HMMC-2Ac 
& β-OH-M 
294 95 234 15 
160 30 
132 35 
HHMC-3Ac 322 100 280 10 
178 30 
160 30 
β-OH-M = β-hydroxy-methylone 
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Table 9-3: MRM conditions for acetate derivatives of butylone and its 
metabolites. 
 
Name Precursor 
Ion (m/z) 
Fragmentor 
Voltage (eV) 
Product 
Ions  
(m/z) 
Collision 
Energy (eV) 
bk-BDB-Ac 250 80 190 15 
160 25 
132 30 
Butylone-Ac 264 90 222 10 
204 20 
174 25 
4-OH-3MeO-M-
2Ac 
308 100 248 15 
174 30 
162 30 
β-OH-M-2Ac 308 100 248 15 
   174 30 
   162 30 
Di-OH-M-3Ac 336 100 294 10 
192 20 
174 30 
 
 
9.5 Results and discussion 
9.5.1 Optimisation of LC/MS conditions 
9.5.1.1 LC separation 
In Chapter 8, MDMA, HHMA, HMMA, MDA and HMA were analysed in both HLM 
cultures and urine samples. The same LC method was used for the analysis of 
methylone, butylone and their metabolites in HLM samples but the MS-MRM 
method needed to be further developed. Target analytes in this study included 
hydrophilic compounds, the dihydroxy-metabolites of methylone and butylone 
and derivatisation with acetic anhydride was applied to HLM extracts for the 
purpose of improving LC separations by reversed-phase HPLC. 
 
The retention factors were 5.3 for methylone-Ac and 10.2 for butylone-Ac and 
the hold-up time (t0 = 0.8 min) was determined by injecting pure methanol. 
Figure 9-2 shows the separation of standards of methylone-Ac and butylone-Ac 
on the Gemini C18 column. 
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Figure 9-2: Chromatograms of methylone-Ac and butylone-Ac on a Gemini C18 
column. 
 
9.5.1.2 MRM optimisation 
To optimise MRM conditions, standards of methylone and butylone were 
derivatised with acetic anhydride and re-dissolved in methanol. The Ac-
derivatives of the standards were directly injected into the mass spectrometer 
interface using a syringe pump with positive ESI to obtain the precursor ion, 
product ions, FVs and CEs. Because of unavailability of reference standards of 
methylone and butylone metabolites, a minimum of four identification points 
(IPs)166 was required. One quantifier and two or three qualifier ions were used to 
identify target analytes. FVs and CEs of derivative butylone and methylone 
metabolites were developed based on derivatives of standards of methylone and 
butylone and are summarised in Tables 9-2 and 9-3 respectively. Under 
optimised conditions, most ion reactions had different optimum CEs. For Figures 
9-4 and 9-6, CEs of 10 and 20 eV were chosen to demonstrate the patterns, 
although ion ratios at other CEs are different. 
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Figure 9-3: Keto–enol tautomerism of methylone and butylone. 
 
The fragmentation patterns of derivatives of methylone and butylone in LC-MS 
are rather different from the types of ion reaction found in GC-MS. Previous 
studies have shown that ketones can isomerise to alcohols by keto-enol 
tautomerism, see Figure 9-3. Zuba68 found that in ESI, a proton was attached to 
the oxygen atom of cathinone (in its enol-form) to form a protonated molecule 
(M-H+) and the first fragmentation was the loss of water (H2O). 
 
 
 
Figure 9-4: Product ion scan spectra of the Ac-derivative of a methylone 
standard at CEs of 10 and 20 eV. The optimum CE values for each ion are listed 
in Table 9-2. 
 
Figure 9-4 shows the product ion scan spectra of the Ac-derivative of methylone 
standard using LC/MS/MS. When the CE was 10 eV, the mass spectrum of 
methylone-Ac had a base peak at m/z 208 and a small peak for the protonated 
molecule (M-H+, m/z 250). At a higher CE of 20 eV, the protonated molecular ion 
was absent, the fragment ion peak of methylone-Ac at m/z 208 decreased in 
intensity and the peaks at m/z 160 and 190 increased. The first fragmentation of 
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methylone-Ac was the loss of ketene (COCH2, 42 Da) from the protonated 
molecular ion to give the ion at m/z 208 followed by the loss of water to give 
the ion at m/z 190. 
 
 
 
Figure 9-5: Mass spectral fragmentation of methylone-Ac. 
 
From MRM optimisation, the protonated molecular ion of methylone-Ac at m/z 
250 was used as the precursor ion and its fragment ions at m/z 208, 190 and 160 
were selected as product ions. The most intense product ion peak at m/z 160 
was chosen as a quantifier ion and the ratio of qualifier/quantifier at the 
optimised CEs were approximately 71% for m/z 208 and 34% for m/z 190. The 
mass spectral fragmentation of methylone-Ac is shown in Figure 9-5. 
 
 
 
Figure 9-6: Product ion scan spectra of the Ac-derivative of a butylone standard 
at CE of 10 and 20 eV. The optimum CE values for each ion are listed in Table 9-
3. 
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Butylone-Ac was found to fragment in a similar way to methylone-Ac. Figure 9-6 
shows the product ion scan spectra of the Ac-derivative of butylone standard 
using LC/MS/MS. When the CE was 10 eV, the mass spectrum of butylone-Ac had 
a base peak at m/z 222 and a small peak for the protonated molecular ion (m/z 
264, M-H+). At a higher CE of 20 eV, the fragment ion peak of butylone-Ac at 
m/z 222 decreased in intensity and the peaks at m/z 174 and 204 increased. The 
first fragmentation of butylone-Ac was the loss of the ketene group (COCH2, 42 
Da) from the protonated molecular ion to give the fragment at m/z 222 followed 
by the loss of water to give m/z 204, the same pattern as that obtained for 
methylone. 
 
 
Figure 9-7: Mass spectral fragmentation of butylone-Ac. 
 
From MRM optimisation, the protonated molecular ion of butylone-Ac at m/z 264 
was used as the precursor ion and its fragment ions at m/z 174, 204 and 222 
were selected as product ions. The most intense product ion peak at m/z 174 
was chosen as the quantifier ion and the ratio of qualifier/quantifier at the 
optimised CEs were approximately 81% for m/z 204 and 49% for m/z 222. Mass 
spectral fragmentation of butylone-Ac is shown in Figure 9-7. 
 
9.5.2 General approach for metabolite identification 
Because methylone and butylone have both methylenedioxy and β-ketone groups 
within their structure, their metabolic pathways are likely to resemble those of 
MDMA and cathinone. Demethylenation of the methylenedioxy ring followed by 
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O-methylation of either the 3- or 4-hydroxy group on the benzene ring has been 
reported as the primary metabolic route whereas N-dealkylation has been 
reported as a minor metabolic pathway of methylone and butylone in 
humans74,126,138. In addition, reduction of the β-ketone has been reported as one 
of the major metabolic pathways of butylone in humans74,138. 
 
Part of the purpose of this study derived from the fact that metabolites of 
methylone including HHMC, HMMC and MDC and metabolites of butylone 
including dihydroxy-metabolite, β-hydroxy-butylone and nor-butylone were not 
commercially available and in vitro metabolism provides one route to obtaining 
them. However, the concentrations of metabolites obtained from HLM are too 
low for full scan LC/MS/MS analysis and the MRM mode has to be used, which 
means the product ions must be specified in advance. As a result, the mass 
spectral characteristics of acetate-derivatives of methylone and butylone 
metabolites were predicted based on the mass spectra of the acetate derivatives 
of methylone and butylone and of MDMA metabolites (HHMA-3Ac, HMMA-2Ac and 
HMA-2Ac). Moreover, multiple reaction monitoring (MRM) ions were reviewed 
and compared with mass spectra of synthesised metabolite reference standards 
such as HHMC, MDC, HMMC and nor-butylone described in the previous studies 
referred to above. 
 
9.5.3 Methylone metabolite identification 
Metabolism studies of methylone in humans were first published by Kamata et 
al. in 2006. However, most were in vivo studies and only a few in vitro studies 
have been reported127-129. Both in vivo and in vitro studies on the metabolism of 
methylone in humans found that methylone has several metabolic pathways, 
similar to MDMA, including N-demethylation and demethylenation followed by O-
methylation of either a 3- or 4-hydroxy group on the benzene ring. In addition, 
β-keto reduction to the corresponding amino-alcohols that was partly involved in 
the metabolism of cathinone was not observed in the previous studies of 
methylone metabolism125. 3,4-dihydroxymethcathinone (HHMC), the 
intermediate metabolite leading to 4-hydroxy-3-methoxymethcathinone (HMMC) 
was expected to be the major metabolite of methylone produced by human liver 
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microsomes whereas 3,4-methylenedioxycathinone (MDC) was expected to be a 
minor metabolite of methylone in this study. 
 
9.5.3.1 Predicted mass spectral fragmentation of methylone 
metabolites 
Fragment ions in LC/MS arise from simple cleavages of the chemical bonds and 
some from rearrangements, which are different from the mass spectra obtained 
in GC/MS. Kamata et al.125 reported the identification method of methylone 
metabolites. MDC, HMMC and 3-OH-4-MeO-MC were synthesised and analysed 
with both GC/MS and LC/MS/MS. For methylone, the LC/MS mass spectrum 
shows the base peak to be the protonated molecular ion (m/z 208, M-H+) and 
small fragment peaks are present at m/z 132, 160 and 190.  For MDC, the base 
peak is the protonated molecule (m/z 194, M-H+) and small fragment peaks are 
present at m/z 118, 146 and 176. For HMMC and 3-OH-4-MeO-MC, the base peaks 
in their mass spectra are also the protonated molecular ions (both at m/z 210, 
M-H+) with smaller fragment peaks at m/z 132, 160 and 192. However, the mass 
spectra of isomers, HMMC and 3-OH-4-MeO-MC, were very similar. Small 
fragment ions that correspond to the loss of water (M-H+-H2O) appeared in all 
mass spectra (m/z 190 for methylone, 176 for MDC and 192 for HMMC and 3-OH-
4-MeO-MC). These spectra are in agreement with the ESI-LC/MS and LC/MS/MS 
spectra described by Zaitsu et al.74 and Chen129. 
 
Moreover, Ellefsen et al.130 reported the LC/MS/MS positive ESI MRM ions for 
methylone and its metabolites in rat and human plasma. Standards of HHMC, 
HMMC and MDC were synthesised and analysed. Protonated molecular ions were 
chosen as precursor ions, at m/z 196.1 for HHMC, 210.1 for HMMC and 194.1 for 
MDC. For product ions, those at m/z 160.1 and 132.2 were selected for HHMC, 
160.2 and 132.3 for HMMC and 146.0 and 118.1 for MDC.  
 
In the present in vitro study, HHMC was expected to be a major metabolite and 
MDC was expected to be a minor metabolite in HLM samples. Predicted mass 
spectral fragmentation of MDC, HHMC and HMMC acetates was postulated based 
on the data mentioned above. As described in the previous section, the first 
fragmentation of acetate derivatives is the loss of ketene (-COCH2, 42 Da). The 
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molecular ions of MDC-Ac, HMMC-2Ac and HHMC-3Ac were at m/z 236, 294 and 
322, respectively. The product ions from the loss of the ketene would be at m/z 
194 for MDC (Figure 9-8), 252 for HMMC and 280 for HHMC. Other product ions at 
m/z 146 and 118 for MDC, m/z 160 and 132 for HMMC and m/z 178,160 and 132 
for HHMC were expected, based on the spectra from Kamata and Ellefsen. Each 
predicted fragment ion was subsequently included in the initial LC/MS/MS 
analysis of HLM samples to identify which metabolites were present and the 
fragment ions they actually produced. 
  
 
Figure 9-8: Mass spectral fragmentation of MDC-Ac and HHMC-3Ac. 
 
The MRM method for analysis of acetate derivatives of methylone and its 
metabolites finally adopted was as summarised in Table 9-2, in Section 9.4.4.2 
above. 
9.5.3.2 Residual methylone identification in HLM samples 
Pooled human liver microsomes were incubated with methylone and extracted 
and analysed using the LC/MS/MS method described previously. The acetate 
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derivative of a methylone standard was identified at retention time of 5.0 min 
and confirmed by assessing the qualifier/quantifier ion ratios with ± 20% 
tolerance. 
 
The un-metabolised methylone acetate (MDMC-Ac) was identified in HLM 
samples. The retention time and the mass ratio of methylone obtained from HLM 
samples were consistent with those observed for the methylone standard. 
Methylone derivative (MDMC-Ac) was eluted at 5.0 min and was identified and 
confirmed by quantifier and qualifier ions at m/z 250>208, 250>190 and 
250>160. The qualifier/quantifier ion ratio was 74% for m/z 208 and was 35% for 
m/z 190 which were in the acceptable range. LC-MS/MS MRM chromatograms of 
methylone-Ac in HLM sample compared with the Ac-derivative of a standard are 
shown in Figure 9-9. 
 
 
Figure 9-9: Specimen LC-MS/MS MRM chromatograms of methylone-Ac in HLM 
samples compared with the Ac-derivative of a methylone standard. 
 
9.5.3.3 In vitro nor-methylone (MDC) identification 
The acetate of nor-methylone (3,4-methylenedioxycathinone, MDC-Ac, a minor 
metabolite) was identified in HLM samples by MRM transitions at m/z 236>176, 
236>146 and 236>118 and was eluted at 3.2 min. The MRM transition at m/z 
236>118 gave the highest corresponding peak area for MDC-Ac in all HLM 
samples, followed by the transitions m/z 236>146 and 236>176. LC/MS/MS MRM 
chromatograms of nor-methylone-Ac in HLM samples are shown in Figure 9-10. 
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Figure 9-10: Specimen LC/MS/MS MRM chromatograms for nor-methylone-Ac in 
HLM samples. 
 
9.5.3.4 In vitro HHMC identification 
The derivative of 3,4-dihydroxymethcathinone (HHMC-3Ac), a major metabolite, 
was identified in HLM samples by MRM transitions at m/z 322>280, 322>178 and 
322>160 and was eluted at 5.7 min. The MRM transition at m/z 322>280 gave the 
highest corresponding peak area for HHMC-3Ac in all HLM samples, followed by 
the transitions m/z 322>178 and 322>160. LC/MS/MS MRM chromatograms of 
HHMC-3Ac in HLM samples are shown in Figure 9-11. 
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Figure 9-11: Specimen LC-MS/MS MRM chromatograms for dihydroxy-
methcathinone-3Ac in HLM samples. 
 
9.5.3.5 In vitro HMMC identification 
The acetate of 4-hydroxy-3-methoxymethcathinone (HMMC-2Ac) was identified 
in HLM samples by MRM transitions at m/z 294>234, 294>160 and 294>132 and 
was eluted at 5.5 min. The MRM transition at m/z 294>234 gave the highest 
corresponding peak area for HMMC-2Ac in all HLM samples, followed by the 
transitions m/z 294>160 and 294>132. LC/MS/MS MRM chromatograms of 4-
hydroxy-3-methoxymethcathinone-2Ac in HLM samples are shown in Figure 9-12. 
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Figure 9-12: Specimen LC/MS/MS MRM chromatograms for 4-hydroxy-3-
methoxymethcathinone-2Ac in HLM samples. 
 
Moreover, 4-hydroxy-3-methoxymethcathinone and β-hydroxy-methylone are 
structural isomers which have similar fragmentation ions (Figure 9-13). Previous 
studies of methylone metabolites in human urine reported that the ketone-
reduction metabolite was not observed74,125,138. However, Mueller and Rentsch127 
reported that the ketone-reduction metabolite and hydroxy metabolite of 
methylone were both detected in in vitro study on the metabolism of 11 
cathinones using HLM.  
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Figure 9-13: Structures of HMMC and methylone ketone-reduction metabolites. 
 
Because HMMC and β-hydroxy-methylone are structural isomers, transitions for 
HMMC and β-hydroxy metabolite would be the same. In the present study, MRM 
transitions at m/z 294>234, 294>160 and 294>132 for HMMC would also be valid 
for β-hydroxy metabolite identification. The problem was then to decide on 
which isomer was actually present in the absence of standards.  
 
There is evidence that the isomer present is the β-hydroxy metabolite, as these 
transitions had the highest corresponding peak areas among the three 
metabolites (Figure 9-14), i.e. this was the main metabolite. The previous study 
on MDMA, reported in Chapter 8, showed that the major metabolite of MDMA 
generated by HLM is HHMA and only a trace of HMMA was detected in MDMA-HLM 
samples. Because HHMA is an intermediate metabolite leading to HMMA, 
concentrations of HHMC detected in HLM samples should, by analogy, be higher 
than HMMC. It is unlikely that the metabolic pattern would be reversed for 
methylone such that HMMC was the major metabolite. It was therefore 
tentatively concluded that this was the β-hydroxy metabolite.  
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Figure 9-14: Specimen LC-MS/MS MRM chromatograms for methylone 
metabolites in an HLM sample. 
 
These results suggest that the ketone-reduction product is one of the major 
metabolites of methylone in humans. However, authentic standards of HMMC 
and ketone-reduction metabolite are required to confirm the identification of 
both metabolites. 
 
9.5.4 Butylone metabolite identification 
The 3,4-dihydroxy-metabolite (di-OH-M) and β-OH-metabolite (β-OH-M) were 
expected to be the major metabolites of butylone formed by human liver 
microsomes whereas nor-butylone (bk-BDB) was expected to be a minor 
metabolite of butylone in this study. Multiple reaction monitoring (MRM) ions 
were reviewed and compared with mass spectral characteristics of synthesised 
reference standards of bk-BDB and 4-OH-3-MeO-M described in previous studies 
by other workers which are summarised below. 
The first metabolism study of butylone was reported by Zaitsu et al.138 in 2009. 
All metabolites in urine samples were determined based on GC/MS with TFA 
derivatisation. In 2011, Zaitsu et al.74 reported a review of methylone, butylone 
and ethylone metabolism in humans. Butylone metabolites (bk-BDB, 4-OH-3-
MeO-M and 3-OH-4-MeO-M) were synthesised and analysed by both GC/MS and 
LC/MS/MS.  
M-H+ 294 
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For butylone, the mass spectrum shows large fragment ion peaks at m/z 174, 
146, 131 and 204 and a small peak for the protonated molecule (m/z 222, M-H+).  
For bk-BDB, the mass spectrum shows large fragment ion peaks at m/z 117 and 
160 and small fragment ion peaks at m/z 132 and 190. For 4-OH-3-MeO-M and 3-
OH-4-MeO-M, the mass spectrum shows large fragment peaks at m/z 134, 174 
and 162 and small fragment peaks at m/z 146, 206 and 224 (the protonated 
molecule, M-H+). However, the mass spectra of the isomers, 4-OH-3-MeO-M and 
3-OH-4-MeO-M, were very similar. As in the case of methylone, the small 
fragment ions that correspond to the loss of water (M-H+-H2O) were present in all 
mass spectra (m/z 204 for butylone, 190 for bk-BDB and 206 for 4-OH-3-MeO-M 
and 3-OH-4-MeO-M). 
 
Since 2009, only four metabolism studies of butylone have been reported. Three 
of them were in vivo studies in human urine whereas only one was an in vitro 
study with human liver microsomes (HLM). Mueller and Rentsch127 reported the 
metabolism of 11 cathinones using human liver microsomes with LC-MS(n) 
analysis. Nor-butylone and demethylenyl-diol-metabolites were reported as 
phase I metabolites produced by HLM and the β-ketone reduction metabolite 
that was reported by Zaitsu et al.74 and Meyer et al.126 was not observed. 
However, information on the MS2 and MS3 spectra of butylone metabolites was 
not provided in this paper. 
 
9.5.4.1 Identification of residual butylone in HLM samples 
Pooled human liver microsomes (HLM) were incubated with butylone and 
extracted and analysed using the LC/MS/MS method described previously. The 
acetate derivative of a standard of butylone was identified at a retention time 
of 8.95 min and confirmed by assessing the qualifier/quantifier ion ratios with ± 
20% tolerance. 
 
The derivative of un-metabolised butylone (bk-MBDB-Ac) was detected in 
extracts. The retention time and the mass ratio of butylone obtained from HLM 
samples were consistent with those observed in the standard. Butylone acetate 
derivative (bk-MBDB-Ac) was eluted at 9.0 min and was identified and confirmed 
by quantifier and qualifier ion reactions at m/z 264>222, 264>204 and 264>174. 
The qualifier/quantifier ion ratio was 82% for m/z 222 and 49% for m/z 204 
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which were in the acceptable range. LC/MS/MS MRM chromatograms of 
butylone-Ac in HLM extracts compared with the Ac-derivative of a standard are 
shown in Figure 9-15. 
 
 
 
Figure 9-15: Specimen LC/MS/MS MRM chromatograms of butylone-Ac in HLM 
sample compared with the Ac-derivative of a butylone standard. 
 
9.5.4.2 In vitro nor-butylone identification  
9.5.4.2.1 Predicted mass spectral fragmentation of nor-butylone (bk-
BDB) 
 
As described for methylone metabolites, the first fragmentation of acetate 
derivatives is the loss of ketene (COCH2, 42 Da). The protonated molecular ion of 
bk-BDB-Ac would be at m/z 250 and the product ion from the loss of ketene 
would be at m/z 208. Other product ions at m/z 190, 160 and 132 for bk-BDB are 
predicted, based on Zaitsu et al.74 A comparison of butylone and nor-butylone 
LC/MS/MS mass spectra in Zaitsu’s paper shows that both of them have the same 
fragmentation pattern. The first fragment of both is the loss of H2O (m/z 204 for 
bk-MBDB and m/z 190 for bk-BDB). The second fragment is the loss of m/z 30 
(CH2O, m/z 174 for bk-MBDB and m/z 160 for bk-BDB). The next fragment is the 
A
bu
nd
an
ce
 
Time (min) 
141 
 
loss of m/z 28 (m/z 146 for bk-MBDB and m/z 132 for bk-BDB). These results 
indicate that the LC/MS/MS fragmentation occurs at the methylenedioxy ring 
rather than on the side chain. 
 
9.5.4.2.2 Identification of nor-butylone in HLM samples 
The acetate derivative of nor-butylone (bk-BDB-Ac, a minor metabolite) was 
identified in HLM extracts by MRM transitions at m/z 250>190, 250>160 and 
250>132 and was eluted at 4.7 min. The MRM for m/z 250>160 gave the highest 
corresponding peak area for bk-BDB-Ac in all HLM samples, followed by 
transitions at m/z 250>132 and 250>190. LC/MS/MS MRM chromatograms of nor-
butylone-Ac in HLM samples are shown in Figure 9-16. The small peak that was 
observed at 5.0 min in HLM sample was expected to be a peak of a nor-butylone 
isomer, as yet unidentified. 
 
 
Figure 9-16: Specimen LC-MS/MS MRM chromatograms of nor-butylone-Ac in HLM 
samples. 
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9.5.4.3 In vitro dihydroxy metabolite of butylone identification 
9.5.4.3.1 Predicted mass spectral fragmentation of the dihydroxy 
metabolite of butylone 
For the dihydroxy metabolite of butylone, no information on the LC/MS/MS mass 
spectrum and MRM transitions have been published before. The protonated 
molecular ion of di-OH-M-3Ac would be at m/z 336 and the product ions from 
the loss of ketene groups would be at m/z 294, 252 and 210. A predicted 
fragment ion at m/z 192 would come from the loss of H2O from the dihydroxy 
metabolite itself (M-H+, m/z 210). Moreover, previous studies on methylone 
metabolites have shown that synthesised standards of HHMC and HMMC gave the 
same fragment ions at m/z 160 and 132. A standard of 4-OH-3-MeO-butylone 
metabolite has been synthesised by Zaitsu et al.74 and fragment ions at m/z 174 
and 146 were observed in its mass spectrum. By analogy with the two 
methylone-derived compounds, these two ions are also expected to be present 
in the mass spectrum of the dihydroxy metabolite of butylone.  
The predicted ESI-LC/MS/MS fragmentation patterns of the acetate derivatives 
of the dihydroxy metabolite are summarised in Table 9-4 and shown in Figure 9-
17. The table also indicates which ions were subsequently detected in HLM 
samples and three MRM transitions from amongst these that provided high 
response peak areas were chosen for the identification method described in 
Section 9.4.4.2 above. 
Table 9-4: The predicted ESI-LC/MS/MS fragmentation patterns of a dihydroxy 
metabolite of butylone. 
 
Compound M-H
+ 
(m/z) 
Product 
ion 
(m/z) 
Predicted losses Detection 
in HLM 
sample Da Possible composition 
di-OH-M-3Ac 336 294 -42 COCH2 Y 
  252 -42 294-COCH2   (2Ac) Y 
  234 -18 252–H2O N 
  210 -42 252-COCH2  (3Ac, di-OH-M) N 
  192 -18 H2O Y 
  174 -18 H2O, Ref*74 Y 
  162 -12 C N 
  146 -16 NH2, Ref*74 Y 
Ref* = predicted from literature data 
Bold are selected ions 
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Figure 9-17: Predicted ESI LC/MS/MS fragmentation patterns of acetate 
derivatives of butylone metabolites (4-OH-3-MeO-M-2Ac and di-OH-M-3Ac). 
Fragmentations are marked in red. Hydrogen transfers are indicated by an “H” 
adjacent to the bond which is broken. 
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9.5.4.3.2 Identification of the dihydroxy metabolite of butylone in 
HLM samples 
 
The acetate derivative of the 3,4-dihydroxy metabolite (di-OH-M-3Ac), a major 
butylone intermediate metabolite, was identified in extracts by MRM transitions 
at m/z 336>294, 336>252, 336>192, 336>174 and 336>146. This compound was 
expected to elute after butylone-Ac itself, which eluted at 9.0 min (Section 
9.5.4.1). It was in fact detected in HLM samples and was eluted at 
approximately 10.1 min. Amongst the predicted MRM transitions, the transition 
at 336>294 gave the highest corresponding peak area for di-OH-M-3Ac in all HLM 
samples, followed by 336>174, 336>192, 336>252 and 336>146, respectively. 
LC/MS/MS MRM chromatograms of di-OH-M-3Ac in HLM samples are shown in 
Figure 9-18. 
 
 
 
Figure 9-18: Specimen LC/MS/MS MRM chromatograms for di-OH-M-3Ac in HLM 
samples. 
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9.5.4.4 In vitro β-OH and 4-OH-3-MeO metabolites of butylone 
identification 
9.5.4.4.1 Predicted mass spectral fragmentation of β-OH and 4-OH-3-
MeO metabolites of butylone 
 
Because the β-hydroxy-butylone and 4-OH-3-MeO butylone metabolites are 
structural isomers, predicted LC/MS/MS fragmentation patterns of both acetate 
metabolites contain quite similar fragment ions.  
 
The molecular ion of β-OH-M-2Ac would be at m/z 308 and the product ions from 
the loss of ketene groups would be at m/z 266 and 224. A product ion at m/z 
248 was predicted from the loss of one ketene and H2O. A predicted fragment 
ion at m/z 206 would come from the loss of H2O from the β-OH-metabolite itself 
(M-H+, m/z 224). Other product ions at m/z 174, 162 and 134 were chosen from 
predicted fragmentation patterns.  
 
The molecular ion of 4-OH-3-MeO-M-2Ac would be at m/z 308. The product ions 
in the mass spectrum of the 4-OH-3-MeO-M-2Ac from the loss of two molecules 
of ketene would be at m/z 248 and 224. Other product ions at m/z 206, 174, 162 
and 134 were predicted following Zaitsu et al.74 The product ion at m/z 206 
would come from the loss of H2O from the 4-OH-3-MeO-M itself (M-H+, m/z 224). 
 
The predicted ESI-LC/MS/MS fragmentation patterns of the acetate derivatives 
of β-hydroxy metabolite 4-OH-3-MeO-M are summarised in Table 9-5 and shown 
in Figure 9-19. The table also indicates which ions were subsequently detected 
in HLM samples and three of these MRM transitions that provide high response 
peak areas were chosen for the identification method, described in Section 
9.4.4.2 above. 
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Figure 9-19: Predicted ESI LC/MS/MS fragmentation patterns of acetate 
derivatives of butylone metabolites (4-OH-3-MeO-M-2Ac and β-OH-M-2Ac). 
Fragmentations are marked in red. Hydrogen transfers are indicated by an “H” 
adjacent to the bond which is broken. 
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Table 9-5: The predicted ESI-LC/MS/MS fragmentation patterns of β-hydroxy and 
4-OH-3-MeO metabolites of butylone. 
 
Compound M-H
+ 
(m/z) 
Product 
ion 
(m/z) 
Predicted losses Detection 
in HLM 
sample Da Possible composition 
β-OH-M-2Ac & 
4-OH-3-MeO-M 308 
266 -42 COCH2 N 
248 -18 266-H2O    Y 
224 -42 266–COCH2 (2Ac) N 
206 -18 224-H2 O, Ref*  N 
174 -32 CH3OH, Ref*74 Y 
162 -12 C, Ref*74 Y 
146 -16 NH2, Ref*74 Y 
Ref* = predicted from literature data 
Bold are selected ions 
 
9.5.4.4.2 Identification of β-OH and 4-OH-3-MeO metabolites of 
butylone in HLM samples 
 
The ketone-reduction metabolite of butylone has been identified and reported 
by Zaitsu et al.74,138 and Meyer et al.126 The acetate derivatives of the β-hydroxy 
metabolite (β-OH-M-2Ac) and 4-hydroxy-3-methoxy-metabolite (4-OH-3MeO-M-
2Ac) were identified in extracts by MRM transitions at m/z 308>248, 308>174, 
308>162 and 308>134. The corresponding peaks for the molecular ion at m/z 308 
were detected in HLM samples at approximately 8.8 and 10.3 min. The MRM 
transition at m/z 308>248 gave the highest corresponding peak area in all HLM 
samples, followed by the transitions at m/z 308>174, 308>162 and 308>134, 
respectively. LC/MS/MS MRM chromatograms of β-OH-M-2Ac and 4-OH-3MeO-M-
2Ac in HLM samples are shown in Figure 9-20. 
 
As mentioned above in Section 9.5.4.4.1, the 4-hydroxy-3-methoxy-metabolite 
and the β-hydroxy metabolite of butylone are structural isomers. MRM 
transitions set up for determination of β-OH-M-2Ac and 4-OH-3MeO-M-2Ac were 
detected in all HLM samples, with the highest corresponding peak area amongst 
the three metabolites. Also, as mentioned in Section 9.5.3.5 for the 
identification of β-hydroxy-methylone metabolite in HLM samples and 
concerning MDMA-HLM results in which only a trace of HMMA was detected, all 
information obtained in these studies supported the conclusion that the peak 
detected at 10.2 min was the ketone-reduction metabolite rather than the 4-
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hydroxy-3-methoxy-metabolite. The earlier peak eluted at 8.8 min was expected 
to be 4-OH-3MeO-M-2Ac. However, confirmation of β-OH-Met and 4-OH-3-MeO-
Met will depend on the availability of authentic reference standards. 
 
 
 
Figure 9-20: Specimen LC/MS/MS MRM chromatograms for β-OH-M-2Ac (at 10.3 
min) and 4-OH-3MeO-M-2Ac (at 8.8 min) in two HLM samples. 
 
9.6 Conclusions 
Knowledge of the metabolic pathways of methylone and butylone is important 
for method development in forensic toxicology analysis, especially for the 
analysis of blood and urine specimens. This study has confirmed that human liver 
microsomes can be used to simulate drug metabolism in humans and to provide 
chromatographic and mass spectrometric data on drug metabolites. The 
analytical method for metabolites was developed based on reviewed data and 
MRM transitions predicted from drug chemical structures which achieved an 
adequate sensitivity for the analysis and identification of methylone, butylone 
and their metabolites in HLM samples. 
 
In summary, the results show that ketone-reduction and demethylenation are 
major phase I metabolic pathways of methylone and butylone in humans whereas 
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N-demethylation is a minor pathway. To our knowledge, this is the first method 
designed for the identification of the dihydroxy metabolite of butylone. 
However, both methylone and butylone major metabolites (ketone-reduction 
and 4-OH-3-MeO metabolites) are structural isomers. To apply this method for 
routine analysis, reference standards of both metabolites are required. Finally, 
this method could be developed and applied as a routine quantitative method to 
detect and confirm abuse of butylone and methylone in authentic samples. 
Future studies in vitro and/or in vivo on phase II metabolites of β-keto-
amphetamines are required. 
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Chapter 10 In vitro metabolism study on PMA using 
human liver microsomes and LC/MS/MS 
with chemical derivatisation 
 
10.1 Introduction 
para-Methoxyamphetamine (PMA), a classic amphetamine-type designer drug, 
has been implicated in deaths since the 1970s101,113. PMA is a toxic mono-
methoxy ring-substituted amphetamine derivative with strong stimulant and 
hallucinogenic properties. PMA has been controlled in the UK since 1977 and was 
added to the 1971 UN Convention on Psychotropic Substances in 1986175. 
Although studies of PMA have been carried out since the late 1970s, few 
metabolism studies of PMA have been reported. Moreover, deaths related to PMA 
alone or PMA in conjunction with other drugs such as MDMA have been reported 
until 2013. In 1998, six deaths related to PMA were reported in Australia114. 
Three years later, three fatalities were reported in the Midwest of the United 
Stated of America106 and three cases of PMA overdose were reported in 
Canada115. In 2012, the National Programme on Substance Abuse Deaths reported 
that the number of UK deaths from “Legal highs” had risen to at least 68 cases 
and that 17 of these were linked to PMA175. Moreover, seven deaths linked to 
fake ecstasy containing PMA were reported in Scotland in 2013176. 
 
A few previous metabolism studies of PMA have shown that the major metabolic 
pathway in humans is O-demethylation to 4-hydroxyamphetamine (PHA) which is 
then partially conjugated.  A minor metabolic pathway is beta-hydroxylation to 
β-hydroxy-PMA, followed by O-demethylation to 4-hydroxynorephedrine109. 
Furthermore, PHA is also found as an important metabolite of both amphetamine 
and methamphetamine177-179. Identification and confirmation of PMA is included 
in routine analysis of the amphetamines group in forensic toxicology 
laboratories. However, routine analysis of PMA has regularly detected only PMA 
itself in both blood and urine samples180,181. To confirm the misuse of PMA from 
urine samples in some cases such as in workplace drugs testing, PMA metabolites 
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need to be identified and confirmed. Moreover, Hubbard et al.182 reported that 
PHA was detected in monkey urine samples at concentrations higher than those 
of PMA itself 24 h after administration of a single dose of 0.75 mg/kg. This result 
has shown that the simultaneous analysis of PMA and PHA in biological samples is 
more useful than analysis of PMA alone. 
 
10.2  Aims 
Although methods for quantitative analysis of PMA have been published, most 
methods for the identification of drugs in the amphetamines group are based on 
GC/MS. Few LC/MS methods have been developed for quantitative analysis of 
PMA and its metabolites (PHA, β-hydroxy-PMA and 4-hydroxy-norephedrine). The 
primary aim of the present study was to identify the metabolites of PMA in 
humans with the assistance of an in vitro metabolism model using human liver 
microsomes. Moreover, there have been no studies performed for identification 
of in vitro metabolites of these drugs using triple quadrupole LC-MS. Then, the 
second aim of this study was to develop a reliable, sensitive, and selective 
method for identification of PMA and its metabolites in biological samples by 
reversed-phase LC/MS/MS with chemical derivatisation. 
 
10.3 Review of previous analytical methods for the 
determination of PMA and its metabolites 
Early analytical methods for PMA were reported and published in the late 1970s, 
all based on GC/MS. Previous analytical methods for identification and 
quantification of PMA and its metabolites in biological samples are reviewed 
below and summarised in Table 10-1. 
 
A metabolism study of PMA in humans was first reported and published in 1971 
by Schweitzer et al.183 In humans, little PMA was reported to be excreted in 
unchanged form following oral administration. In 1974, Beckett et al.184 
described the identification of four metabolite products of PMA in rabbit, pig 
and rat liver fractions: 1-(p-methoxyphenyl)-propan-2-one, 1-(p-
methoxyphenyl)-propan-2-ol, 1-(p-methoxyphenyl)-propan-2-one oxime and N-
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hydroxy-p-methoxy-amphetamine were determined using TLC, GC/FID and 
GC/MS. All metabolites were separated using three different GC columns and 
detected with a flame ionisation detector and mass spectrometry in full scan 
mode at an electron energy of 70 eV. 1-(p-Methoxyphenyl)-propan-2-one oxime 
was found as a decomposition product of N-hydroxy-p-methoxyamphetamine. 
 
Hubbard et al.182 described the in vitro metabolism of PMA in the dog and 
monkey using GC/MS with trifluroacetyl derivatisation. PHA and p-
hydroxybenzoic acid (PHBA) were separated using a silanised spiral glass column 
(1.8 m x 2.0 mm i.d.) packed with 5% OV-225 on 80-10 mesh Chromosorb W-AW-
DMSC and detected with FID and MS. O-Demethylation was found to be an 
important process in the in vitro biotransformation of PMA in the dog and 
monkey. Only 3% of unchanged PMA was excreted in the monkey and the 
excretion of PHA was 44% of the dose in 24 h. 
 
In 1979, Kitchen et al.109 described a detection method for PMA and its 
metabolites in humans using a radiochemical method. PHA and hydroxy-
norephedrine were synthesised and used as analytical standards. PHA (free and 
conjugated) was found as a major metabolite and 4-hydroxy-norephedrine as a 
minor metabolite in urine. 
 
In 2015, Lai et al.110 described a liquid chromatography-quadrupole/time-of-
ﬂight mass spectrometry (QTOF-MS) method for screening in vitro drug 
metabolites of seven phenethylamine-based designer drugs in humans, including 
PMA. The HLM method consisted of 100 mM phosphate buffer pH 7.4, HLM 0.5 
mg/ml and substrate. The mixture was pre-incubated at 37oC for 5 min and the 
reaction was initiated by addition of 10 µl of NADPH solution and incubated for 2 
h. The reaction was stopped by adding ice-cold acetonitrile. Analytes were 
separated using a C8 Zorbax Eclipse Plus column (2.1 mm x 150 mm, 3.5 µm) and 
identified using QTOF-MS in scan mode over the range m/z 50 - 1000. Only the 
para-hydroxy-metabolite (PHA) was found in phase I metabolism of PMA in HLM 
samples. The molecular ion of PHA was detected at m/z 152.1063 and major 
fragment ions were at m/z 135.0799, 107.0495, 91.0552, 77.0390 and 65.0364. 
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Table 10-1: Previous GC/MS and LC/MS methods for PMA and its metabolites. 
 
 
Analytes Matrices Chromatography Extraction 
Method 
Year 
1-(p-Methoxyphenyl)-
propan-2-one,  
1-(p-Methoxyphenyl)-
propan-2-ol,  
1-(p-Methoxyphenyl)-
propan-2-one oxime, 
N-hydroxy-p-
methoxyamphetamine 
Rabbit, 
pig,  
rat liver 
fraction 
TLC 
GC-FID and GC/MS 
Column I: Gas Chrom Q (1 m x 6.4 mm o.d.) 
Column II: Gas Chromsorb W (2 m x 6.4 mm o.d.) 
Column III: Gas Chrom W (2 m x 6.4 mm o.d.) 
 
Incubated PMA with liver 
LLE: diethyl ether (3x3 ml)  
Reduction with TiCl3 
1974184 
PHA, 
p-hydroxybenzoic acid 
(PHBA) 
Dog and 
monkey 
urine 
GC/MS 
Column: silanised spiral glass column (1.8 m x 2.0 mm i.d.) packed with 
5%OV-225 on 80-10 mesh Chromosorb W-A W-DMSC 
 
Enzymatic and acid  
hydrolysis  
LLE: Methylene Chloride 
Derivatised with TFA 
1977182 
PMA, 
PHA 
HLM LC-TOF-MS 
Column: C8 Zorbax Eclipse Plus column (2.1 mm x 150 mm, 3.5 µm) 
Mobile phase: gradient of 5 mM ammonium acetate in ultrapure water and 
acetonitrile  
Flow Rate: 0.2 ml/min 
HLM Incubation 2015110 
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10.4 Methods and materials 
10.4.1 Reagents and standards 
A standard of PMA hydrochloride was obtained from Sigma-Aldrich Co, LLC (UK). 
A standard of 4-hydroxy-3-methoxyamphetamine-HCl (HMA) was purchased from 
Lipomed (supplied by Kinesis, Ltd UK). All other reagents were the same as those 
described in Section 8.6.1. 
 
10.4.2 In vitro assay (human liver microsomes) 
This was the same as described in Section 8.6.2. 
 
10.4.3 Derivatisation 
This was the same as described in Section 9.4.3. 
 
10.4.4 Liquid chromatography/mass spectrometry conditions 
10.4.4.1 Liquid chromatography conditions 
Chromatographic separation was performed using an Agilent Binary SL 1200 LC 
from Agilent Technologies Inc. Isocratic elution was performed on a Gemini C18 
column (150 x 2.0 mm, 5 μm) protected by a Gemini C18 Security Guard Pre-
Column (4 x 2.0 mm, 5 μm, Phenomenex Inc.), which was maintained at 40ºC 
with a ﬂow rate of 0.35 ml/min. The injection volume was 20 µl and the mobile 
phase was composed of 0.1% formic acid in water and 0.1% formic acid in 
acetonitrile (67: 33 v:v) giving a run time of 10 min per injection. 
 
10.4.4.2 Mass spectrometry conditions 
Analysis of PMA and its metabolites was performed using an Agilent 6410 Triple 
Quad LC/MS/MS instrument (Agilent Technologies Inc.) equipped with an Agilent 
Binary SL 1200 LC system interface. Nitrogen was from a nitrogen generator (In 
House Gas (Manufacturing) Ltd, UK). 
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Ionisation of analytes of interest was carried out using ESI. The mass 
spectrometer was operated in the positive ion multiple reaction monitoring 
(MRM) mode. Nitrogen was used as nebuliser gas at 30 psi. The gas temperature 
was set to 350oC and the gas flow to 11 ml/min. The MRM transitions, FVs and 
CEs for the acetate derivative of PMA were optimised by direct infusion of 
acetate solutions of derivatised standards at a concentration of 5 μg/ml in 
mobile phase (50:50 v:v) into the MS. All analytes were identified and quantified 
based on their retention times and quantifier and qualifier ion ratios obtained 
from the MRM transitions. 
 
The MRM transitions, FVs and CEs used for the measurement of PMA and its 
metabolites are summarised in Table 10-2. 
 
Table 10-2: MRM conditions for acetate derivatives of PMA and its metabolites. 
 
Name Precursor 
Ion (m/z) 
Fragmentor  
Voltage (eV) 
Product Ions  
(m/z) 
Collision 
Energy (eV) 
PMA-Ac 208 90 149 5 
121 20 
91 30 
PHA-Ac 236 90 194 5 
135 20 
107 40 
4-HMA-2Ac 266 90 165 20 
137 30 
105 40 
β-OH-PMA-2Ac 266 95 224 10 
165 20 
91 40 
 
 
10.5  Results and discussion 
10.5.1 Optimisation of LC/MS conditions 
10.5.1.1 LC separation 
The LC method used for detection of MDMA and its metabolites was used for the 
analysis of PMA and its metabolites in HLM samples. To separate Ac-derivatives 
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of PMA and its metabolites, LC separation was applied on a Gemini C18 column 
with isocratic elution with an organic solvent containing 0.1% formic acid in 
aqueous acetonitrile at flow rate of 0.35 ml/min. The retention factor was 4.2 
for PMA-Ac and the hold-up time (t0 = 0.8 min) was determined by injecting pure 
methanol. Figure 10-1 shows the chromatogram for a standard of PMA-Ac on the 
Gemini C18 column. However, the MS-MRM method needed to be developed. 
 
 
Figure 10-1: LC/MS/MS MRM chromatograms of a PMA-Ac standard on a Gemini 
C18 column. 
 
10.5.1.2 MRM optimisation 
To optimise the MRM conditions, PMA standard was derivatised with acetic 
anhydride and re-dissolved in methanol. The Ac-derivative of PMA was injected 
directly into the mass spectrometer interface using a syringe pump with positive 
ESI to obtain the precursor ions, product ions, FVs and CEs. Because of 
unavailability of reference standards of PMA metabolites, a minimum of four 
identification points (IPs) was required for evaluating PMA metabolites. One 
quantifier and two or three qualifier ions were used to identify target analytes. 
FVs and CEs of derivative PMA metabolites were developed based on derivatised 
standard PMA. 
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Figure 10-2: LC/MS/MS product ion scan spectra of the Ac-derivative of PMA 
standard at CE of 10 and 25 eV. The optimum CE values for each ion are listed in 
Table 10-2. 
 
Figure 10-2 shows the LC/MS/MS product ion scan spectra of the Ac-derivative of 
PMA standard. When the CE was 10 eV, the mass spectrum of PMA-Ac had two 
large peaks at m/z 149 and 121 and a small peak for the protonated molecule 
(m/z 208, M-H+). At a higher CE of 25 eV, the fragment ion peak at m/z 149 was 
decreased and the peaks at m/z 121 and 91 were increased. The optimised CEs 
values for PMA-Ac which were finally selected are listed in Table 10-2. The 
LC/MS mass spectral fragmentation of PMA-AC is shown in Figure 10-3. 
 
 
Figure 10-3: Mass spectral fragmentation of PMA and PMA-Ac. 
 
After MRM optimisation, the protonated molecular ion of PMA-Ac at m/z 208 was 
used as a precursor ion and its fragment ions at m/z 149, 121 and 91 were 
selected as product ions. When the optimised CE values were used, the most 
intense product ion peak was at m/z 121 and was chosen as a quantifier ion and 
the ratio of qualifier/quantifier was approximately 61% for m/z 149 and 32% for 
m/z 91. 
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10.5.2 Predicted mass spectral fragmentation of PMA 
metabolites 
O-Demethylation of PMA to PHA has been reported as a primary metabolic 
pathway whereas β-hydroxylation of the side chain to β-hydroxy-PMA, followed 
by loss of the methyl group to give 4-hydroxy-norephedrine has been reported as 
a minor metabolic pathway of PMA in humans109. PHA was expected to be the 
major metabolite and β-hydroxy-PMA (β-OH-PMA) a minor metabolite of PMA 
resulting from metabolism by human liver microsomes. However, PHA and β-OH-
PMA were commercially unavailable. In order to identify both metabolites in 
HLM samples by LC/MS/MS, the mass spectral characteristics of acetate-
derivatives of PHA and β-OH-PMA were predicted based on the mass spectral 
characteristics obtained from the acetate derivative of PMA. Moreover, possible 
multiple reaction monitoring (MRM) ions were reviewed and compared with mass 
spectral characteristics of synthesised reference standards of PHA described in 
previous studies110,185. 
 
Although metabolism studies of PMA have been published from the late 1900s, 
all of them were restricted to GC/MS analysis. PMA has some metabolites similar 
to amphetamine/methamphetamine such as PHA and 4-hydroxynorephedrine and 
some similar to MDMA such as 3- or 4-HMA104,186,187. However, not all 
amphetamine metabolites are included in routine analysis and basic analytical 
methods for amphetamine-type stimulants (ATS) by GC/MS. Only a few LC/MS 
methods for the determination of PMA and other ATS have been published.  
Hendrickson et al.185 reported a quantitative method for the determination of 
methamphetamine and its metabolites by LC/MS. A standard of PHA, one of the 
active metabolites of methamphetamine, was obtained from NIDA and was 
analysed by LC/MS with MRM at m/z 152>107. Lai et al.110 also investigated PMA 
metabolites produced by HLM with liquid chromatography-quadrupole time-of-
flight mass spectrometry. PHA was found in HLM samples and was identified with 
a precursor ion at m/z 152.1070 (M-H+) and product ions at m/z 135.0810, 
107.0497, 91.0548 and 77.0386. 
 
As described in Sections 9.5.3 and 9.5.4, dealing with predicted butylone and 
methylone metabolites, the first fragmentation of acetate derivatives is the loss 
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of ketene (COCH2, 42 Da). The molecular ion of PHA-2Ac would be at m/z 236 
and the product ion from the loss of the ketene group would be at m/z 194. 
Other product ions at m/z 135 and 107 are expected based on the fragmentation 
of PMA-Ac and on reviewed data from Hendrickson et al. and Lai et al. The 
fragment ion at m/z 135 results from the loss of [NH2]+ from the side chain of 
PHA itself and next fragment ion at m/z 107 comes from the loss of 28 Da (C2H4) 
from the side chain. The predicted ESI-LC/MS/MS fragmentation pattern for the 
acetate derivative of PHA is shown in Figure 10-4. 
 
 
Figure 10-4: Postulated ESI LC/MS fragmentation pattern of PHA-2Ac. 
 
For β-hydroxy-PMA, no information on the LC/MS mass spectrum and MRM 
transitions has been published before.  The molecular ion of β-OH-PMA-2Ac 
would be at m/z 266 and the product ion from the loss of ketene would be at 
m/z 224. Predicted fragment ions are at m/z 165 and 147 from the loss of side 
chain of β-OH-PMA itself and m/z 91 that is expected based on the fragment ion 
of PMA-Ac. The predicted ESI-LC/MS/MS fragmentation pattern of β-OH-PMA-2Ac 
is shown in Figure 10-5. 
 
Other possible PMA metabolites are 3´-hydroxy-4-methoxyamphetamine (3-HMA) 
and 4´-hydroxy-3-methoxyamphetamine (4-HMA). The MRM transitions for HMA-
2Ac identification were predicted based on reference standard spectra as 
explained in Section 8.5.1.2. Each predicted fragment ion was subsequently 
included in the initial LC/MS/MS analysis of HLM samples to identify which 
metabolites were present and the fragment ions they actually produced. 
 
Finally, an MRM method for the expected acetate derivatives of PMA and its 
metabolites was as summarised in Table 10-2, in Section 10.4.4.2 above. 
 
PHA-2Ac 
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Figure 10-5: Postulated ESI LC/MS/MS fragmentation pattern of β-OH-PMA-2Ac. 
 
10.5.3 In-vitro metabolism studies of PMA 
Pooled human liver microsomes (HLM) were incubated with a PMA standard and 
extracted and analysed using the LC/MS/MS method described previously. PHA, 
the major metabolite of PMA, and β-hydroxy-PMA (a minor metabolite) were 
expected from the experimental procedure involving in-vitro metabolism with 
human liver microsomes. The acetate derivative of a PMA standard was 
identified at 4.2 min and confirmed by assessing the qualifier/quantifier ion 
ratios with ± 20% tolerance. 
β-OH-PMA-2Ac 
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The derivative of un-metabolised PMA (PMA-Ac) was identified in extracts by 
MRM transitions at m/z 208>149, 208>121 and 208>91. The acetate derivative of 
PHA (PHA-2Ac, a major metabolite), was identified by MRM transitions at m/z 
236>194, 236>135 and 236>107 and the acetate derivative of the β-hydroxy 
metabolite (β-OH-PMA-2Ac, a minor metabolite) was identified by MRM 
transitions at m/z 266>224, 266>165 and 266>91. Another metabolite, the 
acetate derivative of 4-hydroxy-3-methoxyamphetamine (4-HMA-2Ac) was 
identified by MRM transitions at m/z 266>165, 266>137 and 266>105. 
 
Three phase I metabolites (both major and minor metabolites) of PMA were 
detected in HLM samples. The retention time and the mass ratios for PMA 
obtained from HLM samples were consistent with those observed for the 
standard. Residual PMA as its acetate derivative (PMA-Ac) was eluted at 4.2 min 
and was identified and confirmed. The qualifier/quantifier ion ratio was 61% for 
m/z 149 and 32% for m/z 91 which were in the acceptable range. LC-MS/MS MRM 
chromatograms of PMA-Ac in HLM samples compared with the Ac-derivative of a 
standard are shown in Figure 10-6. 
 
 
 
Figure 10-6: Examples of LC/MS/MS MRM chromatograms for PMA-Ac in two HLM 
samples compared with the Ac-derivative of a PMA standard. 
 
Derivatives of both major and minor PMA metabolites were identified in HLM 
samples by the MRM transitions explained in Section 10.5.2. The derivative of 
PHA-2Ac was detected in HLM samples and was eluted at 3.7 min. The MRM at 
m/z 236>107 gave the highest corresponding peak area for PHA-2Ac in all HLM 
samples, followed by those at m/z 236>135 and 236>194.  
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Because the corresponding peak area of PHA in HLM samples gave quite a high 
response, it was possible to analyse HLM samples by LC/MS using product ion 
scan mode to fragment the target ion at m/z 236 with FV at 90 eV and CE at 20 
eV. LC/MS ESI spectra obtained at 3.64 min showed the fragmentation pattern of 
PHA-2Ac that correlated with the predicted PHA-2Ac fragmentation in Section 
10.5.2. The LC-MS spectrum of PHA-2Ac in HLM samples is shown in Figure 10-8 
and LC-MS/MS MRM chromatograms of PHA-2Ac in HLM samples are shown in 
Figure 10-7. 
 
 
 
 
Figure 10-7: Examples of LC/MS/MS MRM chromatograms for PHA-2Ac in two 
HLM samples.  
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Figure 10-8: Mass spectrum of the Ac-derivative of PHA-2Ac in HLM samples at 
CE of 20 eV in product ion scan mode. 
 
The acetate derivative of the β-hydroxy metabolite of PMA (β-OH-PMA-2Ac) was 
detected in HLM samples and was eluted at approximately 2.6 min. The 
transition at m/z 266>91 gave the highest corresponding peak area for β-OH-
PMA-2Ac in all HLM samples, followed by those at m/z 266>224 and 266>165. 
LC/MS/MS MRM chromatograms for β-OH-PMA-2Ac in HLM samples are shown in 
Figure 10-9. 
 
 
 
 
Figure 10-9: Examples of LC/MS/MS MRM chromatograms for β-OH-PMA-2Ac in 
HLM samples. 
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Figure 10-9 (cont.): Examples of LC/MS/MS MRM chromatograms for β-OH-PMA-
2Ac in HLM samples. 
 
The acetate derivative of a 4-HMA-2Ac standard was identified at a retention 
time of 3.8 min. The ion ratios obtained for the 4-HMA-2Ac standard were 52% 
for m/z 137 and 57% for m/z 105. 4-HMA-2Ac was also detected in HLM samples 
at 3.7 min. To confirm the detection of 4-HMA-2Ac, quantifier/qualifier ion 
ratios needed to be assessed. The ion ratio obtained from HLM samples was 74% 
for m/z 137 and 80% for m/z 105 which were out of the acceptable range 
(±20%). However, peaks corresponding to 4-HMA-2Ac were small and this can 
affect the ion ratios.  Moreover, 4-HMA has an isomer, 3-HMA, the standard of 
which is not commercially available. The peak corresponding to MRM transitions 
at m/z 266>165, 266>137 and 266>105 may be 3-HMA rather than 4-HMA. The 
peak might also be a mixture of the two. So, finally, the peak eluting at 3.7 min 
cannot be confirmed as 4-HMA alone. LC/MS/MS MRM chromatograms for the 
possible metabolite 4-HMA-2Ac in an HLM sample compared with a 4-HMA-2Ac 
standard are shown in Figure 10-10. 
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Figure 10-10: Examples of LC/MS/MS MRM chromatograms for 4-HMA-2Ac in an 
HLM sample compared with the 4-HMA-2Ac standard. 
 
10.6  Conclusions 
This chapter describes an in vitro metabolism study of PMA using human liver 
microsomes with LC/MS/MS analysis. The results show that loss of the methyl 
group from the 4-position is a major phase I metabolic pathway and β-
hydroxylation and COMT-methylation to 4-HMA/3-HMA are minor metabolic 
pathways of PMA in humans. To our knowledge, this is the first LC/MS method 
designed for identification and confirmation of both major and minor 
metabolites of PMA (PHA, β–hydroxy PMA and 4-HMA/3-HMA). The LC/MS method 
described in Section 10.4.4 could be applied and used in routine analysis for the 
determination of PMA and its metabolites in biological samples such as blood and 
urine. However, reference standards of all metabolites are required. Future in 
vivo studies on phase II metabolites of PMA are required. 
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Chapter 11 Formaldehyde/formalin 
11.1  Chemical properties 
Formaldehyde is an important precursor in many chemical industries and has 
many uses, including as an embalming fluid for tissue-fixation in pathology and 
anatomy labs. Formaldehyde was first synthesised in 1859 by Aleksandr Butlerov 
and its structure was identified as an aliphatic aldehyde in 1867 by August 
Wilhelm von Hofmann188. The chemical formula of formaldehyde is CH2O with a 
relative molecular mass of 30.03, see Figure 11-1. It is a colourless flammable 
gas at room temperature and has a characteristic, irritating aroma. 
Formaldehyde dissolves rapidly in water, alcohols, and other polar fluids. It is a 
highly reactive substance and breaks down at 150oC into methanol and carbon 
monoxide. The solid form of formaldehyde is (CH2O)3, commercially known as 
trioxane or paraformaldehyde, which is a mixture of polymers of formaldehyde 
that contains 91 percent formaldehyde or more. Solid paraformaldehyde is 
commonly used for room disinfection by slow release of formaldehyde vapour189-
191. 
 
 
Figure 11-1: Chemical structure of formaldehyde. 
 
Formalin is the name of commercial solutions of formaldehyde gas in water that 
have been used as a chemical disinfectant and embalming fluid for biological 
specimens. 100% formalin contains a 37-40% saturated aqueous solution of 
formaldehyde and 12-15% methanol which is added as a stabiliser to delay  
polymerisation of the formaldehyde188. Formaldehyde can be both reduced and 
oxidised192. 
 
Formaldehyde   oxidation      Formic acid 
Formaldehyde   reduction      Methanol 
 
167 
 
11.2  Pharmacokinetics of formaldehyde 
Formaldehyde is a highly toxic substance to animals and is well known as a 
human carcinogen. Formaldehyde can be absorbed into the body by ingestion, 
inhalation, skin absorption and eye contact. Ingestion and eye contact are not 
significant routes of exposure to formaldehyde whereas inhalation and dermal 
absorption of formaldehyde are major routes of occupational exposure for 
workers in the industry. Formaldehyde inhalation can cause several symptoms 
which vary from headaches (small exposure) to severe difficulty in breathing, 
dependent on the formaldehyde concentration, length of exposure and 
individual sensitivity. For example, inhaling formaldehyde at 10 to 20 parts per 
million (ppm) may cause cough, difficulty in breathing, heavy lachrymation and 
burning of the nose and throat. As well as dermal absorption, skin contact with 
formaldehyde can cause a range of effects from acne or dermal irritation to 
severe allergic dermatitis191. 
 
When formaldehyde is absorbed into the blood circulation, it binds reversibly 
with glutathione to form S-(hydroxymethyl) glutathione, a non-enzymatic 
hemiacetal adduct. After that, formaldehyde dehydrogenase oxidises this adduct 
compound to S-formylglutathione, which is further metabolised to formate, 
releasing free glutathione, by S-formylglutathione hydrolase. Formate, the 
metabolite of formaldehyde, can be incorporated into proteins and nucleic acids 
via one-carbon pathways or can be metabolised to CO2 and water and eliminated 
in exhaled air (as CO2) and urine188. 
 
11.3  Tissue fixation 
Historically, the majority of fixation procedures and fixative solutions were 
developed for histological studies. Tissue fixation is a chemical process that is 
used for preserving biological tissues from post mortem decomposition. From the 
early 1900s, formalin has been the most commonly used fixative solution for 
permanent preservation of tissue specimens and autopsy materials. Previous 
studies indicated that formaldehyde preserves tissue by reversibly cross-linking 
with primary amino groups and thiols in biological macromolecules such as 
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proteins, nucleic acids and polysaccharides through a CH2 linkage. Moreover, 
formaldehyde can also form reactive hydroxymethyl groups, a product between 
the aldehyde and reactive amino groups. Reversible cross-linking by 
formaldehyde usually occurs at neutral pH. Therefore, neutral buffered formalin 
solution can induce more cross-link reactions in contrast with acid formalin 
solution193. The concentration and pH of formalin solution used in tissue fixation 
may vary between laboratories. A 10% buffered formalin solution (4% 
formaldehyde) is most frequently used as an embalming fluid in pathology and 
histology laboratories. A 10% buffered formalin solution may be prepared by 
adding 100 ml of 37-40% formaldehyde to 900 ml of water containing 6.5 g of 
dibasic sodium phosphate (anhydrous) and 4 g of monobasic sodium 
phosphate194. 
 
11.4 Previous studies on the reactions between drugs 
and formalin 
In forensic toxicology it is sometimes necessary to analyse biological samples 
that have been treated with formalin, usually when no other samples are 
available, and the problem is to assess the original identities and concentrations 
of drugs or poisons in the samples. 
 
The study of the stability and the reactions between drugs and formalin solution 
was first reported in 1990 by Dettling et al.195 Nortriptyline was unstable in 
formalin solution dependent on the pH and concentration of formaldehyde. A 
high percentage of formaldehyde and basic pH (9.5) caused more decomposition 
of nortriptyline. Amitriptyline was detected in this experiment and reported as 
an N-methylated product of nortriptyline from formaldehyde. However, the loss 
of nortriptyline did not correlate with the formation of corresponding amounts 
of amitriptyline.  
 
The second study about the stability of several compounds in formalin-fixed 
tissues and formalin-blood solution was published in the same year by Winek et 
al.196 This study demonstrated that diazepam and phenytoin decreased by at 
least 41% and 31%, respectively in buffered formalin blood after 30 days. 
Phenobarbital and desipramine showed losses of more than 60% in liver tissue 
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fixed in formalin solution, whereas carbon monoxide and cyanide were not 
detected after adding buffered formalin solution to blood. 
 
Winek et al.197 also reported the stability of four major tricyclic  antidepressants 
(amitriptyline, nortriptyline, desipramine, and imipramine) in formalin-fixed 
human liver tissue and formalin solutions. All drugs were unstable in 10% 
buffered formalin fixed tissue and in formalin solution and some methylation of 
secondary amines (nortriptyline and desipramine) to tertiary amines 
(amitriptyline and imipramine) was observed. Moreover, this study suggested 
that acidic compounds are more stable than basic drugs in formalin samples and 
that drugs analysed in formalin-fixed liver and formalin medium may be 
detected for up to 22 months. Xiang et al.198 also reported the stability of 
tetramine, morphine  and meperidine in formalin solution.  The results showed 
that concentrations of these three drugs decreased in formalin-fixed tissues 
(liver, kidney, lung and heart) compared with frozen tissues. 
 
Cingolani et al.199 reported a quantitative method to detect morphine in fixed 
tissue and in formalin solutions. Morphine was detected at approximately 30% to 
36% of the original concentrations in kidney and liver tissues stored in 10% pH 7 
buffered formalin solutions and at 42% to 75% of the original concentrations in 
formalin solution after 12 weeks. This study suggested that morphine has good 
stability in fixed tissue, which can be used in forensic toxicology diagnosis in 
cases of morphine poisoning. 
 
Studies of the reaction of drugs with formaldehyde were more often published 
from 2001. Gannett et al.200 reported the in vitro reaction of formaldehyde with 
fenfluramine. Fenfluramine is unstable in formalin solution and is converted to 
its N-methyl derivative, N-methyl fenfluramine, based on the Eschweiler-Clarke 
reaction, which involves the methylation of primary and secondary amines to 
tertiary amines by formaldehyde. Fenfluramine was totally converted to N-
methyl fenfluramine in 24h at pH 9.5 in 20% formaldehyde solution. Moreover, 
Gannett et al.201 also reported the in vitro reaction of three barbiturates 
(phenobarbital, pentobarbital, and secobarbital) in formalin solution. The results 
showed that decomposition of barbiturates occurred rapidly at higher pH and 
phenobarbital rapidly decomposed under basic conditions (pH 9.5). 2-
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Phenylbutyric acid was reported as the main decomposition product in formalin. 
Moreover, this study suggested that analysis for the parent drug and its 
predicted decomposition product may reduce the likelihood of false negative 
reports. 
 
Tracy et al.202 reported the stability of 10 benzodiazepines in formaldehyde 
solutions over a 30 day period. Alprazolam, chlordiazepoxide, diazepam, 
flunitrazepam, flurazepam, lorazepam, midazolam, oxazepam, prazepam and 
triazolam were applied in this study. The study found that the decomposition 
rate of benzodiazepines depended on both the pH and formaldehyde 
concentration, the same as previous studies. Diazepam and prazepam were the 
most stable benzodiazepines in formalin solution (approximately 40% decrease in 
concentration after 30 days) whereas alprazolam and midazolam were not stable 
in acidic pH formalin solution. This study suggested that determination of 
benzodiazepines in post mortem embalming samples must be done with caution 
because benzodiazepines can react with formaldehyde to form conversion 
products. 
 
In 2005, Tirumalai et al.203 reported that N,N-dimethylamphetamine (DMA), the 
product of methamphetamine in formalin solution, was observed at both neutral 
(pH 7) and basic pH (pH 9.5) after a few days. At pH 9.5 in 20% formalin solution, 
90% of the methamphetamine was rapidly converted to DMA in 24 h. This study 
suggested that determination of methamphetamine in post mortem embalming 
tissue can give misleading results due to conversion of methamphetamine to 
DMA. Shakleya et al.204 studied the methylation of methamphetamine in 
formalin-fixed liver tissue. The results showed that DMA was detected only in 
liver tissues treated with formalin.  
 
The conversion of secondary amines to tertiary amines in formalin solution was 
confirmed when Shakleya et al.205 reported that MDMA is methylated, producing 
3,4-methylenedioxydimethylamphetamine (MDDMA) in formalin solution and 
Suma and Prakash206 reported that sertraline can be converted to N-methyl-
sertraline in embalming fluid. Moreover, Ramagiri et al.207 also reported that 
fluoxetine was totally converted to N-methyl-fluoxetine in formalin solution 
after 30 days in 20% formalin at pH 9.5. 
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Viel et al.208 reported the stability of cocaine in formalin solution and ﬁxed 
tissues (brain and liver) over a period of 30 days. Cocaine was stable in 
unbuffered formalin (pH 3.5) over 30 days and unstable in buffered formalin (pH 
7.4) in which cocaine was hydrolysed to benzoylecgonine. This study also found 
that both cocaine and benzoylecgonine were rapidly extracted into the formalin 
solution from the embalmed tissues. However, the study suggested that the 
hydrolysis of cocaine did not occur by reaction with formalin. 
 
In 2013, Takayasu192 and Nikolaou et al.209 reviewed the toxicological analysis of 
formalin-fixed tissue and solution. Finally in 2015, Uekusa et al.210 reported the 
analysis of drugs in tissues in formalin solutions and in fixatives. Drug-positive 
autopsy liver and kidney were preserved in formalin solution for 1, 3, 6 and 13 
months and applied in this study. Concentrations of chlorpromazine, 
levomepromazine, and promethazine decreased to 23–39% of their starting 
values in embalmed liver after 1 month and bromazepam was not detected after 
13 months. Moreover, chlorpromazine sulfoxide and levomepromazine sulfoxide, 
which were not observed before preservation, were detected in ﬁxed-liver 
tissues and formalin solution at all analysed time periods. 
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Chapter 12 In vitro reactions of formaldehyde with 
drugs and poisons: introduction and 
experimental section 
 
12.1  Introduction 
In South-East Asia and in Buddhist countries such as Thailand, cremation is a 
common practice for disposal of the dead. Cremation is accepted in Buddhism, 
Hinduism, Jainism, Sikhism, and Shintoism211. In Thailand, the corpse is kept for 
three to seven days in the temple to allow distant relatives to attend a memorial 
and funeral rite before cremation. In some cases, especially for an important or 
wealthy person, the corpse is kept for a year or more in a special building at a 
temple212. To maintain a body longer in tropical wet and dry climates, formalin 
is injected into the body as an embalming solution to reduce body 
decomposition. Therefore, all drugs present in the body will be exposed to 
formaldehyde, a highly reactive substance that can react chemically with drugs 
of interest resulting in decreasing concentrations of the original compounds and 
production of new substances. 
 
In some cases, forensic toxicologists are required to perform analyses on samples 
from an embalmed body or of embalmed tissue stored in formaldehyde. An 
analysis of an embalmed sample or of embalming fluid may create a false 
negative or false positive because of the reaction between drugs and formalin. 
Not only methamphetamine and MDMA but the degradation products of other 
drugs in formalin solution also need to be identified and reported. Information 
about the reaction and degradation of drugs in formalin is currently insufficient 
and needs to be identified and reported and also presents a continuing challenge 
in the forensic toxicology field. 
 
12.2  Aims 
Post mortem forensic toxicology involves the detection and quantification of 
drugs and poisons, including pesticides, in autopsy blood and other tissues in 
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order to determine their possible role in the cause of death. In some 
jurisdictions, as mentioned above, fatalities are subject to embalming before 
blood can be obtained at autopsy for toxicological analysis. This presents 
problems of identification of poisons in blood because the embalming process 
used in hot climates involves the chemically-reactive material formalin. This 
modifies drugs or other substances such that they are chemically different from 
the starting materials and are no longer easily detectable by conventional 
means. There is a need to identify markers of the original drugs or poisons which 
can be used to indicate the original species in the blood. 
 
The primary aim of the present study was to identify the degradation products of 
drugs and pesticides in formalin solution. In order to evaluate the effects of 
formaldehyde on drugs and poisons, a range of model compounds was used, 
including amphetamine-type stimulants (amphetamine, methamphetamine, and 
MDMA), benzodiazepines (alprazolam and diazepam), opiates (morphine, 
hydromorphone, codeine, and hydrocodone) and a carbamate insecticide 
(carbosulfan), which are often associated with cases of suicide, homicide, 
accidental poisoning and road traffic accident because of their toxicity and 
potential for abuse. Typical approaches to this involve in vitro simulation of the 
reactions between analytes and formalin followed by LC/MS analysis. The second 
aim was to examine the conversion products in formalin-blood to which the 
target analytes have been added. These steps evaluated which reaction products 
might serve as markers of the original substances. 
 
12.3  Amphetamine-type Stimulants (ATS) 
In the last 10 years, abuse of Amphetamine-type Stimulants or ATS such as 
amphetamine, methamphetamine, MDMA and MDEA has become a global 
problem especially in East and South-East Asia where consumption of 
methamphetamine is dominant. The United Nations Office on Drugs and Crime 
(UNODC) reported in the World Drug Report 2015 that treatment for ATS use is 
increasing globally, especially in Asia, and ATS, excluding ecstasy, comprise one 
of the two most widely used types of illicit drugs globally. In parts of North 
America and Europe, the use of crystalline methamphetamine is also 
increasing65. ATS are a group of substances, mostly synthetic in origin, that are 
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structurally derived from β-phenethylamine213. ATS can be divided into three 
major sub-groups by structural characteristics following substitution patterns on 
the aromatic ring. The first group has no substituents on the aromatic ring, such 
as amphetamine, methamphetamine, and fenethylline. The second group 
features methylenedioxy-substitution on the aromatic ring and includes MDMA 
and its analogues. The third group contains other substitution patterns which 
usually include one or more alkyloxy groups, such as 2,5-dimethoxy-4-
bromophenethylamine (2C-B) or 4-methyl-2,5-dimethoxyamphetamine (DOM)213.  
 
12.3.1 Mechanism of action 
ATS are a group of CNS stimulant drugs that act on the cerebral cortex producing 
effects similar to adrenaline. Amphetamines, which have a chemical structure 
similar to dopamine (functions as a neurotransmitter in brain), can cross through 
the blood-brain barrier and act on the monoamine neurotransmitter system, 
which involves neuromodulators and neuro-transmitters that contain one amino 
group, such as dopamine, noradrenaline and serotonin. Amphetamines can bind 
to and also act as substrates for a low-affinity monoamine transporter protein 
for dopamine, noradrenaline and serotonin, resulting in increasing levels of 
neurotransmitter. Whereas MDMA has more potent effects on the serotonin 
system than on the dopamine and noradrenaline systems, for amphetamine and 
methamphetamine the opposite is true213. ATS may produce one or more dose-
related symptoms, including increased alertness and euphoria, increased heart 
rate, blood pressure, respiration and body temperature. Agitation, tremors, 
hypertension, memory loss, hallucinations, psychotic episodes, paranoid 
delusions and violent behavior can result from chronic abuse214. 
 
12.3.2 Amphetamine 
Amphetamine was first synthesised in 1887 and has been used since 1935 for 
treatment of obesity, narcolepsy, hypertension and attention deficit 
hyperactivity disorder (ADHD), with different trade names; Adderall®, 
Benzedrine® and Dexedrine®215. Because of its addiction potential, it is 
controlled under Schedule II of the United Nations Convention on Psychotropic 
Substances. Amphetamine is a phenethylamine derivative which has two 
175 
 
enantiomers, levorotatory (l-) and dextrorotatory (d-) that have different plasma 
half-lives216. Amphetamine is available as the l-, d- or dl-racemic forms, of which 
the d-isomer is 3-4 times more potent than the l-form. The chemical formula of 
amphetamine is C9H13N with a relative molecular mass of 135.20, see Figure 12-
1. It is commonly produced as tablets and can be administered orally, injected, 
snorted, or smoked102. 
 
 
Figure 12-1: Chemical structures of amphetamine and methamphetamine. 
 
Amphetamine is rapidly absorbed from the gastrointestinal tract. It is a lipophilic 
compound that can cross through the blood-brain barrier and which is also 
concentrated in the lung, kidney, cerebrospinal fluid, and brain.  The major 
metabolic pathway of amphetamine involves hydroxylation to para-
hydroxyamphetamine and deamination to phenylacetone by the CYP2D6 enzyme, 
a member of the cytochrome P450 mixed-function oxidase system. Peak plasma 
levels occur within 1 to 3 h and complete absorption occurs in 4 to 6 h after oral 
administration. It is eliminated in urine via the renal system and approximately 
30% is excreted unchanged in 24 h. However, the elimination rate of 
amphetamine is dependent on the urinary pH: acidic urine (pH 5.5 to 6.0) can 
eliminate amphetamine faster than basic urine (pH 7.5 to 8.0)102,217. 
 
12.3.3 Methamphetamine 
Methamphetamine is the N-methyl derivative of amphetamine. It is a strong CNS 
stimulant and is controlled under Schedule II of the United Nations Convention 
on Psychotropic Substances. Methamphetamine hydrochloride was first 
synthesised in 1919 and has been used for treatment of obesity and ADHD with 
trade names such as Desoxyn® and Methedrine®102. Methamphetamine is 
produced in a variety of forms (powder, tablets, capsules or crystals) that may 
be ingested orally, injected, snorted, or smoked. Similar to amphetamine, 
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methamphetamine has both d- and l-forms although illicit methamphetamine is 
usually sold as a racemic dl-mixture. The chemical formula of methamphetamine 
is C10H15N, with a relative molecular mass of 149.24. 
 
Methamphetamine is rapidly absorbed from the gastrointestinal tract and readily 
moves through the blood-brain barrier due to its high lipophilicity. The average 
peak plasma level of methamphetamine is reached approximately 3 h after oral 
administration and the plasma half-life is approximately 10 h in humans218. The 
major metabolic pathway of methamphetamine involves N-demethylation to 
amphetamine, a major active metabolite, and p-hydroxylation to 4-
hydroxymethamphetamine. Minor metabolites of methamphetamine include 4-
hydroxyamphetamine, 4-hydroxynorephedrine, 4-hydroxyphenylacetone, benzoic 
acid, norephedrine, phenylacetone and hippuric acid. Approximately 43% of 
methamphetamine is eliminated as unchanged drug and about 4-7% as 
amphetamine in the 24 h period after oral administration102. 
 
12.3.4 MDMA 
See Section 7.2.1. 
 
12.4  Benzodiazepines 
Benzodiazepines are psychoactive drugs that have been widely used for the 
treatment of psychoneurological disease since the 1960s. Chlordiazepoxide, the 
first medicinal benzodiazepine, was discovered accidentally in 1955 by Leo 
Sternbach219. The core chemical structure of this group is the fusion of a 
benzene ring and a diazepine ring (Figure 12-2). There are more than 50 
different medicinal drugs in this group. All of the benzodiazepines that are 
precribed in the UK are controlled under the Misuse of Drugs Act 1971 as Class C 
drugs. 
 
Benzodiazepines are commonly misused and are often implicated in crimes such 
as suicide, murder, sexual assault and traffic accidents and are usually taken in 
combination with other drugs of abuse. Most forensic laboratories have routine 
screening and confirmation assays for benzodiazepines in urine and post mortem 
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blood. However, analysis of benzodiazepines in biological samples is quite 
difﬁcult because of the similar chemical structures of drugs in this group, which 
provide similar mass spectra and retention times in chromatographic methods. 
Some previous studies196,202 of benzodiazepines in formalin-fixed tissue and 
formalin solution suggested that benzodiazepines are not stable in formalin 
solution. Nevertheless, further study of the reactions of benzodiazepines and 
formalin solution is needed. 
 
 
Figure 12-2: Core chemical structure of benzodiazepines. 
 
12.4.1 Mechanism of action 
Benzodiazepines are positive modulators of the neurotransmitter gamma- 
aminobutyric acid (GABA). Benzodiazepines act by binding to a specific site at 
the GABAA receptor, a ligand-gated chloride-selective ion channel, in the CNS. 
Benzodiazepines have special receptors, BZ1 and BZ2 receptors, which differ 
from GABAA subunit receptors220. However, drugs in this class can interact with 
different affinities to each receptor, resulting in corresponding differences in 
their pharmacology. Benzodiazepines are highly lipophilic compounds that have 
high absorption rates and fast onset of effects, the main ones being sedative, 
hypnotic, muscle relaxant and decreased anxiety. However, high doses of 
benzodiazepines may cause impairment of memory and cognition221. 
Benzodiazepines are used for treating insomnia and anxiety, as anticonvulsants, 
and for other purposes such as anesthetic adjuncts and alcohol withdrawal222. 
Benzodiazepines can be classified by their elimination half-life as short-, 
intermediate- and long-acting. 
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12.4.2 Alprazolam 
Alprazolam (also known as Xanax®), a triazolobenzodiazepine derivative, was 
first clinically used in 1976 as an anxiolytic agent. The chemical formula of 
alprazolam is C17H13ClN4 with a relative molecular mass of 308.77, see Figure 12-
3. Today, it is commonly used for the short-term treatment of agoraphobia, 
anxiety disorders and panic disorder223. Alprazolam is available as a free base 
tablet of 0.25-1 mg and as a capsule102. It is one of the most misused 
benzodiazepines and is controlled under Schedule IV of the United Nations 
Convention on Psychotropic Substances. 
 
 
 
Figure 12-3: Chemical structures of alprazolam and diazepam. 
 
Similar to other benzodiazepines, alprazolam binds to specific sites on the GABAA 
receptor and produces anxiolytic, sedative, hypnotic and skeletal muscle 
relaxant effects. Adverse effects of alprazolam include drowsiness, hypotension, 
confusion, nausea and tachycardia. Alprazolam is a short-acting benzodiazepine 
that has a fast onset of action as well as a short elimination half-life. Peak 
plasma concentrations of alprazolam occur 1-2 h following oral administration. 
The average plasma half-life of alprazolam is 12-15 h. Alprazolam is metabolised 
by oxidation to two active metabolites (4-hydroxyalprazolam and α-hydroxy-
alprazolam) via by CYP3A4 followed by conjugation with glucuronic acid and 
excretion in urine102,222. 
 
Alprazolam Diazepam 
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12.4.3 Diazepam 
Diazepam (also known as Valium®) was first used clinically in 1963 and was the 
second medicinal benzodiazepine derivative. The chemical formula of diazepam 
is C16H13ClN2O with a relative molecular mass of 284.7, see Figure 12-3. 
Diazepam is one of the most frequently prescribed benzodiazepines and is 
controlled under Schedule IV of the United Nations Convention on Psychotropic 
Substances. It is commonly used for anxiety disorders, insomnia and the short-
term treatment of acute alcohol withdrawal, acute agitation and tremor223. 
Common adverse effects of diazepam are fatigue, drowsiness, and muscle 
weakness. Diazepam is available as both a free base tablet for oral 
administration and as a solution for injection. 
 
Diazepam also acts on the GABAA receptor. It is a long-acting benzodiazepine 
with an average plasma half-life of 24-48 h. Peak plasma concentrations of 
diazepam occur at 30-90 min after oral administration. Diazepam is metabolised 
by N-demethylation to nordiazepam via CYP3A4 and CYP2C19 and then both 
parent and metabolite are further metabolised to the active metabolites 
oxazepam and temazepam, which are subsequently conjugated with 
glucuronide223. Diazepam is excreted in urine as oxazepam glucuronide 
approximately 33% and 20% conjugated nordiazepam and temazepam. 
 
12.5  Opioids 
The term “opioids” refers to compounds that act on the nervous system in a 
similar way to opiates whereas “opiates” are natural alkaloids that are found in 
the opium poppy plant. Opium is the dried milky juice (latex) obtained from the 
unripe seed pods of Papaver somniferum L., more commonly referred to as the 
opium or oil poppy224. The major important opiates are morphine, codeine and 
thebaine whereas hydromorphone, hydrocodone and buprenorphine are semi-
synthetic opioids derived from morphine, codeine and thebaine, respectively. 
Morphine and codeine are used to treat mild to moderate and chronic severe 
pain and codeine is also used to relieve cough and diarrhoea. However, both 
opiates and opioids have a high addiction potential225. Previous studies on the 
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detection and quantitation of morphine in fixed tissues and formalin solutions 
suggested that morphine is unstable in these matrices. 
 
12.5.1 Mechanism of action 
Opioids act by binding to specific opioid receptors (mu, delta and kappa) located 
within various nervous system sites and also found in the spinal cord and 
peripheral sensory and autonomic nerves. The mu (μ) receptor, which has three 
subtypes μ1, μ2 and μ3, is the site at which the prototype opiate morphine binds 
whereas the delta (δ) and kappa (κ) receptors are the site for the endogenous 
opioid ligand enkephalin226. Some opioids act as agonists or partial agonists on 
one type of receptor and antagonists at another, resulting in a very complicated 
pharmacological action. Mu receptors produce respiratory depression, euphoria, 
reduced gastrointestinal tract motility and vasodilation whereas delta and kappa 
receptors have analgesic properties227. Adverse effects of opioids include 
sedation, respiratory depression and euphoria225. High enough doses of opioids 
can cause death from respiratory failure. 
 
12.5.2 Morphine and hydromorphone 
Morphine is a natural alkaloid found in latex of the opium poppy (10-17% by 
weight) and was first isolated from opium in 1803 by Friedrich Sertürner. It acts 
directly on the central nervous system to decrease the feeling of pain. It is the 
prototype of narcotic analgesic drugs and is still made from opium. Morphine is 
available as the sulphate salt for oral, subcutaneous, intramuscular and 
intravenous administration. Oral morphine is recommended by the World Health 
Organization (WHO) for the treatment of chronic cancer pain. The chemical 
formula of both morphine and hydromorphone is C17H19NO3 with a relative 
molecular mass of 285.3, see Figure 12-4. Because of their high addictive 
potential, morphine and hydromorphone are controlled under Schedule I of the 
United Nations Convention on Narcotic Drugs. 
 
Morphine acts predominantly on mu opioid receptors (strongly binding) and is 
also a kappa and delta opioid receptor agonist. Adverse effects of morphine are 
nausea, delirium and constipation. Morphine is primarily metabolised by 
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conjugation to form morphine-3-glucuronide (M3G) and morphine-6-glucuronide 
(M6G), of which M3G is the main metabolite (45-55%). A minor metabolic route is 
N-demethylation to normorphine via CYP3A4 and CYP2C8. Other minor 
metabolites include normorphine-6-glucuronide, normorphine-3-glucuronide and 
codeine228. 
 
 
Figure 12-4: Chemical structures of morphine and hydromorphone. 
 
Hydromorphone (a hydrogenated ketone of morphine) is a semi-synthetic opioid 
agonist derived from morphine. It was first synthesised in 1921 and was first 
clinically used in 1926229. The structure of hydromorphone is similar to morphine 
only differing in the hydrogenation of the double bond at the C7-C8 position and 
the presence of a 6-keto group230. Hydromorphone is used as a second-line drug 
to morphine in the treatment of moderate to severe pain and is commonly used 
in hospital, mostly intravenously230. It is approximately 4-8 times more potent 
than morphine229. 
 
Hydromorphone acts primarily on mu opioid receptors and to a lesser degree on 
delta receptors but does not act on kappa receptors. It has a fast onset of 
action, approximately 30 min, and the average plasma half-life is 2.5h. Unlike 
other opioids, hydromorphone is not metabolised via CYP450 enzyme230. 
Metabolites of hydromorphone are dihydromorphine, dihydro-isomorphine and 
conjugated metabolites, hydromorphone-3-glucuronide and hydromorphone-6-
glucuronide229. 
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12.5.3 Codeine and hydrocodone 
Codeine, a methylated morphine derivative, is a natural alkaloid found in latex 
of the opium poppy (0.7-4% by weight) that was first isolated from opium in 1832 
by Pierre Robiquet in France. It is a weak opiate. Codeine is used to treat pain 
and diarrhoea and is also included in cough medicine227. It is a weak base and is 
available as the phosphate or sulphate salt for oral, subcutaneous and 
intravenous administration102. Hydrocodone (a potent analogue of codeine) is a 
semi-synthetic opioid derived from codeine used to treat moderate to severe 
pain and used as an antitussive to treat cough. It is available as the bitartrate 
salt and in combination with ibuprofen and acetaminophen. Hydrocodone is 6 
times more potent than codeine with respect to its analgesic property. Pure 
codeine and hydrocodone are prescribed drugs, although some weaker 
formulations of codeine are pharmacy medicines, and are controlled under the 
United Nations Convention on Narcotic Drugs, in which hydrocodone is under 
Schedule I and codeine is under Schedule III. The chemical formula of both 
codeine and hydrocodone is C18H21NO3 with a relative molecular mass of 299.36, 
see Figure 12-5. 
 
 
Figure 12-5: Chemical structures of codeine and hydrocodone. 
 
Codeine is rapidly absorbed following either oral or intramuscular 
administration. Average peak plasma concentrations of codeine occur 2 h after 
oral administration and the average plasma half-life is 2-4 h. Metabolism of 
codeine is by O-demethylation to morphine via CYP2D6 and by N-demethylation 
to nor-codeine. All three compounds are further conjugated with glucuronide 
and excreted in urine102,231. 
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A major metabolic route of hydrocodone is by N-demethylation to nor-
hydrocodone which is predominantly formed by CYP3A4. Hydrocodone is also 
metabolised by O-demethylation to hydromorphone via CYP2D6 and keto-
reduction to hydrocodol which is further metabolised to hydromorphol before 
conjugation and excretion in urine. Peak plasma concentrations of hydrocodone 
occur at 1.5 h following oral administration and the average plasma half-life is 3-
8 h102. 
 
12.6 Carbamate Insecticides 
Carbamates, including aldicarb, carbosulfan, and methomyl are a class of 
synthetic pesticides that contain esters of carbamic acid in their structures 
(Figure 12-6). They are the most commonly used pesticides in agriculture around 
the world. The first carbamate compound was isolated in the mid-1860s from 
calabar beans of the plant Physostigma venenosum. Most carbamate pesticides 
were synthesised in the 1960s and 1970s and carbaryl was the first carbamate 
compound that was used as an insecticide. Today, carbamates have replaced 
organophosphates for pesticide use because organophosphates were found to be 
extremely toxic to mammals232. 
 
 
Figure 12-6: General structure of carbamates (A), methomyl and aldicarb. 
 
Some carbamate insecticides such as carbosulfan and methomyl were banned by 
the European Union because of their high toxicity to humans. In agricultural 
countries, including Thailand, carbamates are commonly used in the fruit and 
vegetables industry. Carbosulfan, carbofuran and methomyl were reported as 
pesticide residues found in fruit and vegetables originating from Southeast 
Asia233. In 2008, more than ten thousand tonnes of carbofuran were imported 
into Thailand234. Moreover, these substances are also commonly encountered in 
the author’s laboratory in Thailand in cases of suicide235. However, information 
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about the stability and reactivity of carbamate insecticides in formalin solution 
has not previously been published. 
 
12.6.1 Mechanism of action 
The primary target organ of carbamates is the nervous system. Acetylcholine 
(ACh) is the neurotransmitter found at the neuromuscular junction to activate 
muscles and which is also released at synapses in the ganglia of the visceral 
motor system and in the CNS236,237. ACh is released from storage vesicles in nerve 
endings and quickly binds to ACh receptors in the post-synaptic membrane. The 
neurotransmitter is usually deactivated through hydrolytic cleavage into choline 
and acetic acid by the enzyme acetylcholinesterase (AChE), as shown in Figure 
12-7. During this cleavage reaction, the acetate group binds to the active site of 
the enzyme but is easily released again. Cleavage of ACh is required to allow a 
cholinergic neurone to return to its resting state after activation. Similarly, for a 
muscle to relax after a contraction is triggered by ACh at a neuromuscular 
junction, rather than persisting in a contracted state, ACh must be broken down 
by AChE.  
 
 
Figure 12-7: The mechanism of inhibition of AChE with carbamate pesticides. 
The diagram on the left shows the normal mode of action of the enzyme, 
through which ACh is cleaved into choline plus acetic acid. When a carbamate is 
cleaved by AChE, the carbamoyl group binds (reversibly) to the active site and 
blocks its action, as shown in the diagram on the right. 
 
Carbamates are anti-AChE substrates which can reversibly inhibit the enzyme at 
the synapses in the brain and at neuromuscular junctions, resulting in 
accumulation of acetylcholine and leading in turn to the overstimulation of 
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muscarinic and nicotinic acetylcholine receptors232. Cleavage of a carbamate by 
AChE results in binding of the carbamate moiety to the active site of the enzyme 
and inhibiting its activity. However, the carbamylation process resulting in anti-
AChE action is quickly reversible, unlike the phosphorylation of AChE by an 
organophosphate, which is only very slowly reversible. For this reason, 
carbamates are less toxic than organophosphates and have largely replaced the 
latter as pesticides.  
 
Carbamates are rapidly absorbed, metabolised in the liver and eliminated in the 
urine. Effects associated with muscarinic and nicotinic receptors are salivation, 
urination, diarrhoea, tremors and convulsions238. 
 
12.6.2 Carbosulfan 
Carbosulfan is a widely used insecticide. The chemical formula of carbosulfan is 
C20H32N2O3S with a relative molecular mass of 380.55, as shown in Figure 12-8. 
Carbosulfan is available as dusts, granular formulations and emulsifiable 
concentrates239. 
 
 
Figure 12-8: Chemical structures of carbosulfan and carbofuran. 
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Figure 12-9: The overall scheme of carbosulfan metabolism. 
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Hepatic metabolism of carbosulfan involves CYP450 isozymes through which 
sulfoxidation of carbosulfan is mediated mainly by CYP3A4 enzymes. The major 
metabolic pathway of carbosulfan in humans is the cleavage of the nitrogen 
sulfur bond (N–S) to carbofuran (Figure 12-9), which is itself used as a pesticide, 
and the minor pathway is formation of carbosulfan sulfoxide240. Carbofuran is 
further hydroxylated to 3-hydroxycarbofuran and 3-ketocarbofuran. Other 
metabolites are 3-hydroxy-7-phenol-carbofuran, 3-keto-7-phenolcarbofuran and 
7-phenolcarbofuran. Whereas all carbosulfan metabolites are toxic compounds, 
carbofuran is found to be more toxic than its parent, carbosulfan. 3-
Hydroxycarbofuran was reported as the main metabolite in all species241,242. 
 
12.7  Methods and materials  
12.7.1 Reagents and standards 
Acetonitrile, ethyl acetate and methanol (HPLC grade) were obtained from VWR 
International Ltd (UK).  Standards of N,N-dimethylamphetamine (DMA) and 3,4-
methylenedioxy-N,N-dimethylamphetamine (MDDMA) were obtained from 
Lipomed (supplied by Kinesis, Ltd UK). Standard 3,4-
methylenedioxymethamphetamine (MDMA), hydrocodone, carbosulfan, 
carbofuran, alprazolam-d5, hydromorphone-d3, hydrocodone-d3, 3-
hydroxycarbofuran, 3-ketocarbofuran and formaldehyde solution in water were 
obtained from Sigma-Aldrich, Co., LLC (UK). 
 
12.7.1.1 Preparation of stock standard solutions 
Individual stock standard solutions were prepared by dissolving each compound 
in methanol to achieve a concentration of 1 mg/ml of drug or pesticide 
substance. Working standard solutions were prepared by serial dilution of stock 
standard solutions with methanol. All stock and working standard solutions were 
stored at 4oC. 
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12.7.1.2 Preparation of formalin solutions 
10% and 20% formalin solutions were prepared by adding 10 ml or 20 ml, 
respectively, of formaldehyde solution into a 100 ml volumetric flask and 
making up to 100 ml with deionised water.  
 
12.7.2 Reaction of formalin solution with drugs and pesticide 
12.7.2.1 Spiked samples in formalin solution  
Spiked samples in 10% formalin solution were prepared separately for each of 
the following substances: amphetamine, methamphetamine, MDMA, alprazolam, 
diazepam, morphine, codeine, hydromorphone, hydrocodone and carbosulfan. 
Drug concentrations were set at 20 µg/ml for LC/MS analysis and carbosulfan 
was at 50 µg/ml for subsequent GC/MS analysis. All samples were stored at 
room temperature prior to processing. 
 
12.7.2.2 Spiked samples in control solution 
Spiked samples in water were prepared separately for each of the following 
substances: amphetamine, methamphetamine, MDMA, alprazolam, diazepam, 
morphine, codeine, hydromorphone, hydrocodone and carbosulfan. Drug 
concentrations were set at 20 µg/ml for LC/MS analysis and carbosulfan was at 
50 µg/ml for subsequent GC/MS analysis. All samples were stored at room 
temperature prior to processing. 
 
12.7.3 Reaction of formalin blood with drugs 
12.7.3.1 Spiked samples in formalin blood 
Spiked samples in 10% formalin blood were prepared separately for each of the 
following substances: amphetamine, methamphetamine, MDMA, alprazolam, 
diazepam, morphine, codeine, hydromorphone, hydrocodone and carbosulfan. 
Drug concentrations were set at 20 µg/ml for LC/MS analysis and carbosulfan 
was at 50 µg/ml for subsequent GC/MS analysis. The appropriate amount of 
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standard was added to blood which was then carefully mixed with an equal 
volume of 20% formalin solution. All samples were stored at room temperature 
prior to processing. 
 
12.7.3.2 Spiked samples in whole blood 
Spiked blood samples were prepared were prepared separately for each of the 
following substances: amphetamine, methamphetamine, MDMA, alprazolam, 
diazepam, morphine, codeine, hydromorphone, hydrocodone and carbosulfan. 
Drug concentrations were set at 20 µg/ml for LC/MS analysis and carbosulfan 
was at 50 µg/ml for subsequent GC/MS analysis. All samples were stored at 
room temperature prior to processing. 
 
12.7.4 Liquid-liquid extraction 
12.7.4.1 Liquid-liquid extraction for carbosulfan 
0.5 ml of a spiked sample containing 50 µg/ml of carbosulfan was extracted 
with 2 ml of ethyl acetate. The organic layer was transferred to a labelled 4 ml 
screw-capped vial and evaporated by a gentle flow of nitrogen gas at ambient 
temperature, and residues were reconstituted in 200 µl of ethyl acetate and 
transferred to labelled 1.5 ml screw-capped vials with inserts before analysis by 
GC/MS. 
 
12.7.4.2 Liquid-liquid extraction for LC/MS 
200 µl of spiked samples containing 20 µg/ml of amphetamine, 
methamphetamine, MDMA, alprazolam, diazepam, morphine, codeine, 
hydromorphone or hydrocodone were treated with 400 µl of acetonitrile and 
centrifuged at 12,000 rpm for 10 min. 200 µl of the supernatant layer was 
transferred to a labelled 1.5 ml capped vial with insert before analysis by 
LC/MS. 
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12.7.5 Instrumentation 
12.7.5.1 Gas chromatography/mass spectrometry conditions  
GC/MS analysis was carried out using an Agilent 7890A gas chromatograph 
equipped with an Agilent 7693 autosampler and connected to an Agilent 5975C 
inertXL MSD with Triple-Axis mass selective detector, operated in the EI positive 
ion mode. Chromatographic separation was performed on an HP-5MS fused silica 
capillary column (30 m × 0.25 mm i.d., film thickness, 0.25 μm, Agilent 
Technologies Inc.). Helium gas at a constant ﬂow of 1 ml/min was used as the 
carrier gas. The injection port temperature was 225oC, and the transfer line 
temperature was 250oC. The injection volume was set at 1 µl in the splitless 
mode. The oven temperature was maintained at 80oC for 2 min, and then it was 
increased at a rate of 8oC/min and ﬁnally held at 250oC for 1 min. 
 
The mass-selective detector was operated in the full scan mode with a mass 
range between m/z 40 and 500 and was tuned and calibrated with 
perfluorotributylamine. The ion source and quadrupole temperatures were 250oC 
and 150oC, respectively. A solvent delay was set at 5 min to protect the 
filament. All compounds were identified by their retention times (tR) and mass 
spectral fragmentation patterns. The molecular ion at m/z 323, base peak ion at 
m/z 160 and fragment ions at m/z 118 and 135 were monitored for carbosulfan. 
The molecular ion at m/z 221, base peak ion at m/z 164 and fragment ions at 
m/z 149 and 131 were monitored for carbofuran. 
 
12.7.5.2 Liquid chromatography/mass spectrometry conditions 
Chromatographic separation was performed using an Agilent Binary SL 1200 LC 
from Agilent Technologies Inc. Gradient elution was performed with a ﬂow rate 
of 0.3 ml/min on a Gemini C18 column (150 x 2.0 mm, 5 µm) protected by a 
Gemini C18 Security Guard Pre-Column (4 x 2.0 mm, 5 µm) from Phenomenex 
Inc., which were maintained at 40ºC. The injection volume was 10 µl and the 
mobile phase was composed of 2 mM ammonium acetate in water (A) and 2 mM 
ammonium acetate in methanol (B). The initial condition was maintained at 15% 
B for 2 min, increased to 50% B within 3 min and then increased to 90% B within 
191 
 
5 min and held for 5 min. Finally, the initial condition was restored within 0.5 
min and held for 6.5 min to re-equilibrate the system: the total run time was 22 
min. 
 
Analysis of all analytes was performed using an Agilent 6420 Triple Quad 
LC/MS/MS instrument (Agilent Technologies Inc.) equipped with an Agilent 
Binary SL 1200 LC system interface. Nitrogen was from a nitrogen generator (In 
House Gas (Manufacturing) Ltd, UK). 
 
Ionisation of analytes of interest was carried out using ESI. The mass 
spectrometer was operated in both positive ion full scan and multiple reaction 
monitoring (MRM) modes. Nitrogen was used as nebuliser gas at 30 psi. The gas 
temperature was set to 300oC and the gas flow to 11 ml/min. For full scan mode, 
the mass range was set at m/z 50 to 500 and the FV at 20 eV. The MRM 
transitions, FVs and CEs for each analyte were optimised separately by direct 
infusion into the MS of each standard solution at a concentration of 5 μg/ml in 
mobile phase (50:50 v:v). All analytes were identified and quantified based on 
their retention times and quantifier and qualifier ion ratios that were obtained 
from MRM transitions. The MRM transitions, FVs and CEs used for the 
measurement of amphetamines, benzodiazepines, opiates and carbosulfan are 
summarised in Table 12-1. 
 
 
 
 
 
 
 
 
192 
 
Table 12-1: MRM conditions for amphetamines, benzodiazepines, opiates and 
carbosulfan. 
 
Name Precursor 
Ion (m/z) 
Product 
Ions (m/z) 
Fragmentor  
Voltage (eV) 
Collision Energy 
(eV) 
AP 136.1 91.2 80 20 
136.1 119.1 5 
MA 150.0 91.1 90 20 
150.0 119.1 10 
MDMA 194.2 163.1 100 10 
194.2 135.2 20 
MDDMA 208.2 163.1 110 10 
208.2 72.2 10 
DMA 164.1 91.2 100 20 
164.1 119.2 10 
Morphine 286.3 201.1 170 25 
286.3 153.2 45 
Hydromorphone 286.3 185.1 170 30 
286.3 157.1 45 
Codeine 300.3  165.2 160 45 
300.3  215.1 21 
Hydrocodone 300.3  199.2 170 30 
300.3  128.2 60 
Alprazolam 309.2  281.2 180 30 
309.2  205.1 45 
Diazepam 285.2  193.2 180 30 
285.2  154.2 25 
Carbosulfan 381.2  160.2 120 15 
381.2  118.2 20 
Carbofuran 222.1  165.1 120 10 
222.1  123.0 15 
3-Hydroxy 
Carbofuran 
238.1  220.0 80 5 
238.1 163.1 10 
3-keto 
Carbofuran 
236.0  165.0 100 5 
236.0 151.0 10 
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Chapter 13 In vitro reaction of formaldehyde with 
drugs and poisons: identification of the 
conversion products 
 
13.1 Introduction 
This chapter will provide the results of the reactions of formaldehyde with 
drugs and poisons obtained using the methods described in Chapter 12.  
 
13.2 Reactions of formaldehyde with ATS 
13.2.1 Reactions of ATS in formalin solution 
Based on the Eschweiler-Clarke reaction, amphetamine, which is a primary 
amine, is expected to react with formalin solution to form methamphetamine 
and DMA. Methamphetamine, which is a secondary amine, is expected to form 
DMA. Also, MDMA, which is a secondary amine, is expected to form MDDMA. To 
confirm these reactions, amphetamine, methamphetamine and MDMA were 
spiked in 10% formalin solution and also in water as a control.  
 
The aim of these tests was to identify the products of reactions with formalin. In 
these initial tests, spiked samples were analysed qualitatively after spiking (day 
0) and at day 1 and day 7. Because the samples were analysed qualitatively 
rather than quantitatively and no internal standards were added, comparisons of 
peak areas between chromatograms acquired on different days is subject to 
larger errors than if the analyses had been quantitative, as the sensitivity of the 
instrument varied from day to day. However, comparison of peak area ratios, 
that is, relative amounts of each analyte in a sample, can be made. Further 
stability studies based on quantitative analysis will be required to prepare true 
stability curves over a period of several days.   
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The formation of MA and DMA was confirmed by comparing the retention times, 
M-H+ ESI mass spectra and MRM transitions of the products with those of 
standards. Standards of amphetamine, methamphetamine and DMA were 
detected in full scan mode at 5.8, 6.0 and 6.1 min, respectively using the 
molecular ions at m/z 136, 150 and 164, as shown in Figure 13-1. 
 
 
 
Figure 13-1: EICs of unextracted standards of amphetamine, methamphetamine 
and DMA analysed by LC/MS. 
 
In amphetamine-spiked samples in 10% formalin solution (with no pH 
adjustment), amphetamine was rapidly converted to methamphetamine after 
spiking, which was clearly visible in chromatograms acquired on days 1 and 7 
(Figure 13-2) but which was also detected even on day 0. The peak area ratios of 
methamphetamine/amphetamine in formalin solution on days 0, 1 and 7 were 
approximately 0.66%, 3.06% and 12.58%, respectively. No DMA was detected in 
any of the samples.  
 
By contrast, amphetamine in water was not converted to methamphetamine at 
all, indicating that the reaction product obtained in formalin was due only to the 
formalin. It should be noted that the peak area of amphetamine in water on day 
7 is approximately 50% of the area on day 1 and that this is due to a change in 
the absolute sensitivity of the instrument rather than to a 50% loss of 
Time (min) 
A
bu
nd
an
ce
 
195 
 
amphetamine. Future quantitative analyses would be required to confirm the 
stability of amphetamine in water. 
 
 
 
Figure 13-2: MRM chromatograms from LC/MS/MS analysis of amphetamine (AP) 
spiked samples in 10% formalin and in water at days 1 and 7 showing the 
formation of methamphetamine (MA) on days 1 and 7. 
 
In methamphetamine-spiked samples in 10% formalin solution (with no pH 
adjustment), methamphetamine was rapidly converted after spiking to DMA, 
which was clearly visible on both day 1 and day 7 (Figure 13-3) but which was 
also detected even on day 0. The peak area ratios of DMA/methamphetamine in 
formalin solution on days 0, 1 and 7 were approximately 0.76%, 0.78% and 0.83%, 
respectively.  
 
By contrast, methamphetamine in water was not converted to DMA at all, 
indicating that the reaction product obtained in formalin was due only to the 
formalin. 
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Figure 13-3: LC/MS/MS MRM chromatograms of methamphetamine-spiked 
samples in 10% formalin and in water at days 0 and 7. 
 
 
Similar to amphetamine and methamphetamine, MDMA was rapidly converted to 
MDDMA after spiking. Detection of MDMA and MDDMA was confirmed by 
comparing the retention times and the M-H+ ESI mass spectra with those of 
standards. Standards of MDMA and MDDMA were detected in full scan mode at 
6.0 and 6.3 min, respectively, using the molecular ions at m/z 194 and 208 
(Figure 13-4). MDDMA was clearly visible on both day 1 and day 7 (Figure 13-5) 
but was also detected on day 0. The peak area ratios of MDDMA/MDMA in 10% 
formalin solution on days 0, 1 and 7 were approximately 2.4%, 2.2% and 5.7%, 
respectively.  By contrast, MDMA in water was not converted to MDDMA, 
indicating that the reaction product obtained in formalin was due only to the 
formalin. 
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Figure 13-4: LC/MS EIC chromatograms of unextracted standards of MDMA and 
MDDMA. 
 
 
 
Figure 13-5: LC/MS/MS MRM chromatograms of MDMA-spiked samples in 10% 
formalin and in water at days 0 and 7. 
 
Time (min) 
A
bu
nd
an
ce
 
Time (min) 
A
bu
nd
an
ce
 
MDMA in formalin Day 1 
MDMA  
MDMA in water Day 1 
MDDMA  
MDMA  
MDMA  
MDMA  
MDDMA  
MDDMA  MDDMA  
MDMA in water Day 7 
MDMA in formalin Day 7 
198 
 
However, amphetamine, methamphetamine and MDMA do not appear to be 
completely converted by the Eschweiler-Clarke reaction. Results from 10% 
formalin spiked samples indicated that the sum of the peak areas of 
amphetamine and the conversion product detected at days 1 and 7 comprised 
approximately 42% and 30% of the peak area of the original starting material, 
respectively. Similarly, methamphetamine and its conversion product DMA 
comprised approximately 54% and 59% of the starting material at days 1 and 7, 
respectively and MDMA and its conversion product, MDDMA, comprised 
approximately 68% and 70% of the starting material at days 1 and 7, 
respectively.  
 
These discrepancies in peak areas suggest that other chemical reactions have 
taken place in addition to the Eschweiler-Clarke reactions which have not yet 
been identified but which should be the subject of future quantitative studies. 
 
13.2.2 Reactions of ATS in formalin blood 
To evaluate the Eschweiler-Clarke reaction in formalin blood, which has a 
different matrix from formalin solution, amphetamine, methamphetamine and 
MDMA were spiked in 10% formalin blood and control blood (whole blood with no 
formalin). Spiked samples were analysed after spiking (day 0) and at days 1, 7 
and 20. 
 
The results showed that amphetamine, methamphetamine and MDMA are slowly 
methylated in 10% formalin blood. Conversion products were not detected after 
spiking or after 24 h. At day 7, traces of conversion products were detected but 
only with the more sensitive MRM method (Figures 13-6 and 13-7). Amphetamine 
was identified with MRM transitions at m/z 136>119 and 136>91. 
Methamphetamine was identified with MRM transitions at m/z 150>119 and 
150>91 and DMA was identified with MRM transitions at m/z 164>119 and 164>91. 
MDMA was identified with MRM transition at m/z 194>163 and 194>135 and 
MDDMA was identified with MRM transitions at m/z 208>163 and 208>72. 
However, in formalin blood samples at day 20, the results showed that 
amphetamine, methamphetamine and MDMA had been converted to 
methamphetamine, DMA and MDDMA in yields of approximately 4.4%, 0.24% and 
0.68%, respectively, bearing in mind the limitations of these comparisons in the 
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absence of internal standards. In control blood, no conversion products were 
detected in any of the samples. 
 
 
 
Figure 13-6: LC/MS/MS MRM chromatograms of amphetamine (AP)-spiked 
samples in 10% formalin blood and in control (whole) blood at day 7. Arrows 
indicate retention times of conversion products methamphetamine (MA) and 
DMA. 
 
 
 
Figure 13-7: LC/MS/MS MRM chromatograms of MDMA-spiked samples in 10% 
formalin blood and in control (whole) blood at day 7. Arrows indicate retention 
time of the conversion product MDDMA. 
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Comparing the results with those obtained using spiked formalin solution 
samples, amphetamine, methamphetamine and MDMA are more rapidly 
methylated in formalin solution than in formalin blood. Results obtained from 
spiked samples in formalin solution are in agreement with previous studies203-205 
that amine-containing compounds react with formaldehyde by the Eschweiler-
Clarke reaction. Tirumalai et al.203 reported that conversion products of 
methamphetamine were not observed in 5%, 10% or 20% formalin solution with 
no pH adjustment over 30 days. In contrast, results obtained in this study found 
that amphetamine, methamphetamine and MDMA are rapidly methylated in 10% 
formalin solution after spiking. However, Shakleya et al.204,205 reported that 
methamphetamine and MDMA were extensively methylated within 24 h to DMA 
and MDDMA, respectively, in formalin fixed-liver tissue.  
 
An additional observation in the present study was that the formalin blood did 
not produce any additional interferences in the LC/MS/MS analyses. 
 
13.3 Reactions of formaldehyde with benzodiazepines 
13.3.1 Reactions of benzodiazepines in formalin solution 
To evaluate the reactions between benzodiazepines and formaldehyde, 
alprazolam and diazepam were spiked in both 10% formalin solution and, as 
controls, in water. Because a previous study202 found that alprazolam rapidly 
decreased in six days and was not detected in 10% and 20% formaldehyde after 
30 days, spiked samples were analysed after spiking (day 0) at days 1, 5 and 30. 
The formation of conversion products was identified using LC/MS in full scan 
mode. 
 
In the present study, alprazolam appeared to be unstable in both formalin 
solution and water and rapidly decomposed after spiking. The chromatographic 
peak area was approximately 50% of that of the starting material immediately 
after spiking and was 38% on day 30 in formalin solution. These changes should 
be taken as indicative as no internal standards were used. In control samples in 
water, alprazolam appeared to decompose in 24 h to approximately 55% of the 
starting material and slowly decomposed to 49% at days 30 (Figure 13-8). A 
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standard of alprazolam was monitored by LC/MS using the molecular ion M-H+ at 
m/z 309 and was identified at a retention time of 12.9 min. 
 
 
 
Figure 13-8: Relative peak area of alprazolam in 10% formalin and water over 30 
days as a percent of the peak area of the starting material. 
 
Comparing the total ion chromatograms obtained from spiked samples in 
formalin solution with spiked samples in controls, extra peaks were observed at 
11.3, 13.1 and 13.5 min with M-H+ at m/z 327, 429 and 399, respectively (see 
Figure 13-9). A previous study reported by Maślanka et al.243 found that 
triazolbenzophenone, (open-ring alprazolam) is one of the major hydrolysis 
products of alprazolam and can be identified at M-H+ m/z 327.32. The hydrolysis 
of benzodiazepines has previously been studied and reported244-246. The 
diazepinone ring in benzodiazepines is highly sensitivity to hydrolysis245. 
Hydrolysis pathways can follow either 1,2 or 4,5 position cleavage, see Figure 
12-2. The 4,5 position hydrolysis was reported to occur under acidic conditions 
whereas 1,2 cleavage is more important under basic conditions247. The 
diazepinone ring opening can occur by fragmentation of the C=N bond. The 
formation of open-ring alprazolam in spiked formalin samples was confirmed by 
the observation of a molecular ion (M-H+) at m/z 327. Open-ring alprazolam 
increased after spiking and was clearly observed by day 30, see Figure 13-10. 
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Figure 13-9: LC/MS chromatograms of alprazolam samples in 10% formalin after 
spiking (day 0). 
 
 
 
Figure 13-10: LC/MS chromatograms of alprazolam samples in 10% formalin at 
day 30 and chemical structure of open-ring alprazolam. 
 
Furthermore, the results for spiked samples also suggested that alprazolam was 
converted to compounds which had ESI molecular ions (M-H+) at m/z 399 and 
429, which were higher than alprazolam by 90 Da (for m/z 399) and by 120 Da 
(for m/z 429). Because alprazolam is a chlorine-containing compound, the 
isotopic pattern of the chlorine isotopes (35Cl:37Cl = 3:1) was used to identify the 
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degradation products. The isotopic pattern was observed in both degradation 
products. Neither of these conversion products were detected in control samples 
over 30 days. 
 
To confirm the formation of these conversion products, deuterated alprazolam-
d5 standard was spiked in formalin solution and water and was analysed after 
spiking (day 0) and at days 1 and 7. Alprazolam-d5 was detected at 11.6 min with 
an M-H+ ion at m/z 314, and open-ring alprazolam-d5 was detected at 10.7 min 
with an M-H+ ion at m/z 332. A peak of the other conversion product was 
observed at 11.9 min with an M-H+ ion at m/z 404 which was higher than that of 
alprazolam-d5 by 90 Da. However, the conversion product at m/z 434 was not 
observed (see Figure 13-11). 
 
 
 
Figure 13-11: LC/MS chromatograms of alprazolam-d5 samples in 10% formalin 
after spiking (day 0) and mass spectra of open-ring alprazolam-d5, alprazolam-d5 
and the conversion product with M-H+ at m/z 404. 
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By contrast with alprazolam, diazepam was found to be stable in both formalin 
solution and water over 30 days. It was detected in both samples at 
approximately 90% of the starting material at day 30, see Figure 13-12. This 
result is in general agreement with a previous study by Tracy et al.202 who 
reported that diazepam is stable throughout a 30 day period in control solution 
and that it was detected at approximately 65% of the starting amount in 10% 
formalin solution with no pH adjustment after 30 days. 
 
 
Figure 13-12: Relative peak area of diazepam in 10% formalin and water over 30 
days as a percent of the peak area of the starting material. 
 
Traces of conversion products of diazepam in formalin solution were observed in 
all samples at a retention time of 10.9 min, with an M-H+ ion at m/z 303, and at 
14.3 min, with two M-H+ ions at m/z 315 and 375, respectively. A previous study 
by Maslanka et al.243 also reported that 2-glycyloamino-5-chloro-benzophenone 
(open-ring diazepam) is one of the major hydrolysis products of diazepam and 
can be identified at M-H+ m/z 303.3. The isotopic pattern of 35Cl and 37Cl (3:1) 
was also observed in the other two degradation products with M-H+ ions at m/z 
315 and 375, which are higher than that of diazepam by 30 Da and 90 Da 
respectively (see Figure 13-13). 
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Figure 13-13: LC/MS chromatograms of diazepam samples in 10% formalin at 
day 1 and chemical structure of open-ring diazepam. 
 
 
 
Figure 13-14: LC/MS/MS product ion scans of alprazolam conversion products in 
10% formalin solution. 
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Furthermore, more information on the degradation products was obtained using 
LC/MS/MS product ion scan mode. In alprazolam samples in formalin solution, 
the results showed that the product with M-H+ m/z 399 fragmented to ions at 
m/z 339 and 310, whereas open-ring alprazolam (M-H+ at m/z 327) fragmented 
to ions at m/z 310, 298 and 280 (see Figure 13-14). A previous study by 
Gonsalves et al.246 showed that open-ring alprazolam was fragmented to ions at 
m/z 310 and 298 which is in agreement with the fragment ions obtained here for 
alprazolam samples in formalin solution. It can be concluded that the conversion 
product with M-H+ at m/z 327 is open-ring alprazolam. However, this method 
could not be applied to diazepam because of the low concentrations of its 
conversion products.  
 
The data available indicate that the conversion product of alprazolam, with M-
H+ at m/z 399, is alprazolam to which is attached formaldehyde as 
paraformaldehyde (plus 30, 60, 90 Da by the addition of 1, 2 or 3 formaldehyde 
molecules). However, the structure of the conversion compounds will be the 
subject of future work which needs to apply high resolution mass spectrometry 
and NMR to confirm the chemical structures. 
 
13.3.2 Reactions of benzodiazepines in formalin blood 
Because diazepam was found to be stable in formalin solution and only traces of 
conversion products were observed, alprazolam alone was spiked in 10% 
formalin blood and control blood to observe the conversion products at days 1, 
3, 7, 10, 15 and 30.  
 
Alprazolam was found to be stable in control blood but unstable in formalin 
blood. Conversion products of alprazolam were observed in formalin blood from 
day 1 to day 30. Open-ring alprazolam, with M-H+ at m/z 327, as detected at day 
1 in approximately 13% yield compared to alprazolam and then increased to 36% 
yield at day 30. Similarly, the product with M-H+ at m/z 399 was detected in 
approximately 39% yield at day 1 which increased to 78% at day 30 (see Figure 
13-15). A trace of another conversion product with a small peak area was 
observed in formalin solution with M-H+ at m/z 429 but only at days 7, 10 and 15 
and was not included in Figure 13-15. 
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Figure 13-15: (A) Percentage peak area of alprazolam in 10% formalin blood and 
control blood over 30 days. (B) Percentage peak area of alprazolam conversion 
products formed in 10% formalin blood compared with alprazolam. The EIC of 
m/z 327 is for open ring alprazolam and of m/z 399 is for the adduct of 
alprazolam with formaldehyde. 
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13.4 Reactions of formaldehyde with opiates 
13.4.1 Reactions of opiates in formalin solution 
Four drugs (codeine, morphine, hydrocodone and hydromorphone) were 
included in this study to identify the reactions between opiates and 
formaldehyde. Standards of opiates were spiked in 10% formalin solution and 
water as controls and were analysed after spiking, at days 0, 1, 5 and 30. The 
formation of conversion products was identified using LC/MS in full scan mode. 
 
 
Figure 13-16: Percentage peak areas of codeine and morphine in 10% formalin 
and water over 30 days. 
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These initial results indicate that morphine and codeine appear to be more 
stable in formalin solution than hydromorphone and hydrocodone, see Figures 
13-16 and 13-17. After 30 days, codeine was still observed in both formalin 
solution and water and the peak areas relative to the peak area of the starting 
materials were 66% in water and 71% in formalin solution. Likewise, morphine 
was observed at 63% of the starting peak area in both formalin solution and 
water. No conversion products were observed in spiked-codeine and spiked-
morphine in formalin solution and water samples. Standard morphine and 
codeine were identified by LC/MS using their molecular ions (M-H+) at m/z 286 
and 300 and were detected at 6.6 and 7.8 min, respectively. 
 
 
 
 
Figure 13-17: Percentage peak area of hydrocodone and hydromorphone in 10% 
formalin and water over 30 days. 
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Hydromorphone and hydrocodone were found to be more stable in water than 
formalin solution. After 30 days, hydromorphone was still observed in both 
formalin solution and water at a peak area of 55% of the starting peak area in 
water and 20% in formalin solution. Likewise, hydrocodone was observed at 12% 
of the starting peak area in formalin solution and 50% in water, see Figure 13-17. 
Standard hydromorphone and hydrocodone were identified using their molecular 
ions (M-H+) at m/z 286 and 300 and were detected at 6.6 and 7.6 min, 
respectively. 
 
 
Figure 13-18: LC/MS overlay chromatograms and mass spectra of hydrocodone 
samples in 10% formalin at day 1. 
 
Hydrocodone had decomposed by day 1 and only a trace amount was detected. 
The dip in the graph on days 1 and 5 is most likely due to a decrease in 
instrument sensitivity rather than a true decrease. Degradation products of 
hydrocodone were observed after spiking and were clearly identifiable at day 1, 
see Figure 13-18. The molecular ion peak (M-H+) of the product detected at 7.2 
min was at m/z 360, which is higher than that of hydrocodone by 60 Da. A 
second degradation product was detected at 7.5 min with M-H+ at m/z 330, 
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which is higher than that of hydrocodone by 30 Da. All conversion compounds 
were detected in formalin solution over 30 days and the peak areas of both 
compounds were higher than that of hydrocodone after day 1. In contrast, no 
degradation products were observed in spiked-control samples over 30 days. 
 
 
Figure 13-19: LC/MS overlay chromatograms and mass spectra of 
hydromorphone samples in 10% formalin at day 1. 
 
Similar to hydrocodone, degradation products of hydromorphone were observed 
after spiking and were clearly identifiable by day 1, see Figure 13-19. Products 
with molecular ion peaks (M-H+) at m/z 316 and 346, which are higher than that 
of hydromorphone by 30 Da and 60 Da, were detected at 6.3 and 6.2 min, 
respectively. Both conversion compounds were detected in formalin solution 
over 30 days and the peak area of the degradation compound with M-H+ at m/z 
316 was higher than that of hydromorphone by day 30. No degradation products 
were observed in spiked-control samples in water over 30 days. 
 
Furthermore, more information on the degradation compounds was obtained 
using LC/MS in the product ion scan mode. In hydrocodone samples in formalin 
solution, the results showed that the compound with M-H+ at m/z 360 gave 
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fragment ions at m/z 330, 312 and 300 whereas the compound with M-H+ at m/z 
330 gave fragment ions at m/z 312 and 300. In hydromorphone samples in 
formalin solution, results showed that the compound with M-H+ at m/z 316 
produced fragment ions at m/z 298 and 286 whereas the one with M-H+ at m/z 
346 was fragmented to ions at m/z 316, 298 and 286. These indicate that 
conversion products found in formalin solution are hydrocodone or 
hydromorphone to which was attached to formaldehyde in the form of 
paraformaldehyde (plus 30, 60, 90 Da), see Figure 13-20. However, the detailed 
structure of hydrocodone and hydromorphone conversion compounds will also be 
the subject of future work which needs to apply high resolution mass 
spectrometry and NMR to confirm their chemical structures. 
 
 
 
 
Figure 13-20: LC/MS product ion scans of conversion products of hydrocodone 
and hydromorphone in 10% formalin. 
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13.4.2 Reactions of opiates in formalin blood 
To evaluate the reactions of opiates with formalin blood, which is a different 
matrix from formalin solution, codeine, hydrocodone, hydromorphone and 
morphine were spiked in 10% formalin blood and control blood. Spiked samples 
were analysed after spiking (day 0) and at days 1, 3, 7, 10, 15 and 30. In these 
initial studies no internal standards were added and relative peak areas obtained 
over a period of 30 days would have had larger variations due to changes in 
instrumental performance than might have been obtained when using internal 
standards, which might explain the fluctuations observed in drug concentrations.  
 
 
Figure 13-21: Percentage of codeine and morphine in 10% formalin blood and 
control blood over 30 days. 
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The results showed that codeine is more stable in formalin blood than 
hydrocodone. At day 30, codeine was still observed in both formalin blood and 
control blood and the peak area was 74% in control blood and 62% in formalin 
blood compared with the initial spiked peak area. Morphine was observed at 50% 
of the starting peak area in control blood but it was observed at only 7% in 
formalin blood at day 30, see Figure 13-21. No conversion products were 
observed in spiked-codeine and spiked-morphine in formalin blood and control 
blood samples. 
 
 
Figure 13-22: Percentage of hydrocodone and hydromorphone in 10% formalin 
blood and control blood over 30 days. 
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Hydrocodone and hydromorphone were more stable in control blood than 
formalin blood, see Figure 13-22. At day 30, hydrocodone and hydromorphone 
were detected in control blood at 75% and 59% compared with the initial spiked 
peak area, respectively. In contrast, hydrocodone and hydromorphone in 
formalin blood rapidly decreased within 24 h and could not be detected in MS 
full scan mode after 2 days and in MRM mode after 7 days. Moreover, traces of 
the conversion products of hydrocodone with M-H+ ions at m/z 330 and 360 
were detected in formalin blood samples within 3 days but were not detected 
after day 7 whereas a trace of the conversion product of hydromorphone that 
gave the M-H+ ion at m/z 346 was detected within 7 days but was not detected 
after day 10. 
 
The results indicate that reactions continued to progress between the drugs and 
formalin and possibly also with blood components over the period of study. For 
both hydrocodone and hydromorphone reaction products were observed initially 
which were similar to the formalin adducts observed in formalin solution, but 
subsequently these could not be detected, suggesting that further changes had 
occurred. These studies need to be repeated to identify the reaction sequences 
which occur and the initial and subsequent products they produce. 
 
13.5 Reactions of formaldehyde with a carbamate 
insecticide 
13.5.1 Reactions of carbosulfan in formalin solution 
To evaluate the reactions between carbosulfan and formaldehyde, a standard of 
carbosulfan was spiked in 10% formalin solution and in water as a control. A pilot 
study by GC/MS found that carbosulfan rapidly decomposed in formalin solution 
within 7 days. Subsequently, spiked samples were analysed after spiking and at 
24 and 48 h. The formation of the conversion product was identified using 
GC/MS in full scan mode. A standard of carbosulfan eluted at 14.5 min when 
analysed by GC/MS. The GC/MS chromatogram (A) and EI+ mass spectrum (B) of 
carbosulfan are shown in Figure 13-23.  
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Figure 13-23: GC/MS chromatogram (A) and EI+ mass spectrum (B) of 
carbosulfan. 
 
The results showed that carbosulfan reacted with formalin solution and was 
completely hydrolysed to 7-phenolcarbofuran within 24 h whereas carbosulfan in 
water was stable up to 48 h, see Figure 13-24.  
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Figure 13-24: GC/MS chromatograms of carbosulfan in 10% formalin solution at 
days 0 and 1. The degradation product at 6.5 min is 7-phenolcarbofuran. 
 
The mass spectrum showed that the peak at 6.5 min corresponds to 7-
phenolcarbofuran, see Figure 13-25, and ions at m/z 164, 149 and 131 were 
subsequently monitored. 7-phenolcarbofuran which was observed at 6.5 min was 
confirmed by comparing the EI+ mass spectral fragmentation pattern with a 
library spectrum. However, 7-phenolcarbofuran was also observed in the 
carbosulfan standard. It may be an artifact produced in the GC inlet.  
 
Previous studies found that carbosulfan is metabolised to carbofuran, 3-
hydroxycarbofuran, 3-ketocarbofuran, 3-hydroxy-7-phenolcarbofuran, 3-keto-7-
phenolcarbofuran and 7-phenolcarbofuran248. The EI+ mass spectrum of 7-
phenolcarbofuran gives a molecular ion at m/z 164 and a base peak ion at m/z 
149 by the loss of a CH3 radical via α-cleavage from the molecular ion. The 
subsequent fragment ion at m/z 131 is produced by loss of an H2O molecule249. 
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Figure 13-25: GC/MS chromatogram (A) and EI+ mass spectrum (B) of 7-
phenolcarbofuran formed in GC inlet in a spiked formalin sample at day 1. 
 
To confirm the carbosulfan degradation products, standard carbosulfan was 
spiked in 10% formalin solution and water as a control and was analysed using 
LC/MS after spiking and at 24 and 48 h and then left for 15 and 30 days. The 
degradation products formed were identified using LC/MS in full scan mode and 
by MRM transitions compared with reference standards. Standard 3-hydroxy-
carbofuran, 3-ketocarbofuran, carbofuran and carbosulfan were identified using 
their molecular ions (M-H+) at m/z 238, 236, 222 and 381 and were eluted at 8.1, 
9.5, 10.3 and 15.6 min, respectively. 
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Figure 13-26: Percentage peak area of carbosulfan and its degradation 
compound (carbofuran) in 10% formalin and water over 30 days. 
 
The results from LC/MS analysis showed that carbosulfan is more stable in water 
than formalin solution. Carbosulfan was observed in water over 30 days and the 
peak area was 66% of the starting peak area at day 30. Similar to the results 
obtained from GC/MS, carbosulfan rapidly decomposed to carbofuran in 24 h in 
formalin solution. It was detected at 8% after 24 h, 2.5% at day 15 and was not 
detected at day 30, see Figures 13-26 and 13-27.  
 
However, as noted earlier in section 13.4.2, these initial studies were aimed at 
identifying the conversion products: only single replicates were used and no 
internal standards were added. Relative peak areas obtained over a period of 30 
days would have had larger variations due to changes in instrumental 
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performance than might have been obtained when using internal standards, 
which might explain the fluctuations observed in drug concentrations.  
 
Degradation compounds, carbofuran and 3-ketocarbofuran, were detected in 
both formalin solution and water after spiking. In 10% formalin solution, 
carbofuran was detected after spiking at a peak area of 31% relative to 
carbosulfan and increased to 90% at day 30. It was also detected after spiking at 
a peak area of 7% relative to starting material and increased to 46% at day 30 in 
spiked control samples. Traces of 3-ketocarbofuran were detected in all samples 
over 30 days. Moreover, the peak area of carbofuran detected at day 30 was 
higher than the peak area detected at day 15. One explanation of this is that 
carbosulfan is not converted directly to carbofuran but via intermediates which 
have yet to be identified. 
 
 
 
Figure 13-27: LC/MS overlay chromatograms of carbosulfan in spiked formalin 
and control samples at day 1. 
 
13.5.2 Reactions of carbosulfan in formalin blood 
To evaluate the reaction between carbosulfan and formalin blood, standard 
carbosulfan was spiked in 10% formalin blood and control blood. Spiked samples 
A
bu
nd
an
ce
 
Time (min) 
221 
 
were analysed using LC/MS after spiking and at days 1, 2, 3 and then again after 
15 days.  
 
The results obtained from carbosulfan spiked in 10% formalin blood were 
different from those obtained with 10% formalin solution in water. Carbosulfan 
slowly hydrolysed to carbofuran in spiked-blood samples and was still obviously 
present at day 15 whereas in formalin solution carbosulfan was not detected 
after 15 days, see Figure 13-28. Also, when compared with the initial spiked 
peak area, carbosulfan is more stable in control blood than formalin blood until 
72 h. Another degradation compound, 3-ketocarbofuran, was detected in both 
control blood and formalin blood after 24 h. 
 
 
Figure 13-28: LC/MS chromatograms of carbosulfan and carbofuran in formalin-
blood and control-blood samples at day 15. 
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13.6 Conclusions 
This Chapter presents the results of an in vitro study of the reactions of drugs 
and poisons with formaldehyde. It has confirmed that formaldehyde reacts with 
primary and secondary amines to produce tertiary amines by the Eschweiler-
Clarke reaction. However, amphetamine, methamphetamine and MDMA do not 
appear to be 100% converted in formalin solution and formalin blood by the 
reaction. Alprazolam, diazepam and carbosulfan are hydrolysed in formalin 
samples. Moreover, other reaction products of formaldehyde with drugs were 
observed. Alprazolam, diazepam, hydromorphone and hydrocodone react with 
formaldehyde and converted to conversion products which have molecular ions 
(M-H+) higher than those of the parent drugs by increments of 30, 60, 90 or 120 
Da. However, the rates of reaction are difficult to determine and the structures 
of all conversion products will require to be confirmed by additional work in 
future using high resolution mass spectrometry and NMR to confirm their 
chemical structures.  
 
The identification of drugs and poisons in formalin-fixed samples, formalin blood 
or formalin solution will be of great value when fresh biological samples or 
untainted autopsy samples are not available. Forensic toxicologists should be 
aware, when performing a quantitative analysis of drugs in formalin blood, 
formalin-fixed tissue or the formalin solution in which tissue is stored, that the 
concentrations of drugs are likely to decrease as a result of the reactions 
between the drugs and the formalin solution. In the case that original 
compounds cannot be observed in samples, identification of degradation 
compounds may provide evidence of the original presence of the parent drugs. 
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Chapter 14 General conclusions 
The focus of the current work was to study in vitro transformation reactions 
related to forensic toxicology. Part I focused on an in vitro method to identify 
drug metabolites using human liver microsomes whereas Part II focused on the 
identification of products of the reaction between formaldehyde and drugs and 
poisons using in vitro experimental procedures. 
  
Human liver microsomes were found to be useful for producing drug metabolites 
when commercial reference standards of metabolites are not available. 
Moreover, derivatisation was found to be selective for converting hydrophilic 
compounds to more lipophilic compounds which are better suited to analysis by 
LC/MS with conventional reverse-phase columns.  
 
In Chapter 8, a method for analysing MDMA and its metabolites in urine was 
developed and validated in order to study the metabolic pathway of MDMA by 
HLM compared with in vivo samples. Metabolites produced by HLM were 
confirmed by comparing with reference standards and all metabolites were 
detected in real urine samples. HHMA and HMMA were found as major 
metabolites of MDMA whereas MDA and HMA were found as minor metabolites. 
The LC/MS method in combination with derivatisation was found to be sensitive 
and selective for the quantitation of MDMA and its metabolites in urine samples 
with limits of quantitation of 0.025 µg/ml. 
 
In the work described in Chapter 9, the aim was to develop a method to study 
metabolic pathways of cathinones using HLM and to identify the cathinone 
metabolites by LC/MS. Metabolites of butylone and methylone were obtained 
using HLM and were identified by LC/MS using MRM transitions which, in the 
absence of standards, were predicted based on data from previous studies. 
Ketone-reduction and demethylenation were found to be major phase I 
metabolic pathways of cathinones whereas N-demethylation is a minor pathway 
in humans. The LC/MS method developed was found to be selective for the 
identification of butylone, methylone and their metabolites. Moreover, this 
method was designed for the identification of the dihydroxy metabolite of 
butylone which has not previously been studied. 
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In Chapter 10, the metabolic pathway of PMA was determined and its 
metabolites were identified using LC/MS. Metabolites of PMA were prepared 
using HLM and were identified by LC/MS using MRM transitions which were 
predicted based on reviewed data. Loss of the methyl group from the methoxy 
substituent was found to be a major phase I metabolic pathway of PMA in 
humans whereas β-hydroxylation is a minor pathway. The LC/MS method which 
was developed to identify PMA and its metabolites was found to be selective and 
has not previously been published. 
 
In addition, Chapter 12 described methods used to evaluate the in vitro reaction 
of formaldehyde with amphetamines, benzodiazepines, opiates and a carbamate 
insecticide. The results obtained from these experiments were described in 
Chapter 13. For the amphetamines group, which are representative of amine-
containing compounds, the Eschweiler-Clarke reaction was found to be a major 
reaction of formaldehyde with these compounds. For benzodiazepines, 
alprazolam and diazepam were hydrolysed when reacted with formaldehyde. 
Open-ring alprazolam and open-ring diazepam were detected as decomposition 
compounds. Other conversion products formed by the addition of 1 or more 
formaldehyde molecules to the drugs were detected for both compounds. For 
the opiates, hydromorphone and hydrocodone were unstable in formalin solution 
whereas morphine and codeine were more stable. Formaldehyde adduct 
conversion products of hydromorphone and hydrocodone were identified in 
formalin solution. Finally, carbosulfan was less stable in formalin solution than 
water. The major decomposition product of carbosulfan is carbofuran. Other 
decomposition products, 3-ketocarbofuran and 3-hydrocarbofuran, which are 
carbofuran metabolites, were also detected.  
 
The combination of LC/MS with derivatisation is suitable for the analysis of 
hydrophilic compounds such as drug metabolites which are difficult to analyse by 
LC/MS with a conventional C18 column. The detection of parent drugs and their 
metabolites as well as parent drugs and their conversion products in formalin 
samples is very useful for the investigation and interpretation of cases in 
forensic toxicology. 
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Chapter 15 Future work 
In the Part I studies described in Chapters 8-10, drug metabolism could be 
simulated using HLM and all metabolites including highly polar compounds such 
as dihydroxy-metabolites could be identified by the combination of a 
derivatisation technique with LC/MS. However, this study only focused on phase 
I metabolic pathways of some new psychoactive substances which are 
increasingly abused worldwide. 
 
Further work should be carried out to investigate phase I metabolism using other 
liver preparations such as S9 fraction or hepatocytes to allow comparison with 
the results obtained from HLM. Phase II metabolic pathways including 
conjugation reactions which convert parent compounds to highly hydrophilic 
compounds also need to be a subject for future work.  Moreover, other new 
psychoactive substances for which increasing abuse has been reported also need 
to be studied with respect to their metabolic pathways. It is necessary in 
forensic toxicology to develop sensitive and selective methods to identify new 
drugs and their metabolites for the increasing scope of analyses and increasing 
numbers of drug of abuse cases submitted to the laboratory. 
 
In the Part II studies described in Chapters 12-13, all compounds were found to 
be unstable in formalin solution and formalin blood. However, few previous 
studies have tried to identify what conversion products are formed or what 
reactions are occurring. In the present work, only the conversion products of 
amphetamine, methamphetamine, MDMA and carbosulfan were confirmed by 
comparing with reference standards whereas other conversion or decomposition 
products of benzodiazepines and opiates were tentatively identified due to the 
lack of standards. 
 
Future work should therefore also be carried out on the identification and 
confirmation of decomposition or conversion compounds of benzodiazepines and 
opiates in formalin solution using high resolution mass spectrometry to provide 
elemental compositions of the products and nuclear magnetic resonance (NMR) 
techniques, which will provide the chemical structure of these compounds.
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In vitro reaction of formaldehyde with drugs and poisons: 
identification of the conversion products. 
 
Tanasiri Yokchue and Robert Anderson 
Forensic Medicine and Science, University of Glasgow, Glasgow G12 8QQ 
 
Abstract  
In tropical countries, formalin, the active ingredient of which is formaldehyde, is 
injected into cadavers as an embalming solution to reduce body decomposition 
and preserve the body for a longer time. All drugs present in the body will be 
exposed to formaldehyde, a highly reactive substance that can chemically react 
with analytes, resulting in decreasing concentrations of the original compounds 
and producing one or more new substances. Occasionally, in some cases, 
formalin-blood, formalin-fixed tissue or embalming fluid is required for drugs 
analysis, and an analysis of these samples may create a false negative or false 
positive because of the reaction between drugs and formaldehyde. Previous 
studies on the chemical reactivity between formalin solution and drugs 
demonstrated that many drugs are unstable in formalin-fixed tissue and or the 
formalin solution in which the tissue is stored. In particular, primary and 
secondary amines can react with formaldehyde to form secondary and tertiary 
amines by the Eschweiler–Clarke reaction. 
  
The present study was aimed at quantification of the original drugs and 
identification of their degradation products in formalin solution. In order to 
evaluate the effect of formaldehyde on drugs and poisons, a range of model 
compounds was used, including amphetamine-type stimulants (amphetamine, 
methamphetamine, and 3,4-methylenedioxy-N-methamphetamine (MDMA)), 
benzodiazepines (alprazolam and diazepam), opiates (morphine, 
hydromorphone, codeine, and hydrocodone) and a carbamate insecticide 
(carbosulfan), which are often associated with cases of suicide, homicide, 
accidental poisoning and road traffic accident because of their toxicity and 
potential for abuse.  
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Spiked samples in 10% formalin solution (with no pH adjustment) were stored at 
room temperature and analysed at selected times over 30 days. The original 
drugs were quantified and their degradation products in formalin solution were 
identified and confirmed by gas chromatography-mass spectrometry (GC/MS) and 
liquid chromatography - triple quadrupole mass spectrometer (LC/MS/MS).The 
results show that amphetamine (a primary amine) is methylated producing 
methamphetamine and methamphetamine (secondary amine) produces 
dimethylamphetamine (DMA). MDMA is methylated producing 3,4-
methylenedioxy-N,N-dimethylamphetamine (MDDMA). For opiates, hydrocodone 
rapidly changes to a more polar compound that gives an MH+ at m/z 360. 
Hydromorphone also changes to more polar compounds with MH+ at m/z 316 and 
346. Codeine and morphine are stable in formalin solution.  Furthermore, open-
ring alprazolam (5-chloro-[2-(3-aminomethyl-5-methyl-1,2,4-triazol-4-
yl]benzophenone) was observed as the hydrolysis product of alprazolam. 
Carbosulfan is completely hydrolysed to carbofuran within 24 h.  
  
The forensic toxicologist should consider the degradation products as potential 
target analytes when performing drugs analysis in embalming samples. 
 
Keywords: formalin-blood, degradation product, stability studies, LC-MS-MS, 
amphetamines, benzodiazepines, opiates, carbosulfan. 
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In vitro reaction of formaldehyde with drugs and poisons: 
identification of the conversion products. 
 
Tanasiri Yokchue and Robert Anderson 
Forensic Medicine and Science, University of Glasgow, Glasgow G12 8QQ 
 
Abstract  
 In tropical countries, formalin is injected into cadavers as an embalming 
solution to reduce body decomposition and preserve the body for a longer time. 
All drugs present in the body will be exposed to formaldehyde, a highly reactive 
substance that can chemically react with analytes, resulting in decreasing 
concentrations of the original compounds and in the production of one or more 
new substances. Aims: The present study was aimed at quantification of the 
original drugs and identification of their degradation products in formalin 
solution and formalin blood. Methods: In order to evaluate the effect of 
formaldehyde on drugs and poisons, a range of model compounds was used, 
including amphetamine-type stimulants, benzodiazepines, opiates and 
carbamate insecticides. Spiked samples in 10% formalin solution (with no pH 
adjustment) and 10% formalin-blood were stored at room temperature and 
analysed at selected times over 30 days. The original drugs were quantified and 
their degradation products in formalin solution/blood were identified and 
confirmed by gas chromatography-mass spectrometry (GC/MS) and liquid 
chromatography - triple quadrupole mass spectrometer (LC/MS/MS). Result: In 
both, formalin solution and formalin blood, the results show that amphetamine 
is methylated producing methamphetamine and methamphetamine produces 
N,N-dimethylamphetamine (DMA). MDMA is methylated producing 3,4-
methylenedioxy-N,N-dimethylamphetamine (MDDMA). For opiates, hydrocodone 
rapidly changes to a more polar compound that gives an MH+ at m/z 360. 
Hydromorphone also changes to more polar compounds with MH+ at m/z 316 and 
346. Codeine and morphine are stable in formalin solution/blood.  Furthermore, 
open-ring alprazolam (5-chloro-[2-(3-aminomethyl-5-methyl-1,2,4-triazol-4-
yl]benzophenone) was observed as the hydrolysis product of alprazolam and a 
compounds that gives an MH+ at m/z 399 was  observed as a conversion product 
in both formalin solution and blood. Finally, carbosulfan is rapidly hydrolysed to 
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carbofuran and its metabolites, 3-ketocarbofuran and 3-hydroxycarbofuran 
within 24 h. Conclusions: The forensic toxicologist should consider the 
degradation products as potential target analytes when performing drugs 
analysis in embalming samples. 
 
Keywords: formalin-blood, degradation product, stability studies, LC-MS-MS, 
amphetamines, benzodiazepines, opiates, carbosulfan. 
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In vitro metabolism studies on methylenedioxy-substituted 
amphetamines using human liver microsomes and LC/MS/MS with 
chemical derivatization 
 
Tanasiri Yokchue and Robert Anderson.  
Forensic Medicine and Science, University of Glasgow, Scotland, UK. 
 
Abstract 
The abuse of β-keto derivatives of MDMA such as butylone and methylone has 
been reported since the mid-2000s. The forensic toxicologist faces problems 
with these drugs, because of lack of information on their metabolism and 
unavailability of reference standards of the metabolites and the parent drugs 
themselves. Ethical considerations usually preclude human metabolism studies 
under controlled conditions and in vitro methods provide potential alternatives. 
A few previous studies showed that β-keto derivatives of MDMA have similar 
metabolic pathways to MDMA, resulting in metabolites formed by 
demethylenation, demethylenation plus O-methylation (4-OH-3-MeO 
metabolites) and N-demethylation. Another challenge is the analysis of these 
polar metabolites using conventional C18 HPLC columns, resulting in low 
retention volumes. One rapid and simple solution to this is chemical 
derivatization. Conversion of metabolites to more hydrophobic compounds by 
derivatization can improve separations by reversed-phase HPLC and increase 
sensitivity in mass spectrometry.  
 
Aims: To identify metabolites of butylone and methylone in humans using human 
liver microsomes (HLM) in vitro and reversed-phase LC/MS/MS with 
derivatization. MDMA was used in this study as a model compound as its 
metabolites are commercially available.   
 
Method: Pooled human liver microsomes were incubated with NADPH 
regenerating system and MDMA, butylone or methylone in 0.1 M phosphate 
buffer pH 7.4 in a shaking incubator at 37oC for 90 min. Each reaction was 
stopped by the addition of ice-cold acetonitrile and extracts were derivatised 
with acetic anhydride/pyridine (3:2 v:v) for 30 min at 60oC. Derivatised 
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metabolites were identified by LC/MS/MS using multiple reaction monitoring 
(MRM). Ten MDMA positive urines were also analysed to compare the metabolite 
patterns with those obtained in vitro with HLM.  
 
Results: Three phase-I metabolites (both major and minor metabolites) of 
MDMA, butylone and methylone were detected. For MDMA, 3,4-
dihydroxymethamphetamine derivative (HHMA-3Ac) was identified by MRM 
transitions at m/z 308>266, 308>224 and 308>151, 4-hydroxy-3-
methoxymethamphetamine derivative (HMMA-2Ac) at m/z 280>238, 280>165 and 
280>137 and MDA-Ac at m/z 222>163, 222>135 and 222>105. For methylone, 
dihydroxymethcathinone (DHMC), a major metabolite, was identified by MRM 
transitions at m/z 322>280 and 322>178 (DHMC-3Ac). Nor-methylone (a minor 
metabolite) was identified by MRM transitions at m/z 236>146 and 236>118 (bk-
MDC-Ac). Another metabolite, 4-hydroxy-3-methoxymethcathinone (4-HMMC) 
was identified by MRM transitions at m/z 294>234 and 294>160 (4-HMMC-2Ac). 
Furthermore, a major metabolite of butylone (demethylenation metabolite) was 
identified by MRM transitions at m/z 336>294 and 336>174 (butylone-M 
dihydroxy-3Ac). Nor-butylone was identified by MRM transitions at m/z 250>160 
and 250>132 (bk-BDB-Ac). Finally, the 4-OH-3-MeO metabolite was identified by 
MRM transitions at m/z 308>248 and 308>174 (butylone-M (demethylenyl-methyl-
) 2Ac). Derivatives of MDMA and its metabolites were stable in the HPLC mobile 
phase for 30 h at room temperature and were quantified in all 10 positive human 
urine samples. HMMA was the major metabolite in human urine samples whereas 
HHMA was the major metabolite by HLM. However, HHMA is an intermediate 
metabolite leading to HMMA. This result confirms that demethylenation of the 
methylenedioxy ring, followed by catechol-O-methyltransferase (COMT)- 
catalysed methylation is a major metabolic pathway of MDMA in humans.   
 
Conclusions: Human liver microsomes can be used to simulate drug metabolism 
in humans and to provide chromatographic and mass spectrometric data on 
metabolites. Acetate derivatives result in higher molecular weights, providing 
more speciﬁc ions for identification, and in decreased polarities of metabolites, 
improving their analysis on reversed phase C18 columns. This method would be 
suitable for routine analysis of urine to detect and confirm abuse of 
methylenedioxy-substituted amphetamines.  
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Keywords: Methylenedioxy-substituted amphetamines, in vitro metabolism, 
human liver microsomes. 
 
 
